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 I 
1 SUMMARY 
 
Prion  diseases  or  transmissible  spongiform  encephalopathies  (TSEs)  are  rare  neurological 
disorders that may be of genetic or infectious origin, but most frequently occur sporadically in 
humans. Their outcome is invariably fatal. The infectious agent has been defined as prion 
(from proteinaceous infectious only) in 1992 by Stanley B. Prusiner and represent mainly, if 
not solely, an abnormal, protease-resistant isoform (PrP
Sc) of a cellular protein, the prion 
protein  or  PrP
C.  According  to  the  “protein  only”  hypothesis,  the  prion  is  devoid  of 
informational  nucleic  acids  and  consists  of  an  “infectious”  protein  that  is  capable  of 
converting the normal host protein PrP
C into a likeness of itself. 
TSEs can be distinguished from other neurodegenerative diseases because of their infectivity 
and transmission capability. The only organ system in which severe histopathological damage 
can be demonstrated as a consequence of infection with prions is the nervous system. The 
communal lesions are neuronal loss, spongiosis and astrogliosis, accompanied by an intra- 
and extracellular accumulation of PrP
Sc, occasionally in form of amyloid plaques. Even if a 
strong activation of microglia and astrocytes occurs, no immunological response is usually 
detectable as consequence of prion infection. 
 
Despite the considerable attention for its involvement in TSEs, the physiological role of the 
cellular,  nonpathogenic  isoform  of  PrP
C,  has  not  yet  been  determined.  In  the  last  years, 
several putative cellular functions have been attributed to PrP
C: its localization in “lipid rafts” 
is  consistent  with  a  possible  role  in  cell  adhesion,  transmembrane  signalling  or  as  a 
recognition molecule. Furthermore, PrP
C has been implicated in protection against oxidative 
stress,  copper  metabolism,  apoptosis,  cell  proliferation  and  in  the  regeneration  of  blood 
precursors stem cells in the adult. It has also been shown that PrP
C interacts with the neuronal 
cell  adhesion  molecule  NCAM,  promoting  neurite  outgrowth.  However,  both  the  PrP
C-
mediated effects and the role of PrP
C-dependent pathways on neuronal differentiation are still 
not elucidated. 
First objective of this Ph.D thesis was the establishment of a novel in vitro cellular model for 
the study of the role of PrP
C in neuronal differentiation and neurite outgrowth. Furthermore, 
an additional goal of this project was the indentification of the PrP
C domains responsible for 
the induction of neuronal differentiation. 
A novel PrP
C-depleted cell line (PrP
0/0 ML) was derived from murine primary PrP-knockout 
neuronal cells by SV40 large T antigen-mediated immortalization. A temperature sensitive II 
form of this oncogenic protein was used, allowing a temperature-mediated regulation of its 
expression. This cell line was then characterised for its growth potential, for the expression of 
specific cellular markers and for its ability to differentiate. It was found that, under culture 
conditions promoting the expression of the temperature-sensitive SV40 large T antigen, the 
cells expressed nestin, a specific marker of neuronal precursor cells. Therefore, the PrP
0/0 ML 
cell line was identified as a potential neuronal stem cell line. In fact, under nonpermissive 
culture conditions when the expression of the temperature-sensitive SV40 large T antigen is 
downregulated, the PrP
0/0 ML cells differentiated into neurons. Noteworthy, maintenance of 
the cells in conditions that promote cell differentiation induced a progressive reduction in the 
expression  levels  of  nestin,  an  event  that  strongly  correlated  with  the  appearance  of  the 
specific neuronal markers MAP-2b and NeuN. 
In order to investigate the role of PrP
C in the process of neuronal differentiation, the PrP
0/0 
ML cells were then reconstituted for the expression of either the full-length PrP or a N-
terminal truncated PrP
C form (PrP32-134). The differentiation potential of both reconstituted 
cell  lines  under  nonpermissive  culture  conditions  was  then  compared  with  that  of  the 
parenteral PrP
0/0 ML cells. This in vitro study clearly highlights that PrP
C expression in the 
PrP
0/0 ML cell line accelerates neuronal differentiation and that the N-terminal domain of the 
prion protein is not necessary for this PrP-mediated function. 
 
 
Prion diseases like BSE, vCJK, Kuru and the majority of iatrogenic cases of CJK are caused 
by a peripheral infection. Infectious prions accumulate in the central and peripheral nervous 
system  as  well  as  in  extracerebral  tissues,  such  as  the  secondary  lymphoid  organs  and 
muscles. The prion pathogenesis is a dynamic process which can be defined temporary and 
spatially  in  different  phases:  i)  infection  and  peripheral  replication,  ii)  neuroinvasion, 
transport  of  prions  from  the  periphery  to  the  central  nervous  system  (CNS),  and  iii) 
neurodegeneration.  In the last  years, progresses  in  the elucidation of the peripheral  prion 
pathogenesis  were  achieved.  The  identification  of  the  cell  types  involved  in  the 
lymphoreticular  prion  replication  phase  and  the  recognition  of  the  role  of  the  peripheral 
nervous system in the process of prion spread from the periphery to the CNS have elucidated 
some  of  the  cellular  mechanisms  that  are  involved  in  prion  uptake,  replication  and 
propagation.  However,  relatively  little  information  is  available  about  the  mechanism(s) 
underlying intercellular prion transfer and tissue-to tissue prion spread. III 
Microvesicles (MVs) are submicron vesicles (0,03-1 m) with a single membrane and are 
shed  from  most  eukaryotic  cells  undergoing  activation  or  apoptosis.  The  segregation  of 
specific proteins is followed by blebbing of the membrane surface, leading to the formation of 
MVs and their release in the extracellular environment. MVs can be also secreted upon fusion 
of multivesicular endosomes with the plasma membrane (exosomes). The secretion of MVs is 
the result of a complex cellular process involving changes in the metabolism of lipids and 
proteins. 
The functional role of MVs is still largely unknown. However, there is evidence showing that 
they  are  important  modulators  of  cell-to-cell  communication,  participate  in  a  variety  of 
intracellular adhesion processes and are able to induce cellular response(s). 
The release of PrP
C and infectious PrP
Sc by prion infected epithelial, neuroglial and neuronal 
cells in association with exosomes has recently been highlighted. Furthermore, it has been 
shown that exosomes can propagate prion infectivity both in vitro and in vivo, suggesting that 
PrP
Sc-bearing exosomes may provide a mechanism for intercellular transmission of infectious 
prions in addition to cell-to-cell contact. 
Second objective of this Ph.D thesis was to determine the possible role of plasma membrane-
derived microvesicles in the propagation and transmission of prions. The release of MVs was 
first studied in different murine neuronal cell lines. Here it is shown for the first time that 
neurons also shed plasma membrane derived MVs, in addition to exosomes. 
Immunoelectron microscopy and immunoblot analyses clearly demonstrated the presence of 
PrP
C on the membrane of MVs released from PrP
C-expressing cells. Characterization of lipid 
rafts  components  in  MVs  highlighted  the  presence  of  the  ganglioside  GM2,  the  tyrosine 
kinase p59Fyn, flotillin-2 and the neuronal protein GAP-43. 
In order to investigate whether MVs are involved in the intercellular transmission of prions, 
MVs  were  first  isolated  from  two  prion  infected  murine  neuronal  cell  lines,  namely  the 
Neuro-2a PK1 and the N2a58 cells, and then used for in vitro and in vivo infection assays. 
Immunoblot analyses after proteinase K treatment demonstrated the association of PrP
Sc with 
the secreted MVs. The PrP
Sc-bearing MVs were then used to perform infection experiments 
on noninfected cells. By the use of cell blot assay, a method that allows the detection of PrP
Sc-
amplification and -accumulation in cultured cells, the kinetic of prion infection in the de novo 
infected cells was followed. Noteworthy, it was found that PrP
Sc-bearing MVs were capable 
to transmit prions in vitro and to stably infect the recipient cells. In order to investigate the 
role of MVs in the transmission of infectivity in vivo, PrP
Sc-bearing MVs as well as MVs 
isolated from noninfected cells (as negative control) were injected intracerebrally in PrP
C-IV 
overexpressing indicator mice (tga20). The development of clinical disease was followed in a 
time-dependent manner. Clinical symptoms could be observed only in the group of indicator 
mice  inoculated  with  the  PrP
Sc-bearing  MVs,  which  then  succumbed  to  desease.  These 
findings  clearly  demonstrated  that  MVs  are  biological  carriers  of  both  PrP
Sc  and  prion 
infectivity. MVs could  therefore participate  in  vivo in  the processes of intercellular prion 
transmission and propagation. V 
ZUSAMMENFASSUNG 
 
Die transmissiblen spongiformen Enzephalopathien (TSEs) oder Prionenerkrankungen bilden 
eine  Gruppe  fataler  neurodegenerativer  Erkrankungen,  welche  einen  weiten  Wirtsbereich 
(Mensch und Tier) aufweisen. Sie treten in vererbbarer, sporadischer sowie infektiöser Form 
auf. Der infektiöse Erreger wurde als „Prion“ (proteinaceous infectious only) in 1992 von 
Stanley B. Prusiner gennant und ist auf die enge Korrelation von Infektiösität und PrP
Sc , einer 
partiell Protease-resistenten Isoform (Scrapie-Isoform) des zellulären, physiologischen Prion 
Protein (PrP
C), zurückzuführen. Gemäss der „protein only“ Hypothese bezeichnen Prionen 
infektiöse Einheiten, welche sich durch das Fehlen einer Erbinformation von konventionellen 
Erregern unterscheiden und in der Lage sind, das normale endogene PrP
C in der infektiöse 
Form umzuwandeln. TSEs unterscheiden sich von anderen neurogenerativen Erkrankungen 
durch Ihre Infektiosität und Übertragbarkeit.  
Prionen  verursachen  im  Gehirn  einen  herdförmigen  Neuronenzelluntergang,  spongiforme 
Veränderungen  des  Nervengeflechts  (Neuropil),  Astrozytenvermehrung  (Astrozytose)  und 
charakteristische intra- und extrazelluläre PrP
Sc-Ablagerungen. Außer einer mitunter massiven 
Mikroglia- und Astrozytenaktivierung sind üblicherweise keine zellulären immunologischen 
Reaktionen erkennbar. 
 
Die Funktion des zellulären, nicht pathogenen PrP
C ist trotz intensiven Anstrebungen während 
der letzten Jahre noch nicht eindeutig identifiziert worden. Verschiedene putative Funktionen 
wurden zu PrP
C zugeschrieben: die Lokalisierung von PrP
C in „lipid rafts“ lässt eine Rolle in 
der  Zelladhäsion,  in  der  transmembranären  Signalkaskaden  sowie  als  Ligand/Rezeptor 
vermuten. Es wurde weiterhin gezeigt, dass PrP
C in der Regulierung von oxidativem Stress, in 
dem Kupfer-Stoffwechsel, in der Apoptose, in der Regenerierung von adulten blutbildenden 
Stammzellen und in der Regulierung der Zellvermehrung involviert ist. Die nachgewiesene 
Interaktion  von  PrP
C  mit  dem  zellmembranären  Protein  NCAM  (neuronal  cell  adhesion 
molecule) hat  zur Postulierung  geführt,  dass  PrP
C  in  der neuronalen Differenzierung  eine 
wesentliche Rolle spielt. Die PrP
C-abhängigen zellulären Mechanismen, die in der Induktion 
der neuronalen Differenzierung involviert sind, sind bis heutzutage noch nicht vollständig 
aufgeklärt. 
Erstes Ziel dieser Dissertation war, ein neues zelluläres Modell für die Untersuchung der 
Rolle von PrP
C in der neuronalen Differenzierung zu etablieren. Dieses neue in vitro Modell 
wurde  dann  verwendet,  um  die  PrP
C-bedingten  Einflüsse  auf  diesen  Prozess  zu 
charakterisieren. Die Identifizierung der Domäne des Prionproteins, die für die Induktion der VI 
neuronalen Differenzierung notwendig sind, war ein zusätzliches Ziel dieses ersten Projektes. 
Um diese biologische Fragenstellungen experimentell zu bearbeiten, wurde erstens eine neue 
PrP-depletierte Zelllinie (PrP
0/0 ML) durch SV40-Large T Antigen-bedingte Immortalisierung 
aus  murinen  primären  PrP-knockout  neuronalen  Zellen  generiert.  Die  biologischen 
Eigenschaften dieser Zelllinie wurden dann vollständig charakterisiert: Wachstum, Expression 
von spezifischen zellulären Antigenen und Differenzierung wurden untersucht. Es stellte sich 
heraus, dass unter Kulturbedingungen, bei welcher die temperatursensitive Form des SV40-
Large T Antigen exprimiert wird, die PrP
0/0 ML Zellen die Expression des Antigens Nestin 
vorwiesen. Da Nestin ein zellulärer Marker ist, der spezifisch in neuronalen Vorläuferzellen 
vorkommt,  wurden  die  PrP
0/0  ML  Zellen  als  potenziellen  neuronalen  Stammzellen 
identifiziert. Unter nicht permissive Kulturbedingungen, differenzierten sich die PrP
0/0 ML 
Zellen ausschliesslich zur Neuronen.  
Es  wurde  in  der  Tat  nachgewiesen,  dass  in  einem  zeitabhängigen  Prozess  die 
Unterregulierung von Nestin der Hochregulierung der spezifischen neuronalen Markern Map-
2b und NeuN vorausgeht. 
Um die Rolle des Prionproteins in der neuronalen Differenzierung zu untersuchen, wurden 
dann die PrP
0/0 ML Zellen für die Expression entweder von „wild Type“ PrP
C oder von einer 
N-terminalen  trunkierten  Form  von  PrP
C  (PrP32-134)  rekonstituiert.  Der  Prozess  der 
Differenzierung der beiden rekonstituirten Zelllinien wurde mit jenem der PrP
0/0 ML Zellen 
verglichen. Die durchgeführten Experimente zeigten eindeutig, dass die Expression von PrP
C 
in  der  PrP
0/0  ML  Zelllinie  die  neuronale  Differenzierung  beschleunigt  und  dass  der  N-
Terminus des Prionproteins für diese Funktion nicht notwendig ist. 
 
 
Prionenerkrankungen,  wie  BSE,  vCJK,  Kuru  und  die  meisten  Fälle  von  iatrogener  CJK, 
entstehen normalerweise durch eine peripherale Infektion. Infektiöse Prionen akkumulieren 
sich  nicht  nur  innerhalb  des  zentralen  und  peripheren  Nervensystems  aber  auch  in 
extrazerebralen  Geweben,  wie  in  den  sekundären  lymphatischen  Organen  und  in  den 
Muskeln.  Die  Pathogenese  der  Prionerkrankung  ist  ein  dynamischer  Prozess,  den  man  in 
sowohl  zeitlich  als  auch  räumlich  getrennten  Phasen  unterteilen  kann:  i)  Infektion  und 
periphere Replikation, ii) Neuroinvasion, der Transport von Prionen von der Peripherie zum 
Zentralnervensystem,  und  iii)  Neurodegenerierung.  In  den  letzen  Jahren  wurden  grosse 
Vorschritte in der Aufklärung der periphere Pathogenese erzielt. Die Identifizierung von den 
Zellen,  welche  die  Prion-Propagation  im  lymphoretikulären  System  unterstützen,  und  die VII 
Erkenntnisse über die wichtige Rolle des peripheren Nervensystems bei der Ausbreitung von 
Prionen von der Peripherie ins Zentralnervensystem haben einige der zellulären Mechanismen 
aufgeklärt, die bei der Prionen-Aufnahme, -Replikation und –Ausbreitung beteiligt sind. Die 
molekularen Mechanismen der Prionenübertragung von Zelle zu Zelle und von Gewebe zu 
Gewebe sind jedoch noch nicht vollständig aufgeklärt. 
Mikrovesikel (MVs) sind submikroskopische (0,03-1 m in Durchmesser) Vesikel, die von 
einer einfachen Membran umgeben sind und von eukaryotischen Zellen nach Aktivierung 
oder  während  der  Apoptose  freigesetzt  werden.  Mikrovesikel  werden  sowohl  von  der 
Plasmamembran als auch nach der Verschmelzung von multivesikulären Endosomen mit der 
Plasma Membran (Exosomen) sezerniert. Die Freisetzung der Mikrovesikel ist das Resultat 
eines  sehr  komplexen  zellulären  Vorgangs,  der  unter  anderem  Veränderungen  in  dem 
Metabolismus sowohl von Lipiden als auch von Proteinen beinhaltet. 
Die biologischen Funktionen von freigesetzten MVs sind heutzutage noch nicht aufgeklärt 
worden.  Es  wurde  postuliert,  dass  MVs  wichtige  Modulatoren  für  die  Kommunikation 
zwischen Zellen sein könnten. MVs spielen auch eine Rolle in verschiedenen intrazellulären 
Adhäsionsprozessen und in der Induktion zellulärer Antworten. 
Es wurde schon gezeigt, dass mit Prionen infizierten Zellen PrP
Sc und Prionen-Infektiösität in 
Assoziation  mit  Exosomen  freisetzen.  Zusätzlich  hat  man  nachgewiesen,  dass  solche 
Exosomen  in  der  Lage  sind,  Prionenerkrankungen  sowohl  in  vitro  als  auch  in  vivo  zu 
übertragen.  Diese  Befunde  führten  zur  Hypothese,  dass  Vesikel  für  die  Übertragung  und 
Verbreitung von Prionen verantwortlich sein könnten. 
 
Zweites Ziel dieser Dissertation war, die Rolle von Plasmamembran-stammende Mikrovesikel 
in der Ausbreitung und Übertragung von Prionen festzustellen. Die Freisetzung von MVs 
wurde zuerst in verschiedenen neuronalen murinen Zelllinien untersucht. Es wurde für das 
erste Mal gezeigt, dass Neuronen, zusätzlich zur Exosomen, auch Mikrovesikel sezernieren. 
Immunoelektronenmikroskopische-  und  Immunoblot-Analysen  von  isolierten  MVs  haben 
eindeutig nachgewiesen, dass PrP
C einen Bestandteil von MVs ist. Die Charakterisierung von 
„lipid rafts“ Komponenten hat ergeben, dass in MVs das Gangliosid GM2, die Tyrosinkinase 
p59Fyn, flotillin-2 und das neuronale Protein GAP-43 vorhanden sind. Um die Involvierung 
von den MVs in der interzelluläre Übertragung von Prionen nachzuweisen, wurden MVs aus 
zwei unterschiedlichen stabil infizierten murinen neuronalen Zelllinien, die Neuro-2a PK1 
und  die  N2a  58,  isoliert  und  für  de  novo  in  vitro  und  in  vivo  Infektionsexperimenten 
verwendet. Immunoblot Analysen nach Proteinase K Behandlung haben gezeigt, dass PrP
Sc VIII 
mit  den  freigesetzten  MVs  assoziiert  ist.  Die  PrP
Sc-tragenden  MVs  wurden  in  den  daran 
folgenden Experimenten zur Infektion von uninfizierten Zellen angesetzt. Mittels „cell blot 
assay“, ein Verfahren dass den Nachweis von PrP
Sc-Amplifikation und -Akkumulierung in 
kultivierten Zellen ermöglicht, wurde der Verlauf der in vitro Prioneninfektion verfolgt. Man 
hat eindeutig gezeigt, dass PrP
Sc-tragenden MVs für die Übertragung von Prionen und für 
eine stabile Prioneninfektion in vitro der Empfängerzellen verantwortlich sind. Um die in vivo 
MV-bedingte Prionenübertragung zu untersuchen, wurden PrP
Sc-tragenden MVs und MVs 
gewonnen aus nicht infizierten Zellen (als negativ Kontrolle) in PrP
C überexprimierenden 
Mäusen (tga20) intrazerebral inokuliert. Die Entwicklung einer klinischen manifestierenden 
Prionerkrankung  wurde  in  diesem  „Bioassy”  zeitlich  verfolgt.  Ausschliesslich  Indikator 
Mäuse, die mit PrP
Sc-tragenden MVs inokuliert wurden, entwickelte die Erkrankung. Diese 
Ergebnisse zeigten eindeutig, dass MVs biologische Trägern von PrP
Sc und Infektiösität sind. 
MVs könnten deswegen in vivo in der Prozesse der interzellulären Prionen-Ausbreitung und -
Übertragung beteiligt sein. 1 
2 INTRODUCTION 
 
2.1 Transmissible Spongiform Encephalopathies (TSEs) 
 
The subacute transmissible spongiform encephalopathies (TSE), or prion diseases (Prusiner, 
1982a), are a complex group of fatal neurodegenerative diseases that occur in a wide variety 
of  mammal,  exemplified  by  scrapie  (Kimberlin,  1990;  Prusiner,  1982b;  Prusiner  and 
DeArmond, 1990) in animals and Creutzfeldt-Jakob disease in humans. These disorders can 
be distinguished in genetic, sporadic or infectious forms. The genetic form is dominantly 
inherited whereas the infectious form is acquired exogenously. When there is no source of 
exogenous infection or genetic aetiology, the cases are defined sporadic. The transmission of 
this kind of diseases to experimental animals led to the recognition of the unusual properties 
of  the  pathogenic  agent,  like  the  extremely  long  incubation  time  and  resistance  to  high 
temperatures, formaldehyde treatment and UV irradiation (Alper et al., 1966; Gordon, 1946; 
Pattison, 1965). The association of the infectivity with a protein led to designation “prion” 
(for proteinaceous infectious particle) to distinguish it from conventional pathogens such as 
bacteria and viruses or viroids (Prusiner, 1982a) according to the “protein only” hypothesis. 
The “protein only” hypothesis as proposed by Prusiner suggests that the infectious agent 
causing TSE, the prion, is devoid of nucleic acid and is identical  to  a posttranslationally 
modified form (PrP
Sc or an infectious subspecies PrP*) of a host protein (PrP
C), possibly 
differing only in its conformation from the latter (Cohen et al., 1994). Two different theories 
for the mechanism of PrP
Sc-induced PrP
Sc formation, the heterodimer or “refolding” model 
(Prusiner,  1991;  Prusiner  and  DeArmond,  1990)  and  the  “seeded  polymerization”  model 
(Come  et  al.,  1993;  Jarrett  and  Lansbury,  1993;  Lansbury  and  Caughey,  1995)  were 
presented.  
The “refolding” model proposes that upon infection of an appropriate host cell, the incoming 
infectious  agent  (PrP
Sc or PrP*) starts  a catalytic cascade using PrP
C or PrP
U, a partially 
unfolded intermediate arising from stochastic fluctuations in PrP
C conformations, as substrate, 
converting  it  upon  a  conformational  change  into  new  infectious  PrP,  which  in  turn  will 
convert more PrP
C into the infectious entity. The formation of PrP
C/PrP
U-PrP
Sc heteromeric 
complex may lower catalytically the activation energy barrier to the formation of new PrP
Sc 
from PrP
C/PrP
U, inducing a positive feedback and further recruitment of PrP (autocatalytic 
process). The extensive unfolding and refolding is believed to require chaperone activity and 
energy. 2 
The nucleated or “seed polymerisation” model proposes that the conformational change is 
thermodynamically controlled: the conversion process between PrP
C and PrP
Sc is reversible. 
Converted PrP
Sc is stabilised only when it adds onto a crystal-like seed or aggregate of PrP
Sc. 
Once a seed is present, further monomer addition may be accelerated. 
 
Recently, significant milestones in support of the prion hypothesis were achivied. For the first 
time the conversion of PrP
C to protease-resistant forms similar to PrP
Sc was reported in a cell-
free  system  composed  of  substantially  purified  constituents  (Kocisko  et  al.,  1994).  This 
conversion  was  selective  and  required  the  presence  of  preexisting  PrP
Sc,  providing  direct 
evidence that PrP
Sc derives from specific PrP
C-PrP
Sc interactions. Noteworthy, the generation 
of de novo infectious PrP
Sc in vitro was demonstrated by the use of independent experimental 
approaches (Castilla et al., 2005; Legname et al., 2002). Recombinant mouse prion protein 
produced in Escherichia coli was in vitro polymerized into amyloid fibrils that represent a 
subset of beta sheet-rich structures. Mice intracerebrally inoculated with fibrils consisting of 
recombinant PrP developed neurologic dysfunction typical for prion diseases (Legname et al., 
2004;  Legname  et  al.,  2005),  providing  compelling  evidence  that  prions  are  infectious 
proteins.  Additionally,  a  procedure  involving  cyclic  amplification  of  protein  misfolding 
(PMCA)  has  been  established  that allows a rapid  conversion of large  excess  PrP
C into a 
protease-resistant,  PrP
Sc-like  form  in  the  presence  of  minute  quantities  of  PrP
Sc  template 
(Saborio et al., 2001). In this procedure, conceptually analogous to polymerase chain reaction 
cycling, aggregates formed when PrP
Sc is incubated with PrP
C are disrupted by sonication to 
generate  multiple  smaller  units  for  the  continued  formation  of  new  PrP
Sc.  After  cyclic 
amplification, more than 97% of the protease-resistant PrP present in the sample corresponds 
to newly converted protein (Saborio et al., 2001). Interestingly, the in vitro-generated PrP
Sc-
like form share similar biochemical and structural properties with PrP
Sc derived from sick 
brains. Furthermore, the PMCA-produced PrP
Sc-like form was shown to be infectious in vivo 
(Castilla  et  al.,  2005).  These  data  provide  strong  evidence  in  support  of  the  protein-only 
hypothesis of prion transmission. 
 
Five human neurodegenerative diseases that are caused by prions had been described, namely 
Kuru,  Creutzfeldt-Jakob  disease  (CJD),  new  variant  CJD  (vCJD)  (Will  et  al.,  1996), 
Gerstmann-Sträussler-Scheinker  syndrome  (GSS)  (Gajdusek,  1977),  and  fatal  familial 
insomnia (FFI) (Medori et al., 1992). 3 
Kuru was an epidemic, slowly progressing neurodegenerative disease in the eastern highlands 
of  Papua  New  Guinea  in  the  first  decades  of  last  century.  It  was  hypothesised  that  its 
propagation occurred by ritual cannibalism and may have originated with the consumption of 
the remains of a sporadic CJD sufferer (Alper and Haig, 1968). 
Creutzfeldt-Jakob  disease  may  arise  spontaneously  (so-called  sporadic  form)  or  it  can  be 
familial  (so-called  inherited  form)  or  occur  in  acquired  form  (so-called  iatrogenic  form). 
Gerstmann-Sträussler-Scheinker syndrome and fatal familial insomnia arise only as familial 
diseases. All familial forms of CJD, GSS and FFI have been linked to mutations of the PRNP 
gene (Brown and Gajdusek, 1991; Brown et al., 1991a; Brown et al., 1991b; Brown et al., 
1992; Collinge et al., 1989; Doh-ura et al., 1989; Goldfarb et al., 1990; Goldfarb et al., 1991a; 
Goldfarb et al., 1991b; Haltia et al., 1991; Owen et al., 1990). Aetiology of sporadic cases can 
be  explained  by  somatic  mutations  of  PRNP,  the  human  form  of  the  PrP  gene,  while 
iatrogenic  CJD  is  transmitted  via  medical  treatment,  e.g.  by  the  use  of  contaminated 
neurosurgical instruments or treatment with drugs or tissues of human origin. The new form 
of CJD (vCJD) affecting unusually young people reveals a unique clinical and pathological 
pattern  (Chazot  et  al.,  1996;  Will  et  al.,  1996),  being  caused  by  the  consumption  of 
contaminated meet with BSE. BSE or bovine spongiform encephalopathy is one of at least six 
disorders  of  animals  which  are  included  in  the  ensemble  of  prion  diseases.  Like  the 
transmissible mink encephalopathy (Marsh and Hadlow, 1992), chronic wasting disease of 
captive mule deer and elk (Williams and Young, 1993), feline spongiform encephalopathy 
(Pearson et al., 1992; Wyatt et al., 1991), and exotic ungulate encephalopathy (Kirkwood et 
al.,  1990;  Wells  and  McGill,  1992),  BSE  (Hope  et  al.,  1989)  is  thought  to  result  from 
ingestion of scrapie-infected animal products (Wells, 1993; Wilesmith et al., 1992). Scrapie is 
a naturally occurring affliction of sheep and goats and it was the first prion disease described 
more than 250 years ago.  
However, it is considered equally possible that BSE originated as a sporadic case in cattle and 
was then spread by contaminated cattle offal (Weissmann, 1996). 
 
All human and animal TSEs show a characteristic electroencephalogram (EEG) (Court and 
Bert, 1995). The pathological lesions are found in the brain, in the medulla and in the spinal 
cord, and vary in location and intensity. In the brain, these include neuronal degeneration in 
the cerebral cortex, striatum, thalamus and cerebellum, followed by vacuolation of neurons, 
neuronal cell death and gliosis (singly or in combination) (DeArmond et al., 1993; Marsh and 
Kimberlin, 1975; Zlotnik and Rennie, 1965). Accumulation of PrP
Sc (DeArmond et al., 1985; 4 
Kitamoto et al., 1986; Kretzschmar et al., 1991; Prusiner et al., 1987; Wiley et al., 1987), a 
protease-resistant isoform of an endogenous protein (PrP
C), is a hallmark of TSEs. 
 
2.2 PrP-gene structure and expression 
 
The PrP gene, termed Prnp, consists of two exons in human (Basler et al., 1986; Puckett et al., 
1991) and of three exons in mice, hamster (or, differentially spliced, two) and sheep (Basler et 
al., 1986; Bueler et al., 1992; Goldman et al., 1993; Li and Bolton, 1997; Westaway et al., 
1994) (Fig. 1). In all species examined, the open reading frame (ORF) and the 3' untranslated 
mRNA region are entirely contained within the last exon. This exon has a size of about 2350 
bp in human (Kretzschmar et al., 1986b; Liao et al., 1986; Puckett et al., 1991), and 2000 bp 
in rodents (Basler et al., 1986; Locht et al., 1986; Oesch et al., 1985; Westaway et al., 1994; 
Westaway et al., 1987), whereas ruminants possess a much larger ORF-exon (about 4000 bp) 
(Goldmann et al., 1990). These differences reside within the 3' untranslated region of PrP 
mRNA, whereas all ORFs are of similar length (about 740 bp) (Goldmann et al., 1990) and 
encode  proteins  of  253  to  257  amino  acids  (Basler  et  al.,  1986;  Chesebro  et  al.,  1985; 
Kretzschmar et al., 1986b; Liao et al., 1986; Locht et al., 1986; Oesch et al., 1985; Prusiner, 
1986; Westaway and Prusiner, 1986). PrP promoter regions exhibit some characteristics of so-
called house-keeping genes. The major feature is the lack of typical regulatory elements found 
in most other genes. 
 
PrP
C is a glycosylphosphatidylinositol-anchored cell-surface protein mainly localized in “lipid 
rafts” (Gorodinsky and Harris, 1995; Sarnataro et al., 2002; Taraboulos et al., 1995; Vey et 
al.,  1996)  and  expressed  constitutively  in  both  neuronal  and  non-neuronal  cells,  with  the 
highest expression level found in neurons of the central nervous system (CNS) (Kretzschmar 
et al., 1986a; Moser et al., 1995). 
 
Figure 1. Schematic representation of the murine Prnp gene (drowing not in scale) 
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The primary sequence of PrP protein is highly conserved among mammals (identity ≥ 85%) 
(Chesebro et al., 1985; Kretzschmar et al., 1986b; Oesch et al., 1985; Westaway and Prusiner, 
1986)  (Fig.  2).  A  N-terminal  hydrophobic  signal  sequence  of  22  amino  acids  co-
translationally guides PrP through the membrane of the endoplasmatic reticulum and then is 
cleaved off to generate the N-terminus Lys-Lys-Arg- found in mature PrP protein (Bolton et 
al., 1987; Hay et al., 1987; Hope and Hunter, 1988; Hope et al., 1986; Turk et al., 1988). This 
is followed by a domain containing five octarepeats responsible for copper binding and two 
hexarepeats that are rich in proline and glycine (Bazan et al., 1987). A hydrophobic stretch is 
present between amino acids 113-135, which may, as demonstrated so far only in vitro, serve 
as transmembrane domain (Lopez et al., 1990;  Yost et al., 1990). A second hydrophobic 
stretch is present between amino acids 231-253, which can be regarded as the signal sequence 
for attachment of a glycosylphosphatidylinositol (GPI) moiety (Stahl et al., 1990a; Stahl et al., 
1987; Stahl et al., 1990b). 
    Modified from (Aguzzi and Heikenwalder, 2006) 
 
Figure 2.  Outline  of  the  primary  structure  of  the  cellular  prion  protein  including  post-
  translational modifications. 
 
The cellular prion protein consists of a flexible N-terminal and a C-terminal globular domain. A 
secretory signal peptide resides at the extreme N terminus. The numbers describe the position of the 
respective amino acids. OR (prurple) defines the copper binding octarepeats. CC (orange) defines the 
charged cluster. HC (red) defines the “hydrophobic core”. S-S indicates the single disulfide bridge. 
The protein is post-translationally modified by addition of two glycosylations (CHO) as well as of a 
glycosylphosphatidylinositol (GPI) membrane anchor (MA, membrane anchor region) The proteinase 
K (PK) resistant core of PrP
Sc is depicted in gold and the approximate cutting site of PK within PrP
Sc 
is indicated by the lightening symbol. 
 
Purification  of  a  C-terminal  domain  of  the  mouse  PrP  (mPrP(121-231))  allowed  the 
determination  of  the  three-dimensional  structure  by  NMR  (Hornemann  and  Glockshuber, 
1996; Riek et al., 1996). This PrP fragment showed an overall globular shape with two short 
antiparallel -pleated sheets (residue 128-131 and 161-164) and three -helices (residue 144-
154,  179-193  and  200-217).  Meanwhile  the  three-dimensional  structure  of  the  full-length 
protein  as  determined  by  NMR  revealed  closed  similarities  between  different  species 6 
(Calzolai et al., 2005; Hornemann et al., 1997; Lopez Garcia et al., 2000; Lysek et al., 2005; 
Riek et al., 1997; Zahn et al., 2000). 
 
The  PrP  polypeptide  begins  its  metabolic  cycle  in  the  endoplasmic  reticulum  where  the 
glycosylphosphatidylinositol (GPI) moiety and high mannose glycans are attached and both 
signal sequences (the 22 N-terminal and the 23 C-terminal amino acids peptides) are cleaved 
off.  In  the  Golgi  apparatus  maturation  of  the  Asn-linked  glycans  (residues  181  and  197) 
occurs (Bolton et al., 1985; Caughey et al., 1989; Endo et al., 1989; Haraguchi et al., 1989; 
Turk et al., 1988). The mature PrP
C is then presumably transported within secretory vesicles 
to the external cell surface where it is anchored by the GPI-anchor. Like other GPI-proteins, 
most of PrP
C is found in detergent-resistant microdomains of the plasma membrane (Harmey 
et al., 1995; Naslavsky et al., 1997; Taraboulos et al., 1995). 
 
    From (Aguzzi and Heikenwalder, 2006) 
 
Figure 3. Structural features of the cellular prion protein 
Tertiary structure of the cellular prion protein inserted into a lipid bilayer, as deduced from NMR 
spectroscopy,  including  the  “unstructured”  N-terminal  tail  (grey)  and  the  glycosyl  phosphatidyl 
inositol (GPI) anchor. The globular C-terminal domain contains a two stranded anti-parallel beta-sheet 
and three alpha-helices. The loop connecting the second β-sheet and the third α-helix is indicated by 
the black arrow. OR, octarepeat region. 
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2.3 Normal cellular function of PrP 
 
In  the  last  years,  several  putative  cellular  functions  have  been  attributed  to  PrP
C:  its 
localization in “lipid rafts” is consistent with a possible role in cell adhesion, transmembrane 
signalling or as a recognition molecule.  
As PrP
C protein ligands, the anti-apoptotic molecule Bcl-2 (Kurschner and Morgan, 1995; 
Kurschner and Morgan, 1996), the chaperone Hsp60 (Edenhofer et al., 1996), the 37 kDa 
laminin receptor precursor LRP  (Rieger et al., 1997), as well as synapsin  Ib, the adaptor 
protein Grb2 and the unknown protein Pint 1 (prion interactor 1) (Spielhaupter and Schatzl, 
2001) were identified. 
The PrP
C interacting protein synapsin I is associated with small synaptic vesicles and both 
synapsin I and Grb2 copurify with PrP
C in neuronal microsomal vesicles (Spielhaupter and 
Schatzl, 2001). This would suggest a role for PrP
C in the recycling of the vesicles or a more 
direct role in synaptic activity (Herms et al., 1999). Electrophysiological studies on Prnp
o/o 
mice generated by Büeler et al. (Bueler et al., 1992) showed weakened GABAA (gamma-
aminobutyric  acid  type  A)  receptor-mediated  fast  inhibition  and  impaired  long-term 
potentiation in the hippocampus, which could be both complemented by reintroduction of 
high copy numbers of the mouse or human PrP gene into PrP null mice (Collinge et al., 1994; 
Whittington  et  al.,  1995).  However,  no  electrophysiological  abnormalities  were  found  by 
others in the same line (Herms et al., 1995; Lledo et al., 1996). Interestingly, Prnp
o/o mice 
generated by Manson et al. (Manson et al., 1994) showed short term rather than long term 
potentiation in the CA1 region of the hippocampus. Furthermore, both PrP knock-out mouse 
lines showed an alteration in both circadian activity rhythm and sleep, suggesting that PrP 
might be involved in the regulation of circadian motor activity and in the maintenance of 
sleep continuity and regulation (Tobler et al., 1997; Tobler et al., 1996).  
It was shown that primary neurons isolated from Prnp
o/o mice are less resistant to serum 
deprivation  than  their  PrP
C  expressing  counterparts,  but  this  hypersensitivity  could  be 
counteracted by the overexpression of Bcl-2 (Kuwahara et al., 1999). Moreover, PrP
C could 
protect  human  primary  neurons  against  Bax-mediated  cell  death  to  levels  equal  to  the 
neuroprotective  function  of  Bcl-2  (Bounhar  et  al.,  2001).  This  neuroprotective  function 
requires the presence of the octapeptide repeats of PrP
C. Other data demonstrated that when 
overexpressed, PrP
C  sensitizes  cultured cells  to  staurosporine-induced death  and increases 
caspase 3 activity, an enzyme involved in the apoptotic cascade (Paitel et al., 2002). A similar 
toxicity was shown by the accumulation of cytosolic PrP
C due to proteasome dysfunction (Ma 
et al., 2002). 8 
The fact that mice devoid of PrP
C harbour 50% lower copper concentrations in synaptosomal 
fractions than their PrP
C expressing counterparts suggests that PrP
C could regulate the copper 
concentration in the synaptic region of the neuron (Kretzschmar, 1999). It is known that PrP
C 
is a metal ion-binding protein and binds copper via histidines of the N-terminal region. The 
N-terminal part of the prion protein harbours high structural flexibility and is involved in the 
binding of PrP
C to a number of ligands. Therefore copper binding could influence the binding 
of PrP
C to other proteins. For example, it has been shown that PrP
C binds to the laminin 
receptor via two binding sites, one of them being located in the N-terminal octarepeat domain 
of PrP
C (Hundt et al., 2001). Otherwise, PrP
C could mediate the transport of copper from the 
extra- to the intracellular compartment. 
Another feature attributed to the prion protein is that of the activity as copper/zinc-dependent 
superoxide dismutase (SOD1), which endows PrP
C with antioxidant activity (Brown et al., 
1999a). 
 
It has been shown, that through interaction with stress-inducible protein 1 (STI1), a membrane 
66  kDa  protein,  PrP
C  can  induce  neuroprotective  signals  that  rescue  cells  from  apoptosis 
(Zanata et al., 2002). Moreover, recombinant STI1 added to hippocampal cultures interacts 
with PrP
C at the neuronal surface and elicits neuritogenesis in wild-type neurons but not in 
PrP
C- null cells (Lopes et al., 2005). 
Recently, it has been shown that PrP
C interacts with the neuronal cell adhesion molecule 
NCAM as well as with the extracellular matrix glycoprotein laminin, the 67-kDa high affinity 
laminin receptor and the 37-kDa laminin receptor precursor implying a potential role of PrP
C 
in neuronal differentiation, neurite outgrowth and neuronal survival. It has been proposed that 
interaction of PrP
C with NCAM at the neuronal cell surface of hippocampal neurons induces 
activation  of  p59fyn  kinase  promoting  neurite  outgrowth  (Santuccione  et  al.,  2005). 
Nevertheless the effect of PrP
C on neuronal differentiation is currently unclear.  
 
2.4 Neurotoxic effects of PrP32-134 
 
Common to all knockout mice is resistance to scrapie and inability to propagate the scrapie 
agent,  or  prion,  as  predicted  by  the  “protein  only”  hypothesis.  In  the  past,  in  order  to 
understand the structure-activity relationship of PrP regarding its capacity to support scrapie 
pathogenesis  and  prion  propagation,  different  recombinant  PrP  genes  with  a  series  of 
deletions were expressed into a knockout background. In that study, it was shown that PrP 9 
lacking residues 32-121 or 32-134, but not with shorter deletions, caused severe ataxia and 
neuronal death limited to the granular layer of the cerebellum as early as 1-3 months after 
birth (Shmerling et al., 1998). The investigators demonstrated the complete abolishment of the 
defect after having introduced one copy of a wild-type PrP gene. 
 
2.5 Peripheral prion pathogenesis 
 
As  mentioned  previously,  TSEs  can  occur  in  genetic,  sporadic  or  infectious  forms.  The 
infectious form is acquired exogenously and is represented by vCJD, kuru, iatrogenic CJD in 
humans  and  BSE  in  animals.  In  some  of  these  disorders,  a  process  called  peripheral 
pathogenesis precedes the pathology found in the CNS. The most relevant routes followed by 
the infectious agent to entry the host organism are the oral one and the experimentally related 
i.p. injection. In the case of oral transmission, prions have to cross an epithelial barrier present 
in  the gastroenteric tract  in  order to  reach the  mucosa-associated lymphoid  tissue system 
(MALT). It was suggested that the membranous epithelial cells (M cells) could play a role in 
this process by performing the transepithelial transfer of orally consumed prion infectivity 
(Heppner et al., 2001). Otherwise, the migratory bone marrow-derived dendritic cells (DCs) 
could migrate from the blood vessel compartment to the inner surface of the intestinal wall 
and  trapping  prions  in  the  enteric  tube.  Subsequently  the  infectious  agents  could  be 
transported to the local lymphoreticular system (LRS) including mesenteric lymph nodes and 
probably more distant sites (Huang et al., 2002). 
Of note is the possibility for prions to get into direct contact with the lymphoreticular system 
at the site of the palatine tonsils, thereby perhaps bypassing the intestinal pathway. Supporting 
this hypothesis is the finding of PrP
Sc in tonsils biopsies of patients with vCJD (Hill et al., 
1999).  After  oral  challenge,  prion  infectivity  usually  colonizes  the  lymphoreticular  tissue 
early in the incubation period. It was shown that many sites of the LRS including spleen, 
Peyer`s patches, lymph nodes and tonsillar tissue are involved in PrP
Sc replication (Eklund et 
al.,  1967;  Fraser  and  Dickinson,  1970;  Fraser  and  Dickinson,  1978;  Hill  et  al.,  1997; 
Kimberlin and Walker, 1979; Mould et al., 1970), after both intracerebral and intraperitoneal 
inoculation. The nature of the cells that support prion replication within the lymphoreticular 
system is still uncertain. It seems that besides FDCs (Mabbott et al., 2000; McBride et al., 
1992; Montrasio et al., 2000), other cells of the immune system could be involved. 
Another issue highlighted by the work of Blattler and colleagues (Blattler et al., 1997) is how 
the infectious agent transfers from the lymphoreticular system to the central nervous system. 10 
They reported that transplantation of PrP-positive hematopoietic cells into PrP
0/0 mice sufficed 
to  support  prion  propagation  in  the  spleen  after  i.p.  inoculation,  but  failed  to  induce 
spongiform encephalopathy in PrP-producing neurografts implanted into the brains of these 
mice,  indicating  that  a  further  PrP-expressing  tissue  compartment,  such  as  the  peripheral 
nervous system (PNS), is necessary for neuroinvasion of prions. 
The transport of prions to the PNS as well as from the CNS to the periphery (Koperek et al., 
2002) could be performed by two kind of mobile cells, namely macrophages (Prinz et al., 
2002)  and  DCs  (Huang  et  al.,  2002).  Other  studies  revealed  a  supportive  role  of  the 
complement system in the early phase of peripheral prion pathogenesis. The results obtained 
suggested that opsonization of the infective agent with C3d/C4b facilitated transport to and 
uptake of infectivity by the LRS (Klein et al., 2001; Mabbott et al., 2001). 
The  PNS  represents  the  second  system  (apart  from  the  immune  system)  necessary  for 
peripheral  prion  pathogenesis  (Blattler  et  al.,  1997)  and  it  bridges  the  gap  between  the 
periphery and the CNS. To some degree it could also be involved in the replication and 
accumulation of infectivity  (Glatzel  et  al., 2001). A  group documented granules of PrP
Sc 
within axons, so that intra-axonal transport of prions might be important for their spread not 
only in the CNS, but also in the PNS (Kovacs et al., 2004). 
 
2.6 Prion transmission 
 
As mentioned above, different cell types, including immune cells, contribute to the replication 
and transfer of infectious prions from peripheral sites of replication to the brain (Glatzel and 
Aguzzi,  2000a).  The  mechanisms  underlying  this  intercellular  transfer  are  not  elucidated 
(Harris, 1999b), but close cell contact may be involved (Kanu et al., 2002). Nevertheless, cell-
free conversion data (Baron et al., 2002) indicate that additional pathways involving in non-
cell-associated forms of infectious agent may participate in the propagation of prions. It has 
been already demonstrated that the culture medium of infected cells is infectious (Schatzl et 
al., 1997) suggesting that PrP
Sc may be released from cells. PrP
C could be released at the same 
manner from uninfected cells (Liu et al., 2002). It has been reported that both PrP
C and PrP
Sc 
can be present in the culture medium in a non-cell-associated form and they were both found 
associated with exosomes, secreted intralumenal contents of multivesicular bodies (MVB) 
(Fevrier et al., 2004). More recently, others have reported that platelets activation led to the 
transient  expression  of  PrP
C  on  the  platelet  surface  and  its  subsequent  release  on  both 
microvesicles and exosomes. The presence of PrP
C on platelet-derived exosomes suggests a 11 
possible mechanism for PrP
C transport in blood and for cell-to-cell transmission (Robertson et 
al., 2006). 
 
2.7 Outline of the work described in this thesis 
 
2.7.1 Role of PrP
C in neuronal differentiation 
 
Accumulation within the brain of infected animals of an abnormal, protease-resistant, prion 
protein, PrP
Sc, is a hallmark of scrapie and other related neurodegenerative diseases. Despite 
the considerable attention for its involvement in transmissible spongiform encephalopathies, 
the physiological role of the cellular, nonpathogenic isoform of PrP, termed PrP
C, has not yet 
been determined. Among the several functions attributed to PrP
C as a cell surface molecule, 
an involvement in neurite outgrowth has been proposed through its interaction with NCAM at 
the neuronal cell surface of hippocampal neurons (Santuccione et al., 2005). However, both 
the  PrP
C-mediated  effects  and  the  role  of  PrP
C-dependent  pathways  on  neuronal 
differentiation are still not elucidated. 
 
The aim of this work was to address the role of the cellular prion protein in the process of 
neuronal fate specification and neurite outgrowth by establishing a novel in vitro model as 
well as to identify the domain of PrP
C responsible for such activities. 
A novel PrP
C-depleted cell line (PrP
0/0 ML) was derived from murine primary PrP-knockout 
neuronal cells by SV40 large T antigen-mediated immortalization. This cell line was then 
characterised for its growth potential, for the expression of specific cellular markers and for 
its ability to differentiate. It was found that, under culture conditions promoting the expression 
of  the  temperature-sensitive  SV40  large  T  antigen,  the  cells  expressed  nestin,  a  specific 
marker of neuronal precursor cells. Therefore, the PrP
0/0 ML cell line was identified as a 
potential neuronal stem cell line. In fact, under nonpermissive culture conditions when the 
expression of the temperature-sensitive SV40 large T antigen is downregulated, the PrP
0/0 ML 
cells differentiated into neurons. 
In order to investigate the role of PrP
C in the process of neuronal differentiation, the PrP
0/0 
ML cells were then reconstituted for the expression of either  the full-length PrP or a N-
terminal truncated PrP
C form (PrP32-134), which cause severe ataxia and neuronal death 
limited to the granular layer of the cerebellum and to Purkinje cells when expressed in vivo on 
a PrP-knockout background (Shmerling et al., 1998). The differentiation potential of both 
reconstituted cell lines under nonpermissive culture conditions was then compared with that 12 
of the parenteral PrP
0/0 ML cells. This in vitro study clearly highlights that PrP
C expression in 
the PrP
0/0 ML cell line accelerates neuronal differentiation and that the N-terminal domain of 
the prion protein is not necessary for this PrP-mediated function.  
 
2.7.2 Plasma membrane released microvesicles as carriers of infectious prions 
 
Like  other  GPI-anchored  proteins,  PrP
C  as  well  as  PrP
Sc  localize  in  glycosphingolipid-
enriched microdomains  (or lipid  rafts) of neural  and lymphocytic plasma membrane. The 
association of PrP
C with lipid rafts is required for its conversion to PrP
Sc. Particulary enriched 
in  lipid  rafts  are  microvesicles  (MVs)  which  are  released  during  membrane  blebbing  of 
normal  healthy  or  damaged  cells.  Microvesicles  are  100  nm-1  m  in  size  and  contain 
numerous proteins and lipids similar to those present in the membranes of the cells from 
which they originate but  they may  also  contain proteins  derived  from  the cytoplasm  and 
mRNA. 
Microvesicles can also originate from the endosomal membrane compartment after fusion of 
secretory granules with the plasma membrane: in this case exosomes are formed which are 
more  homogenous  in  size  (30-100  nm)  as  compared  to  the  plasma  membrane-derived 
microvesicles.  It  has  previously  been shown that  both  PrP
C  and PrP
Sc are present  in  cell 
culture supernatants in a secreted, exosome-associated form and that exosomes bearing PrP
Sc 
are infectious in vivo and in vitro. These findings suggest that PrP
Sc-bearing exosomes may 
provide a mechanism for intercellular transmission of infectious prions in addition to cell-to-
cell contact. 
 
Second objective of this Ph.D thesis was to determine the possible role of plasma membrane-
derived microvesicles in the propagation and transmission of prions and in the mechanism(s) 
of PrP
C paracrine diffusion. The release of MVs was first studied in different murine neuronal 
cell lines. Here it is shown for the first time that neurons shed plasma membrane derived 
MVs, in addition to exosomes. 
Immunoelectron microscopy and immunoblot analyses clearly demonstrated the presence of 
PrP
C on the membrane of MVs released from PrP
C-expressing cells. Characterization of lipid 
rafts  components  in  MVs  highlighted  the  presence  of  the  ganglioside  GM2,  the  tyrosine 
kinase p59Fyn, flotillin-2 and the neuronal protein GAP-43. 
In order to investigate whether MVs are involved in the intercellular transmission of prions, 
MVs were first isolated from two prion infected murine neuronal cell lines and then used for 
in  vitro  and  in  vivo  infection  assays.  Immunoblot  analyses  after  proteinase  K  treatment 13 
demonstrated the association of PrP
Sc with the secreted MVs. The PrP
Sc-bearing MVs were 
then  used  to  perform  infection  experiments  on noninfected  cells  and  the  kinetic  of  prion 
infection in the de novo infected cells was followed. Noteworthy, it was found that PrP
Sc-
bearing MVs were capable to transmit prions in vitro and to stably infect the recipient cells. In 
vivo bioassays clearly demonstrated that PrP
Sc-bearing MVs were capable of eliciting a fatal 
prion disease in recipient indicator mice. These findings clearly demonstrated that MVs are 
biological carriers of both PrP
Sc and prion infectivity. MVs could therefore participate in vivo 
in the processes of intercellular prion transmission and propagation. 
 
The establishment of a novel in vitro prion replication system for murine prions was also 
achieved  by  the  use  of  one  of  the  clonal  cell  lines  previously  reconstituted  for  PrP
C 
expression. This finding indicates that reconstitution of homologous or heterologous prion 
protein expression in PrP-depleted cell lines is a powerful approach to develop novel in vitro 
prion replication models. 14 
3 MATERIALS AND METHODS 
 
3.1 Cell culture 
 
3.1.1 Reagents 
 
Amphotericin B  Sigma, Munich, Germany 
Antibiotic-Antimycotic  Sigma, Munich, Germany 
B27 Supplement  Gibco BRL, Eggstein, Germany 
BDNF (brain-derived neurotrophic factor)   R&D, Wiesbaden, Germany 
bFGF (basic fibroblast growth factor)  Invitrogen, Eggstein, Germany 
CMF-PBS (calcium- and magnesium-free PBS)  Gibco BRL, Eggstein, Germany 
Dulbecco´s Modified Eagle Medium (DMEM)  Sigma, Munich, Germany 
Dimethylsulfoxid (DMSO)  Sigma, Munich, Germany 
DNase  Sigma, Munich, Germany 
EDTA 0.5 mM  Sigma, Munich, Germany 
Fetal calf serum (FCS)  Gibco BRL, Eggstein, Germany 
Ham´s F12 nutrient  Sigma, Munich, Germany 
Hank´s balanced salt solution  Sigma, Munich, Germany 
L-glutamine  Sigma, Munich, Germany 
Neurobasal Medium (NB)  Gibco BRL, Eggstein, Germany 
N2 Supplement  Gibco BRL, Eggstein, Germany 
Opti-MEM  Invitrogen, Eggstein, Germany 
Penicillin-Streptomycin  Sigma, Munich, Germany 
Polybrene  Sigma, Munich, Germany 
Trypan blue  Sigma, Munich, Germany 
Trypsin  Sigma, Munich, Germany 
 
3.1.2 Media and buffers 
 
Dulbecco´s Modified Eagle Medium (DMEM) was supplemented with 10% fetal calf serum 
(FCS), 4 mM L-Glutamin and antibiotics (20.000 U/ml penicillin, 20 mg/ml streptomycin and 
25 ug/ml Amphotericin B). 
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Serum-free medium (SFM) was prepared by mixing 250 ml DMEM and 250 ml Ham´s F12 
nutrient  and  supplemented  with  1%  N2  Supplement,  1%  FCS  ,  4  mM  L-Glutamine  and 
antibiotics (20.000 U/ml penicillin, 20 mg/ml streptomycin and 25 ug/ml Amphotericin B). 
 
Neurobasal Medium (NB) supplemented with B27 (50x, 10mlGibco) 
 
Opti-MEM  was  supplemented  with  4  mM  L-Glutamine  only.  Neither  antibiotics  nor 
fungicides were added. 
 
Opti-MEM with 4 mM L-Glutamine was supplemented with 10% fetal calf serum (FCS) and 
antibiotics (20.000 U/ml penicillin, 20 mg/ml streptomycin). 
 
CMF-PBS (PBS w/o Ca
2+/Mg
2+): 120 mM NaCl, 17 mM Na2HPO4, 3 mM KH2PO4, pH 7.2 
 
Trypsin-EDTA: 0.05% (w/v) Trypsin, 0.5 mM EDTA in CMF-PBS  
 
All media and buffers were sterilised by filtration (0.2 um) 
 
3.1.3 Cell lines 
 
3.1.3.1 Generation and maintenance of the PrP
0/0 ML cell line 
 
Prnp
0/0 Zurich  I  cerebella  (Bueler et  al.,  1992)  were dissected into ice-cold calcium- and 
magnesium-free PBS (CMF-PBS). Meninges were removed and the tissue was minced in 
small pieces. Cerebella were digested with 1% trypsin for 3 minutes at room temperature. 
Trypsin was replaced with 0.05% DNase and tissue was triturated with fire-polished Pasteur 
pipettes. Cells were centrifuged and resuspended in CMF-PBS. Supernatant was removed, 
cells were resuspended in Neurobasal medium supplemented with B27 and plated on 35 mm 
Petri dishes at a density of 2 x 105 cells/dish. Twenty-four hours after plating, cells were 
infected with a retrovirus vector carrying the temperature-sensitive SV40 large T antigen in 8 
ug/ml polybrene for 2 hours at 37°C, as previously described (Jat and Sharp, 1989). After 
infection, the virus-containing medium was replaced with fresh medium consisting of DMEM 
supplemented with 10% FCS. Heterogeneous PrP
0/0 cell populations were then cultivated in 
DMEM, 10% FCS, 4 mM L-glutamine, 200 U/ml Penicillin, 0,2 mg/ml Streptomycin and 16 
0,25 μg/ml Amphotericin B and immortalized cells were selected by their capability to grow 
at the permissive temperature of 33°C. The PrP
0/0 ML cell line was isolated from one of these 
heterogeneous preparations by limiting dilution; it was expanded and frozen down in large 
stocks of vials. Each experiment was performed by thawing a new vial of cells propagated for 
limited time. 
To induce differentiation, cells were shifted at the nonpermissive temperature of 39°C under 
low serum concentration (Serum Free Medium (SFM): DMEM:Ham´s F12 Medium in a ratio 
1:1  supplemented  with  1%  N2  Supplement,  1%  FCS,  4  mM  L-glutamine,  200  U/ml 
Penicillin, 0,2 mg/ml Streptomycin and 0,25 μg/ml Amphotericin B). 
 
3.1.3.2 Maintenance of N2a cells  
 
Murine Neuro-2a cells (American Type Culture Collection ATCC CCL 131) were maintained 
in  DMEM  supplemented  with  10%  FCS,  4  mM  L-Glutamin  and  antibiotics  (200  U/ml 
penicillin  and  0,2  mg/ml  streptomycin).  The  cell  lines  were  maintained  at  37°  C  in  a 
humidified 5% CO2 atmosphere. 
 
3.1.3.3 Maintenance of Neuro-2a PK1 cells  
 
Murine Neuro-2a PK1 cells and Rocky Mountain Laboratory strain (RML)-infected Neuro-2a 
PK1 cells (Klohn et al., 2003) were maintained in Opti-MEM supplemented with 10% FCS, 4 
mM L-Glutamin and antibiotics (200 U/ml penicillin and 0,2 mg/ml streptomycin). The cell 
lines were maintained at 37° C in a humidified 5% CO2 atmosphere. 
 
3.1.3.4 Maintenance of N2a58/22L cells 
 
Murine  Neuro-2a58  cells  infected  with  the  prion  strain  22L  (N2a58/22L)  (Nishida  et  al., 
2000) were maintained in Opti-MEM supplemented with 10% FCS, 4 mM L-Glutamin and 
antibiotics (200 U/ml penicillin and 0,2 mg/ml streptomycin). The cells were maintained at 
37° C in a humidified 5% CO2 atmosphere. 
 
3.1.4 Thawing procedure 
 
Cells  were  thawed  in  a  water  bath  at  37°C.  After  being  gently  resuspended,  cells  were 
immediately transferred to a T75-flask in complete DMEM medium. To reduce the cytotoxic 17 
effect of DMSO the medium was replaced with fresh DMEM or Opti-MEM after 20 hours of 
cultivation. 
 
3.1.5 Splitting cells 
 
PrP
0/0 precursor cells were cultivated at 33°C, 5% CO2 in 95% humidity (Heraeus incubator, 
Hanau, Germany). By a 80% - 90% confluency, cultures were split as follows: the medium 
was removed, the monolayers were washed with CMF-PBS and the cells were detached by 
trypsin/EDTA  (0.5  mM  EDTA,  0.05  %  trypsin  in  CMF-PBS)  for  3  minutes  at  33°C. 
Complete medium was then added to neutralize Trypsin/EDTA. Cells were then resuspended 
by  pipetting  up  and  down  several  times,  avoiding  excessive  foaming.  One  fifth  of  the 
suspension was transferred into a new T75-fask or T25-flask. Cells were split twice a week. 
 
Neuro2-a  PK1  and  N2a58/22L  cells  were  cultivated  at  37°C,  5%  CO2  in  95%  humidity 
(Heraeus  incubator,  Hanau,  Germany).  The  cells  were  grown  in  Opti-MEM  and  split  as 
above.  
 
3.1.6 Freezing procedure 
 
Cells were washed once with CMF-PBS, trypsinised and resuspended in DMEM or Opti-
MEM.  Afterwards,  cells  were  transferred  into  a  15  ml  Falcon  tube  and  then  centrifuged 
(Haraeus, Hanau, Germany, 1100 rpm for 5 minutes at 4°C). The pellet was resuspended in 
freezing medium (90% FCS, 10% DMSO) (approximately 1.5 x 10
6 cells/ml). Cells were 
frozen at -80°C for one day, and then transferred to liquid nitrogen. 
 
3.1.7 Subcloning (limited dilution) of PrP
0/0 cells (heterogeneous population) 
 
Several  96-wells  plates  were  prepared  by  adding  100  l  of  complete  DMEM  medium 
containing 10ng/ml bFGF and incubating them at 33°C for 30 min in order to prevent a pH-
shift in the wells during pipetting (“buffering”). 80% confluent T75-fläsks were treated with 
trypsin as usually to detach the cells. The cells were then resuspended in 10 ml of complete 
DMEM  medium  and  counted.  The  cell  suspension  was  serially  diluted  performing  1:10 
dilution steps to achieve a final cell concentration of either 1 cell/300 l or 1 cell/100 l. To 
each well of a 96 well-plate 100 l of each cell suspension were added.  
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3.1.8 Proliferation Assay 
 
The cells were seeded at a density of 6 X 10
4 cells into each well of a six-well plate and 
incubated in DMEM/10% FCS or in SFM at the appropriate temperature. Cells growth was 
monitored at different time points by counting the number of live cells by Coulter Counter 
(Z1 Coulter
® Particle Counter, Beckman Coulter™) 
 
3.1.9 Stable transfection of PrP
0/0 ML cell line 
 
Transfection of PrP
0/0 ML cells was performed using the FuGENE 6 Transfection Reagent Kit 
(Roche, Mannheim, Germany). This lipofection method is based on a complex formation 
between a multi-component reagent and the plasmid DNA, followed by transportation into 
animal cells. 
 
1.4 x 10
6 cells were seeded into each 10 cm petri dish 24 hours before transfection. After 
cultivation overnight, the cell monolayer was 50% confluent. The complete DMEM medium 
was replaced with 10 ml of serum-free medium Opti-MEM (w/o antibiotics). 
The transfection mix was prepared by adding 72 µl FuGENE 6 Transfection Reagent to 728 
µl serum-free medium Opti-MEM (w/o antibiotics), followed by an incubation of 5 minutes at 
RT.  Thereafter,  24  µg  DNA  was  added  to  the  transfection  mix  (ratio  of  FuGENE  6 
Transfection Reagent [µl] to DNA [µg] was 3:1), and the mixture was again incubated for 20 
minutes at RT. The DNA-Reagent solution was then added in a drop-wise manner to the cells. 
After 6 hours incubation at 33°C, FCS was added to a final concentration of 10%. The next 
day, Opti-MEM medium was removed, the cells were washed with CMF-PBS and complete 
DMEM was added. 
In order to select for transfected cells, 48 hours post-transfection the medium was replaced 
with fresh complete medium containing 2 g/ml puromycin. 
48 hours after selection start, bFGF in a concentration of 10 ng/ml was added to improve the 
growth potential of the cells. 
 
3.1.9.1 Isolation of single cell-derived clones 
 
Two  weeks  post-transfection  visible  clones  were  present  on  the  plate.  The  medium  was 
replaced with 10 ml CMF-PBS and the clones were isolated by using a 10l pipette. 19 
The isolated clones were then transferred into 96-wells previously incubated at 33°C for 30 
minutes with 150 l complete medium containing 1 g/ml puromycin and 10 ng/ml bFGF. 
The growing clones were further expanded in DMEM complete medium containing 1 g/ml 
puromycin. 
 
3.1.10 Isolation of microvesicles 
 
Cells  (2-4x10
7  cells)  were  cultured  for  2-3  days  prior  to  MVs  isolation  by  sequential 
centrifugation protocol  (adapted from  Baj-Krzyworzeka et  al.,  2002;  Raposo  et  al.,  1996; 
Thery et al., 2001). Cellular debris was removed by two consecutive centrifugation steps at 
4500x g for 5 min at RT. Supernatants were centrifuged at 20000x g for 1 h at 4°C. MVs were 
pooled, washed in either CMF-PBS or Opti-MEM, repelleted and then either resuspended in 
Opti-MEM for in vitro or in CMF-PBS for in vivo infection experiments or lysed [20 mM 
Tris-HCl  (pH  7,5),  1  mM  EDTA,  100  mM  NaCl,  1%  Triton  X-100,  0,5%  sodium 
deoxycholate, 0,5% SDS] for immunoblot analyses. Exosomes were then enriched from the 
20000x g supernatants by a 100000x g ultracentrifugation for 1 h at 4°C. Exosomes were 
pooled, washed in CMF-PBS, repelleted and then lysed in lysis buffer (see above). 
 
3.1.11 Infection of cells with microvesicles and brain homogenates 
 
The day before infection, cells were seeded in two wells of  a six-well plate so that they 
reached 70% confluency in 24 hours. For infection, either MVs isolated from Neuro-2a PK1 
infected cells (MVs
Inf) or those isolated from N2a58/22L cells (MVs
22L) or 1% of scrapie-
brain homogenate (Chandler) were used as inoculum. Briefly, cells were at first washed with 
CMF-PBS and then overlaid either with 0,5 ml medium + 0,5 ml resuspended MVs or with 1 
ml  brain  homogenate.  As  negative  controls,  samples  incubated  with  MVs  derived  from 
Neuro-2a  PK1  noninfected  cells  (MVs
Noninf)  and  those  incubated  with  wild-type  brain 
homogenate were included. When cells reached confluency (about 24-48 hours p.i), the twin 
wells were pooled and transfer into a T75-fläsk. Cells were then passaged as usual and at each 
passage a cell blot assay (see below) was performed to test for infectivity. 
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3.2 Molecular and biochemical analysis 
 
3.2.1 Reagents 
 
Agarose  Invitrogen life technologies, Karlsruhe, Germany 
Ampicillin  Serva, Heidelberg, Germany 
Guanidinium thiocyanate   Roth, Karlsruhe, Germany 
HRP-conjugated cholera toxin,  
B subunit (HRP-CTxB)  Sigma, Munich, Germany 
Proteinase K  Roche Diagnostics NL, Germany 
PMSF (Protease Inhibitor)  Roche Diagnostics NL, Germany 
Roti-Quant  Roth, Karlsruhe, Germany 
Tween-20  Sigma, Munich, Germany 
Yeast extract  Invitrogen life technologies, Karlsruhe, Germany 
 
All other chemicals were purchased from Merck (Darmstadt, Germany) 
 
3.2.2 Media and buffers 
 
3.2.2.1 General buffers 
 
Guanidinium thiocyanate: 3 M guanidinium thiocyanate, 10 mM Tris-Cl (pH 8.0) 
 
Lysis buffer I: 50 mM Tris-Cl, pH 8.0; 150 mM NaCl; 0.5% sodium deoxycholate; 0,5% 
Triton X-100 
 
Lysis buffer II: 20 mM Tris-HCl (pH 7,5), 1mM EDTA, 100mM NaCl, 1% Triton X-100, 
0,5% sodium deoxycholate, 0,5% SDS, 1mM Na-Vanadate, 1mM Na-Molybdate, 20 mM 
NaF,  10mM  Na-phyrophosphat,  20mM  ß-Glycerophosphat  and  one  complete  protease 
inhibitor tablet (Roche) 
 
CMF-PBS (PBS w/o Ca
2+/Mg
2+): 120 mM NaCl, 17 mM Na2HPO4, 3 mM KH2PO4. The pH 
value was adjusted to 7.2 
 
TBST: 20 mM Tris-HCL, 500 mM NaCl, 0.1% Tween-20. The pH value was adjusted to 7.5 
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1x TAE: 40 mM Tris-Acetat, 2 mM EDTA. The pH value was adjusted to 8.0 
 
20x SSC: 3 M NaCl, 300 mM Na3-citrate. The pH value was adjusted to 7.0 
 
3.2.2.2 Media for bacteria and supplements 
 
SOC medium was prepared using 2% Tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose. The pH value was adjusted to 6.8-7.2 
 
LB-medium:  1%  Tryptone,  0.5%  yeast  extract,  1%NaCl,  1.5%  Agar.  The  pH  value  was 
adjusted to 7.2 
 
LB-agar: 1% Tryptone, 0.5% yeast extract, 1%NaCl, 1.5% Agar 
 
Ampicillin was added in a concentration of 100g/ml 
 
3.2.2.3 Bacterial strain 
 
The  following  bacteria  strain  was  used:  DH5α-T1
®  strain  (Invitrogen  life  technologies, 
Karlsruhe, Germany): F
– φ80lacZΔM15(lacZYA-argF)U169 recA1 endA1 hsdR17(rk
-, mk
-) 
phoA supE44 thi-1 gyrA96 relA1 tonA 
 
3.2.3 Vectors  
 
pIRESpuro2 (Clontech Laboratories, Inc) 
pPrPHG plasmid (Fischer et al., 1996)  
pPrPHG.F vector (Shmerling et al., 1998)  
 
3.2.4 Molecular size markers 
 
1 kb DNA marker (NEB Biolabs, Schwalbach, Germany): 500, 1000, 1500, 2000, 3000, 4000, 
5000, 6000, 8000, 10000 bp. 
 
100 bp DNA marker (NEB Biolabs, Schwalbach, Germany): 100, 200, 300 400, 500, 517, 
600, 700, 800, 900, 1000, 1200, 1517 bp. 22 
2-Log bp DNA marker (NEB Biolabs, Schwalbach, Germany): 100, 200, 300 400, 500, 517, 
600, 700, 800, 900, 1000, 1200, 1517, 2017, 3001, 4001, 5001, 6001, 8001, 10002 bp. 
 
SeeBlue 2 pre-stained (Invitrogen): 3, 6, 14, 17, 28, 38, 49, 62, 98, 188 kDa 
 
MultiMark Multi-Colored (Invitrogen): 3, 6, 11, 17, 19, 31, 52, 98, 185 kDa 
 
3.2.5 Antibodies 
 
3.2.5.1 Primary antibodies 
 
Alix (3A9), mouse (Cell Signaling, USA) 
Flotillin-2, goat (Santa Cruz, CA, USA). 
Fyn (FYN3), rabbit (Santa Cruz Biotechnology, Inc) 
GAP-43, goat (Santa Cruz Biotechnology, Inc) 
GM2 (MK 1-16), mouse (Seikagaku, Corp. Chuo-ku,Tokyo, Japan) 
MAP-2B IgG1, mouse (BD Biosciences), 
Nestin IgG1, mouse (BD Biosciences) 
NF-H, rabbit (Sigma) 
Nonphospho–Src (Tyr416), mouse (Cell Signaling) 
PrP-6H4 IgG1,k, mouse (Prionics) 
SAF-32, mouse (Cayman) 
SV40 Large T Antigen IgG2a, mouse (BD Biosciences) 
tsg 101 (M-19), goat (Santa Cruz Biotechnology, USA) 
 
3.2.5.2 Secondary antibodies 
 
HRP-conjugated anti-mouse IgM (Sigma) 
HRP-conjugated anti-mouse IgG (Zymed-Invitrogen) 
HRP-conjugated anti-rabbit IgG (Sigma) 
HRP-conjugated anti-goat IgG (Dianova) 
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3.2.6 PCR genotyping 
 
The genotype of the PrP
0/0 ML cell line was confirmed by PCR. Prnp
0 and Prnp
+ alleles were 
detected using the primers P3 (specific for the  Prnp
0 allele), P10 (specific for the  Prnp
+ 
allele), and prPrP 3´nc (specific for both the Prnp
0 and Prnp
+ alleles) according to Fischer et 
al. (Fischer et al., 1996). Genomic DNA extracted from either PrP
0/0 ML cells or mouse tail 
lysates was used as DNA template. 
 
3.2.7 Cell viability assay 
 
The activity of LDH released in the supernatant from damaged cells was measured using the 
Cytotoxicity Detection Kit according to the manufacturer’s instructions (Roche). 
LDH release after treatment of the cells with 1% Triton-X100 was set as 100% and relative 
LDH release values of the probes were then calculated. 
 
3.2.8 Immunoprecipitation 
 
Cells were lysed in cold lysis buffer II. Samples were pelleted at 14,000 rpm at 4 °C for 10 
minutes, and supernatants were transferred to a clean microfuge tube. Protein concentration 
was determined by BCA assay as recommended by the manufacturer (Pierce). Two hundred 
fifty micrograms of each cell lysate sample were adjusted to a final volume of 500 l with 
lysis buffer II. To the samples 2,5 g rabbit polyclonal anti-Fyn antibody (FYN3) were added, 
and samples were incubated overnight at 4°C on a rocking platform. After incubation, 20 l 
Protein A-Sepharose beads (Amersham Pharmacia) were added, and samples were incubated 
for 2 hours at 4°C on a rocking platform. Sepharose beads were then washed three times with 
lysis buffer II. Pellets were boiled in SDS sample buffer and analyzed by immunoblotting. 
 
3.2.9 High-performance-thin-layer-chromatography and gangliosides 
immunostaining 
 
Gangliosides  were  extracted  according  to  the  method  of  Svennerholm  and  Fredman 
(Svennerholm and Fredman, 1980). The eluted glycosphingolipids were dried and separated 
by  high-performance-thin-layer-chromatography  (HPTLC)  aluminium-backed  silica  gel  60 
(20x20)  plates  (Merck,  Darmstadt,  Germany).  Chromatography  was  performed  in 
chloroform:methanol:0.25% aqueous KCl (5:4:1) (v:v:v). Plates were immunostained for 1h 24 
at room temperature with HRP-CTxB (to detect GM1), or, alternatively, with anti-GM2 and 
then  with  anti-mouse  IgM-HRP.  Immunoreactivity  was  assessed  by  chemiluminescence 
reaction using the ECL Western blocking detection system (Amersham, Buckinghamshire, 
UK). 
 
3.2.10 Western blot analysis 
 
Cell- and microvesicles lysates were prepared in cold lysis buffer II. Cell lysates only were 
pelleted at 14,000 rpm at 4 °C for 10 minutes and their supernatants were transferred to a 
clean microfuge tube. Protein concentration was determined by BCA assay as recommended 
by the manufacturer (Pierce) or according to Bradford´s. 
80 g of total protein of each cell lysate and the equivalent of 250 g of each cell lysate after 
immunoprecipitation  (see  above)  were  electrophoresed  through  a  NuPAGE  12.0%  SDS 
polyacrylamide  gel  (Invitrogen)  or  7%  Tris-Acetat-Gels  (Invitrogen).  Otherwise  a  self-
prepared 12% SDS-Page gel was used. In the case of microvesicles lysates, 20 g of total 
protein were loaded. When a proteinase  K digestion was  performed, the digested protein 
amounts loaded corresponded to 80 or 250 g for cell lysates and 20 g for microvesicles 
lysates. 
Proteins were transferred to PVDF membranes by semidry blotting. Membranes were blocked 
at  RT  for  1  hr  with  Tris-buffered  saline/0.05%  Tween  20  (TBST)/5%  nonfat  dry  milk, 
incubated with the appropriate primary antibody diluted in Tris-buffered saline/0.05% Tween 
20 (TBST)/1% nonfat dry milk (for PrP, SAF-32, 1:500 or 6H4, 1:5000; for GAP-43, anti- 
GAP-43, 1:500; for flotillin-2, anti-flotillin-2, 1:750; for GM2, anti-GM2, 1:500; for Alix, 
Alix (3A9), 1:1000; for Tsg101, tsg 101 (M-19), 1:750; for Nestin detection, anti-Nestin, 
1:250; for MAP2B, anti-MAP2B, 1:1000 and for NF-H, anti-NF-H, 1:2000) overnight at 4°C. 
After washing with TBST, membranes were incubated for 1 hr at room temperature to HRP-
conjugated secondary antibody (1:10000) diluted in the same buffer as above. Bands were 
visualized by enhanced chemiluminescence (Amersham Pharmacia). 
 
3.2.11 Cell blot assay 
 
Cells were cultured on glass coverslips (Roth, Germany) until confluence, washed with CMF-
PBS, and placed cell side down on lysis buffer I-soaked nitrocellulose membranes (Hybond-
C-Extra, Amersham, Germany) that were previously laid on a lysis buffer-soaked filter paper. 
Membranes were then processed as described (Klohn et al., 2003). Briefly, membranes were 25 
dried at RT, coverslips were carefully removed and then the membranes were incubated in a 
Proteinase K solution [5 µg/ml PK in lysis buffer] for 90 min at 37°C. After twice wash in 
dH20, PK digestion was stopped by incubating the membranes in 2 mM PMSF for 10 min at 
RT. Membranes were than treated with 3 M guanidinium thiocyanate in 10 mM Tris-Cl (pH 
8.0) for 10 min. After extensive washing in dH20, membranes were processed for PrP
C/PrP
Sc 
detection by the use of the monoclonal antibody 6H4 as described above (3.2.10). 
 
3.2.12 PCR using the pPrPHG plasmid and the pPrPHG.F vector as templates  
 
In  order  to  get  the  bicistronic  pPrP-IRESpuro  expression  vector  and  the  pPrP32-134-
IRESpuro construct coding for either the full-length PrP or the PrP32-134 ORF plus the 
puromycin  antibiotic  resistance  gene,  the  pPrPHG  plasmid  (Fischer  et  al.,  1996)  or  the 
pPrPHG.F vector (Shmerling et al., 1998) were used respectively as templates. The same 
primers were used in  both  cases,  namely 5’-P-ORF  (EcoRI site italicized) and 3’-P-ORF 
(BamHI site italicized). The PCR product obtained for the PrP ORF corresponded to a 765 bp 
fragment. 
 
Name  Sequences of designed primers 
5’-P-ORF  (5’- CCGGAATTCACCATGGCGAACCTTGGCTAC)  
3’-P-ORF  (5’-CGCGGATCCTCATCCCACGATCAGGAAGATGAGG) 
 
3.2.13 Agarose gel electrophoresis 
 
1%  agarose  gels  were  prepared  by  adding  1.5  g  agarose  to  150  ml  1x  TAE  buffer.  The 
resulting  emulsion  was  then  heated  in  a  microwave  oven  until  the  solid  agarose  became 
solved. Then ethidium bromide (10 mg/ml) was added to a final concentration of 0.5 µg/ml 
and  the  gel  solution  was  poured  into  the  horizontal  tray  (Invitrogen  life  technologies, 
Karlsruhe,  Germany)  with  inserted  comb  (NEB  Biolabs,  Schwalbach,  Germany).  DNA 
samples were mixed with 1/10 volume of 10x sample buffer (0.5% Bromophenol blue, 0.5% 
Xylene cyanol FF, 30% Ficoll Type 400 in 10xTAE buffer) and applied to the gel. As marker, 
either the 100 bp, 1 kb or the log-2 ladder was used depending on the fragment size amplified. 
Electrophoresis  was  then  performed  at  100  V  for  1  hour.  Afterwards  bands  were 
photographically  documented  (Program:  BioCap  Version  97.03s  f.  Windows,  Printer: 
Mitsubishi P91) under UV light and, if desired, bands were cut out for purification.  
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3.2.14 Extraction of DNA fragments from agarose gels 
 
After electrophoresis, the DNA bands of interest were cut out from the gel and eluted using 
the Gel Extraction Kit (Qiagen, Hilden, Germany) as described by the manufacturer. 
 
3.2.15 Ligation of PCR products with pIRESpuro2 vector  
 
The bicistronic pPrP-IRESpuro expression vector coding for both the full-length PrP and the 
puromycin antibiotic resistance gene under the control of the human cytomegalovirus (CMV) 
major immediate early promoter/enhancer was generated by inserting the PrP ORF into the 
multiple cloning site of the pIRESpuro2 vector (Clontech). Briefly, the 765 bp PCR product 
obtained as described above was cleaved with EcoRI and BamHI and cloned into the EcoRI-
BamHI-digested  pIRESpuro2  backbone  (Fig.  5).  At  the  same  manner,  the  PrP32-134 
amplicon was cleaved and inserted to get the pPrP32-134-IRESpuro construct. 
 
3.2.16 Chemical transformation of bacteria 
 
For  transformation  Escherichia  coli  (E.coli)  bacteria  strain  DH5α-T1
®  (Invitrogen  life 
technologies, Karlsruhe, Germany) was used. 
10 l of ligation-mixture were added to 100 l of DH5α-T1
® cells and after a gently mixing 
the suspension was incubated 30 min on ice. Afterwards the sample was submitted to an heat-
shock at 42°C for 45 sec. followed by an incubation of 2 min. on ice. Then, 250 l SOC 
medium were added and the cells were incubated at 37°C for 1 hr on a shaker. Subsequently, 
they  were  spread  in  different  concentrations  on  prewarmed  LB-plates  with  suitable 
antibiotics. The plates were incubated at 37°C o.n. 
 
3.2.17 Plasmid preparation 
 
Preparation of plasmids from bacteria was performed using the Qiagen plasmid kits (Qiagen, 
Hilden, Germany) according to the manufacture instructions. 
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3.2.18 Restriction enzyme analyses 
 
The presence of the insert and its correct size was checked by restriction enzyme analysis. All 
restrictions  were  performed  using  commercially  available  restriction  enzymes  from  New 
England Biolabs (NEB, Schwalbach, Germany) in line with the manufactures instructions. 
 
Usually, 5U of enzyme should be enough to cut 1 g DNA. The volume of enzyme should not 
be greater than 1/10 of the total volume of the restriction reaction, composed also by 10x 
proper buffer and sometimes 100x BSA depending on the enzyme. ddH20 is added to adjust 
the final volume. The duration and the temperature of the restriction digestion depends on the 
enzyme(s) used. 
 
3.2.19 DNA sequencing 
 
After  confirmation  of  the  DNA  fragment  size  by  restriction  analyses,  the  inserted  DNA 
fragments  were sequenced to  confirm  their identity. Sequencing was  performed  at  MWG 
Biotech (Ebersberg, Germany). For this purpose, samples containing approximately 2 µg of 
DNA were lyophilized using a speedvac centrifuge (Eppendorf, Hamburg, Germany). The 
resulting lyophilized samples were sent to the company, where they were sequenced using the 
designed primer pairs.  
 
3.3 Immunological analysis 
 
3.3.1 Reagents 
 
Acetone  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DAKO mounting medium  DAKO Corporation, Carpinteria, USA 
DAKO Pen  DAKO Corporation, Carpinteria, USA 
Goat serum  Zymed Laboratories, South San Francisco, USA 
bisBENZIMIDE/Hoechst  Sigma, Munich, Germany 
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Triton X-100  Sigma, Munich, Germany 
Tween-20  Sigma, Munich, Germany 
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All other chemicals were purchased from Merck (Darmstadt, Germany) 
 
3.3.2 Media and buffers 
 
3.3.2.1 General buffers 
 
CMF-PBS (PBS w/o Ca
2+/Mg
2+) was generated using 120 mM NaCl, 17 mM Na2HPO4, 3 
mM KH2PO4, and the pH value was adjusted to 7.2 
 
1% paraformaldehyde (PFA)  
1% (w/v) paraformaldehyde  
in CMF-PBS pH 7.4 
 
4% paraformaldehyde (PFA)  
4% (w/v) paraformaldehyde  
in CMF-PBS pH 7.4 
 
2,5% glutaraldehyde 
2,5% (w/v) glutaraldehyde  
in CMF-PBS pH 7.4 
 
1% osmium tetroxide 
1 % (w/v) osmium tetroxide 
in Veronal acetate buffer pH 7.4 
 
Blocking buffer 
4% normal goat serum or 10% normal goat serum 
0.1% Triton X-100 
0.02% NaN3  
in CMF-PBS pH 7.4 
 
FACS buffer  
0.25% BSA 
0.05% NaN3 
in CMF-PBS pH 7.4 29 
3.3.3 Antibodies 
 
3.3.3.1 Primary antibodies 
 
MAP2B IgG1, mouse (BD, Biosciences) 
GFAP IgG2b, mouse (BD, Biosciences) 
TNP-IgG1,k, mouse, monoclonal immunoglobulin isotype standard (BD Biosciences) 
Nestin IgG1, mouse (BD, Biosciences) 
PrP-6H4 IgG1,k, mouse (Prionics) 
PrP-8G8 IgG1,k, mouse (Cayman) 
PSA-NCAM IgM, mouse (Chemicon) 
SV40 Large T Antigen IgG2a, mouse (BD, Biosciences) 
NeuN IgG1, mouse (Chemicon) 
 
3.3.3.2 Secondary antibodies 
 
FITC - conjugated anti-mouse IgM (Santa Cruz Biotechnology) 
RPE - conjugated anti-mouse IgG (DAKO) 
Alexa Fluor
®488 - conjugated anti-mouse IgG, F(ab’)2 Fragments (A-11017, Invitrogen life 
technologies, Karlsruhe, Germany) 
10 nm colloidal gold - conjugated anti-mouse immunoglobulin (1:100, Biocell, UK) 
 
3.3.4 Immunofluorescence analysis of specific cell markers 
 
Cells were plated onto poly-D-lysine overlaid glass coverslips (BD BioCoat
TM Cellware Poly-
D-Lysine 12 mm round Coverslips) and grown under different conditions at 33°C or at 39°C 
for 1 to 6 days. In order to perform a staining after 4 days, 30’000 cells were seeded per 24-
well dish for the 33°C condition and 60’000 cells/well for the 39°C condition. The staining 
was avoid in case of a 80-90% cells confluency. 
At the time-point (24 hours, 48 hours, 72 hours or 96 hours) of investigation, cells were rinsed 
gently with CMF-PBS and fixed either 20 min. at RT with 4% PFA (for GFAP, Nestin, SV40 
Large T Antigen and NeuN staining) or 10 min. at RT with 4% (PFA) followed by 10 min. at 
–20°C in Methanol:Acetone (1:1) (for MAP2B staining). Cells were then washed again with 
CMF-PBS for 5 min. and permeabilised with 0.2% Triton X-100 in CMF-PBS for 5 min. at 30 
RT. Cell nuclei were stained with Hoechst dye during an incubation time of 15 min. at RT. 
The dye was washed out 3 times (5min/each) with CMF-PBS and the cells were pre-incubated 
for 1 h at RT in blocking buffer (4% normal goat serum, 0.1% Triton X-100, 0.02% NaN3). 
After blocking buffer removal, primary antibodies (MAP2B 1:300, GFAP and Nestin 1:250, 
SV40 Large T Antigen 1:100, NeuN 1:50 in blocking buffer) were added to the cells followed 
by incubation o.n. at 4°C. 
The day after, cells were washed 3 times in CMF-PBS for 5min./each and incubated at RT for 
2 h with the secondary antibody (goat -mouse Alexa Fluor
®488, 1:300 in blocking buffer) in 
a humidified chamber. After washing 3 times in CMF-PBS for 5min./each, the coverslips 
were mounted upside down on slides with a drop of DAKO Fluorescent mounting medium. A 
nail polish sealing allowed the storage of the slides at 4°C in complete darkness until the 
epifluorescence microscope analysis. 
 
3.3.5 Immunofluorescence analysis of PrP
C  
 
Cells were fixed 20 min. at RT with 4% PFA, washed with CMF-PBS for 5 min and then 
permeabilised  with  0.2%  Triton  X-100  in  CMF-PBS  for  5  min.  at  RT.  Cell  nuclei  were 
stained with Hoechst dye during an incubation time of 15 min. at RT. The dye was washed 
out 3 times (5min/each) with CMF-PBS and the cells were pre-incubated for 1 h at RT in 
blocking buffer (4% normal goat serum, 0.1% Triton X-100, 0.02% NaN3). After blocking 
buffer removal, primary antibodies against PrP
C (6H4 1:400, Prionics or 8G8 1:200, Cayman) 
were added to the cells followed by incubation o.n. at 4°C. As negative control, the isotype 
antibody anti-IgG1,k-TNP (1:400) was used. 
The day after, cells were washed 3 times in CMF-PBS for 5min./each and incubated at RT for 
2 h with the secondary antibody (goat -mouse Alexa Fluor
®488, 1:300 in blocking buffer) in 
a humidified chamber. After washing 3 times in CMF-PBS for 5min./each, the coverslips 
were mounted upside down on slides with a drop of DAKO Fluorescent mounting medium. A 
nail polish sealing allowed the storage of the slides at 4°C in complete darkness until the 
epifluorescence microscope analysis. 
 
3.3.6 Fluorescent activated cell sorting (FACS) 
 
Cells were detached with CMF-PBS/1mM EDTA, resuspended in 5 ml DMEM/10% FCS and 
counted.  31 
Single  staining  for  PrP  was  achieved  by  incubating  the  cells  (0.5  x  10
6)  with  100  l  of 
monoclonal 6H4 antibody (1:250; Prionics AG) for 30 minutes at 4°C. 
Staining for PSA-NCAM was achieved by incubating the cells (0.5 x 10
6) with 100 l of 
monoclonal PSA-NCAM IgM (1:200, Chemicon) for 30 minutes at 4°C. 
Cells were then washed in cold FACS buffer (CMF-PBS, 1% (w/v) BSA, 10 mM EDTA (pH 
8), 0.1% sodium azide), incubated for 30 minutes at 4°C with 100 l of goat anti-mouse IgG-
RPE (1:200) for PrP detection or with 100 l of goat -mouse IgM-FITC (1:50) for PSA-
NCAM detection. 
One step wash was performed before cytofluorimetry (FACScan, Becton Dickinson). 
 
3.3.7 Immunoelectron microscopy 
 
Microvesicles were isolated as described previously, resuspended in the appropriate volume 
of Opti-MEM and incubated with the anti-PrP monoclonal 6H4 antibody (1:200) for 1h at 
4°C. Samples were then absorbed by nickel-grid before extensive washing with water. A drop 
of immunogold labelled secondary antibody (anti-mouse immunoglobulin-colloidal gold 10 
nm,  1:100  in  CMF-PBS  or  medium)  was  then  applied  on  the  grid  and  incubated  for  20 
minutes at RT. After a three-time washing step, the grid was incubated with one drop of 
uranyl acetate for 10 sec at RT. Samples were then analysed under an electron microscope 
(Zeiss, Germany). 
 
Neuro-2a PK1 cells were incubated with the anti-PrP monoclonal 6H4 antibody (1:200) for 1h 
at 4°C. Cells were washed in CMF-PBS and then fixed with 1% paraformaldehyde for 1h at 
4°C,  washed  and  labelled  with  anti-mouse  immunoglobulin-colloidal  gold  10  nm  (1:100, 
Biocell, UK) for 3h at 4°C. Cells were post-fixed first in 2, 5% glutaraldeyde for 45 min at 
RT and then in osmium tetroxide 1% in Veronal acetate buffer, pH 7.4, for 2h at 4°C, stained 
with uranyl acetate (5 mg/ml), dehydrated in acetone and embedded in Epon 812. Samples 
were then sectioned and examined under an electron microscope (Zeiss, Germany). 
 
3.4 In vivo infectivity bioassay 
 
MVs  were  isolated  both  from  noninfected  and  RML-infected  Neuro-2a  PK1  cells  as 
previously described and resuspendend in 0,2 ml PBS. Noninfected and infected Neuro-2a 32 
PK1 cells were collected and resuspended in 1 ml PBS. MVs and cells were subjected to five 
consecutive cycles of freeze and thawing. Protein concentration for cell lysates and MVs was 
determined by Bradford assay as recommended by the manufacturer’s guidelines. Samples 
were then adjusted to 10 µg total protein per 30 µl with PBS/5%BSA. Different dilutions of 
mouse brain homogenate infected with the Rocky Mountain Laboratory (RML) scrapie strain 
(passage 5.0, 1 x 10
8 LD50/ml 10% brain homogenate) (Prinz et al., 2004) in PBS/5% BSA 
were used as positive controls, whereas mock infected brain homogenate was included as 
negative control. 
Thirty microliters for each sample were administered intracerebrally to groups of four tga20 
mice (Fischer et al., 1996). The indicator tga20 mice were anaesthetized at 4-20 weeks of age 
with metofane (Pitman-Moore, USA) and inoculated with 30 l inocula using a 300-l insulin 
syringe and a 26-gauge hypodermic needle inserted 3-4 mm into the right parietal lobe. 
Disease  in  animals  was  diagnosed  when  at  least  three  of  the  following  symptoms  were 
observed: foot clasping of hindlegs when mice were lifted by the tail, plastic tail; decreased 
motor  activity;  mincing  gait,  disorientation;  mild  hind  leg  paresis,  ataxia;  kyphosis. 
Incubation  time  to  terminal  scrapie  sickness  was  determined  and  infectivity  titers  were 
calculated by using the relationship y =11.45-0.088 x, where y is logLD50/ml homogenate and 
x is incubation time in days to terminal disease (Prusiner et al., 1982). The presence of a 
protease-resistant isoform of PrP (PrP
Sc) in the infected brains was investigated on proteinase 
K-treated  (20  µg/ml;  30  min;  37°C)  homogenates  by  Western  blot  analysis,  as  described 
above. 
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4 RESULTS 
 
4.1  The  role  of  the  cellular  prion  protein  in  the  process  of  neuronal 
  differentiation 
 
Four different PrP-knockout cell lines, named HpL 3-4, F14, Zpl and NpL2, respectively, 
have already been generated to expand studies on the normal function of PrP
C (Holme et al., 
2003; Kim et al., 2005; Kuwahara et al., 1999; Nishimura et al., 2007). However, the HpL 3-4 
cell line (Kuwahara et al., 1999) has been made from PrP-deficient animals of the Nagasaki-
type and, therefore, expresses the neurotoxic protein Doppel (Dpl) (Anderson et al., 2004; 
Genoud et al., 2004; Li et al., 2000; Moore et al., 1999; Moore et al., 2001; Rossi et al., 2001). 
The recently established F14, Zpl and NpL2 cell lines (Holme et al., 2003; Kim et al., 2005; 
Nishimura et al., 2007) have been derived from neuronal primary cells of Zurich I-type mice 
(Bueler et al., 1992; Manson et al., 1994). These cells express neither PrP nor Dpl but, being 
already differentiated into neurons, might not be suitable for studying the possible role of 
PrP
C in processes of cell differentiation. 
The temperature-sensitive tsA58 mutant of the simian virus 40 (tsSV40) large T antigen has 
been previously used to generate several neuronal cell lines (Barber et al., 2000; Cattaneo and 
Conti, 1998; Eves et al., 1992; McManus et al., 1999; Son et al., 1999; White et al., 1994; 
Whittemore  and  White,  1993).  Cells  immortalized  with  this  oncogene  proliferate  at  the 
permissive temperature  (33°C), but  arrest  their  growth and differentiate upon shift  to  the 
nonpermissive temperature (39°C), i.e. when the thermolabile large T antigen is inactivated 
(Jat  and  Sharp,  1989).  Therefore,  this  system  is  particularly  useful  to  study  signalling 
pathways potentially involved in processes of cell differentiation without the interference by 
the transforming oncogene. 
 
4.1.1  Generation of a novel PrP-knockout cell line by SV40 Large T Antigen-
  mediated immortalization 
 
In  order  to  address  the  role  of  the  cellular  prion  protein  in  the  process  of  neuronal  fate 
specification and neurite outgrowth as well as to identify the domain of PrP
C responsible for 
such activities the approach outlined above was used to generate a novel PrP-deficient cell 
line deriving from  cerebellar neuroepithelial  precursor cells  of the PrP-knockout  Zurich  I 
mice (Prnp
0/0 Zurich I, Bueler et al., 1992). 34 
Primary cells prepared from the cerebella of Prnp
0/0 Zurich I animals (Bueler et al., 1992) 
were infected with a retrovirus transducing the tsA58 SV40 large T antigen (Jat and Sharp, 
1989). The derived immortalized heterogeneous cell populations were then selected by their 
ability to grow at the permissive temperature of 33°C in serum-containing medium. Colonies 
that could proliferate in these conditions were subsequently isolated by repeated proliferation 
and  limiting  dilution  of  the  cells.  One  clonal  line,  named  PrP
0/0  ML,  was  selected  in 
consideration  of  morphology,  growth  rate  and  ability  to  adhere  to  the  plates  and  was 
characterized in detail. 
The presence of two Prnp knockout alleles in the PrP
0/0 ML cells was confirmed by PCR 
analysis  (Fig.  4A).  Furthermore,  the  expression  of  the  SV40  Large  T  antigen  and  its 
characteristic nuclear localization was corroborated by immunofluorescence analysis of cells 
maintained at the permissive temperature (Fig. 4, upper panels). Switching the cells to the 
nonpermissive  temperature  (39°C)  caused  a  strong  reduction  of  the  large  T-antigen  as 
revealed by both immunoflorescence (Fig. 4B, lower panels) and western-blot analyses (data 
not shown) indicating that the expression of the oncogene was controlled in a temperature-
sensitive manner. 35 
 
 
Figure 4. Characterization of the PrP
0/0 ML cell line 
 
(A) The genotype of the PrP
0/0 ML cells was confirmed by PCR analysis using primers that allow to 
amplify simultaneously both the wild-type (Prnp
+) and the Prnp knockout (Prnp
0) alleles. PrP
0/0 ML 
cells are homozygous for the Prnp knockout allele (lane 2). Genomic DNAs from Prnp knockout (lane 
1) and Prnp wild-type (lane 3) mice were used as positive controls. A negative control, run in the 
absence of DNA template (lane 4), was included to exclude the presence of contaminants in the 
reaction mixture. (B) Immunoreactivity for the SV40 large T antigen in PrP
0/0 ML cells grown in 
permissive (upper  panels)  and  nonpermissive  culture  conditions  (lower  panels). The  characteristic 
nuclear localization of the oncogene product (tsSV40, green) was detected in the cells maintained in 
permissive conditions (upper panels). Strong reduction of large T antigen expression was noticed after 
cultivation of the PrP
0/0 ML cells in nonpermissive condition for 48 hours (lower panels). Nuclei were 
counterstained with Hoechst 33342 (blue). Scale bar, 50 m. (C) Growth curves of the PrP
0/0 ML cells 
maintained at 33°C or 39°C in high (10% FCS) or low serum concentration (SFM). At 33°C in serum-
containing medium, the cells proliferated with a doubling time of approximately 30 hours. Withdrawal 
of the serum significantly decreased the growth rate. At the nonpermissive temperature of 39°C the 
cells  exhibited  decreased  proliferation  potential  even  in  serum-containing  medium.  This  effect  is 
further enhanced with serum deprivation that led to progressive stoppage  of the cell division and 
reduction in the number of cells. 36 
4.1.2 Proliferative potential of the PrP
0/0 ML cell line 
 
The  proliferative  potential  of  the  PrP
0/0  ML  cell  line  was  subsequently  evaluated  under 
different culture conditions and the number of viable cells at selected time-points was plotted 
as  growth  curves  (Fig.  4C).  At  33°C  in  serum-containing  medium  (10%  FCS),  the  cells 
proliferated with a doubling time of approximately 30 hours. Under these conditions, cell 
growth is sustained by the presence of both the immortalizing oncoprotein and the serum. 
Withdrawal of the serum (SFM) significantly decreased the growth rate and extended the cell 
doubling time to 35 hours. At the nonpermissive temperature of 39°C, when the oncogene 
expression is reduced, the cells exhibited decreased proliferation potential even in serum-
containing  medium,  with  a  doubling  time  of  approximately  46  hours.  At  the  same 
temperature,  serum  deprivation  led  to  progressive  stoppage  of  the  cell  division  with  the 
consequent  reduction  in  the  number  of  cells  (Fig.  4C).  At  nonpermissive  conditions  of 
maintenance, the  addition  of the growth factor  basic fibroblast  growth  factor (bFGF) (10 
ng/ml) rescued the proliferative capability of the cells and extended cell survival beyond 96 
hours. Furthermore, at 33°C in serum-containing medium, bFGF reduced the cell doubling 
time at approximately 12 hours (data not shown). Thus, PrP
0/0 ML cells responded to bFGF 
stimulation by undergoing cell proliferation, a cellular response to this growth factor already 
been  shown  for  cultured  CNS  progenitor  cells  derived  from  the  embryonic  rat  striatum 
(Cattaneo  and  McKay,  1990;  Gage  et  al.,  1995;  Gensburger  et  al.,  1987;  Kilpatrick  and 
Bartlett, 1993; Murphy et al., 1990; Reynolds et al., 1992; Temple and Qian, 1996; Vescovi et 
al., 1993). 
Based on these data, the two most opposite situations (33°C with high serum vs. 39°C in low 
serum concentration) were adopted in further experiments. 
 
4.1.3  Temperature - and growth factor-dependent phenotypic changes of the 
  PrP
0/0 ML cells 
 
The  switch  from  proliferating  precursors  to  differentiated  neurons  in  vivo  is  typically 
associated with changes in specific traits of the cell. In particular, this process is defined by 
progressive stages that can be identified on the basis of the expression of key markers and cell 
morphology (Kempermann et al., 2004). Immortalized CNS progenitor cells were reported to 
efficiently  differentiate  into  neuronal  and  glial  lineages  in  vitro  upon  growth  factor 
withdrawal from the culture medium (Cattaneo and Conti, 1998; Eves et al., 1992). In these 37 
experimental  conditions,  the  different  steps  of  the  differentiation  process  are  featured  by 
progressive  expression  from  immature  to  mature  neuronal  markers  and  by  morphological 
changes  that  reasonably  recapitulate  the  developmental  progression  occurring  during  the 
formation of the CNS (Eves et al., 1992).  
 
Based on these considerations, the immortalized PrP
0/0 ML cells were characterized in terms 
of  cellular  lineage  and  differentiation  potential.  The  expression  of  specific  markers  for 
different cell lineages and for different stages  of neuronal development was evaluated by 
immunofluorescence  analyses.  Nestin  is  an  intermediate  filament  protein  that  is  only 
transiently expressed during the development  of the CNS  and is abundantly expressed in 
neuroepithelial stem cells, radial glial cells and oligodendrocyte precursors. It is therefore 
considered to be a marker of CNS precursor cells (Frederiksen and McKay, 1988; Gallo and 
Armstrong, 1995; Hockfield and McKay, 1985; Lendahl et al., 1990) (for review, see Wiese 
et  al.,  2004).  The  microtubule-associated  protein  (MAP)-2b  is  a  protein  associated  with 
microtubules and plays an essential role in the outgrowth of dendrites (Heidemann, 1996; 
Izant and McIntosh, 1980). It is normally expressed in differentiating neurons. The neuron-
specific nuclear protein NeuN (Mullen et al., 1992) is a protein specifically localized in the 
nucleus of CNS cells and in cells that are terminally differentiated in neuronal phenotypes. 
The  neuronal  filament  (NF)-H  (200  kDa)  is  one  of  the  three  subunits  which  form  by 
copolymerisation  the  neurofilaments  (NFs),  the  most  abundant  cytoskeletal  intermediate 
filaments in neurons of the central and peripheral nervous system (Hirokawa et al., 1984; 
Liem, 1990). During neuronal differentiation there is a temporal regulation of the expression 
of the three neurofilament subunit genes. The NF-L (68 kDa) and NF-M (145 kDa) mRNAs 
and  proteins  accumulate  during  the  embryonic  period  but  detectable  levels  of  the  NF-H 
mRNA and protein are not observed until the post-natal period (Julien et al., 1986; Shaw and 
Weber, 1982; Willard and Simon, 1983). 
As  shown  in  Figure  5  and  Figure  6,  upon  cultivation  at  the  permissive  condition  of 
temperature the PrP
0/0 ML cell line was highly immunoreactive for nestin (Fig. 5A). However, 
the cells growing at 33°C were negative for neuronal antigens, such as the neuron-specific 
nuclear protein NeuN (Fig. 5B), the microtubule-associated protein (MAP)-2b (Fig. 6A) and 
the neuronal  filament (NF)-H (data not shown), as well as for the astroglial marker glial 
fibrillary  acidic  protein  (GFAP)  (Debus  et  al.,  1983)  (data  not  shown),  and  the 
oligodendrocyte marker myelin basic protein (MBP) (Mirsky et al., 1980) (data not shown). 
Interestingly, maintenance of the  cells  in  serum-free medium  at 39°C for up to  96 hour, 38 
conditions that promote cell differentiation, induced a progressive reduction in the expression 
levels of nestin (Fig. 5D, G), an event that strongly correlated with the appearance of NeuN 
(Fig. 5H and Table 1), MAP-2b (Fig. 6D, G, J and Table 1) and NF-H (data not shown). The 
PrP
0/0 ML cells thus resulted positive for MAP-2b after 24 hours cultivation in nonpermissive 
conditions (Fig. 6D, G; J and Table 1), and became immunopositive for NeuN (Fig. 5H and 
Table 1) and NF-H (data not shown) after 96 hours at the same conditions. The expression of 
markers for distinct subtypes of cerebellar neuronal populations, such as calbindin for the 
Purkinje cells and the gammaaminobutyric acid type A receptor α 6 subunit (GABAA Rα6) 
for the  granule  cells,  however, remained negligible for up to  96 hours  (data not  shown). 
Similarly,  antigens  for  other  cell  lineages,  including  GFAP  for  astrocytes  and  MBP  for 
oligodendrocytes,  were  undetectable  at  all  time-points  (data  not  shown).  Moreover, 
maintenance  of  the  cells  in  serum-free  medium  at  39°C  in  the  presence  of  brain-derived 
neurotrophic factor (BDNF) induced an acceleration in the process of neurodifferentiation, as 
shown by both the earlier detection and the stronger expression levels of MAP-2b and NeuN 
(Fig. 7). 
Besides the expression of cell lineage-specific markers, the extent of cell differentiation can 
be figured out also by morphological criteria. Polarization of neuronal cells, with a single 
axon  and  several  dendrites,  is  crucial  for  the  proper  function  of  neurons.  This  process 
normally occurs via the differentiation of one immature neurite to generate a single axon 
whilst the remaining neurites elongate to become dendrites. Therefore, neurite formation and 
specialization is essential to define the shape of neurons and their synaptic connections. Based 
on this, the morphological changes the PrP
0/0 ML cells undergo under the different conditions 
of culture were next examined in detail. After labelling the cells with a generic anti-MAPs 
antiserum that allows to appreciate both axons and dendrites by immunoreacting with the 
cytoskeletal proteins Tau (axonal protein) and MAP2 (dendritic protein), it was possible to 
note that, upon cultivation at 39°C in SFM for 48 or 96 hours, the PrP
0/0 ML cells began to 
acquire an asymmetrical morphology and extended longer neurites (Fig. 5F, I) than the same 
cells maintained at the permissive temperature (Fig. 5C). The neuritogenic response of the 
PrP
0/0  ML  cells  was  subsequently  quantified  by  measuring  both  the  number  of  cells 
harbouring neurites and the mean length of the longest neurites per cell at different time-
points upon cultivation in either permissive or nonpermissive growth conditions. As shown in 
Table 2, the proportion of cells with neurites was significantly lower after cultivation in the 
presence of serum at 33°C than in SFM at 39°C for 48 hours. Their number further increased 
from 48 to 96 hours at the nonpermissive temperature (Table 2). Similarly, the mean length of 39 
the longest neurites per cell was about 50,9 ± 5,3 μm for the cells maintained at 33°C and 
gradually  increased  by  16%  for  cells  grown  at  39°C  for  48  hours  and  by  44%  for  cells 
cultivated at the nonpermissive temperature for 96 hours (Table 2). 
Thus, these results indicate that the PrP
0/0 ML cells are lineage determined precursor cells. 
The  switch  to  nonpermissive  conditions  of  maintenance  then  impels  their  differentiation 
toward  a  phenotype  with  biochemical  features  of  neurons,  though  no  antigenic  traits  of 
specific cerebellar neuronal subtypes are attained. 
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Table 1.  Quantification of the percentage of cells expressing neuron - specific markers 
  at different time - points under nonpermissive conditions of culture. 
 
Culture 
conditions  39°C in SFM 
Genotype  PrP
0/0 ML  PrPA117  PrPA57** 
Hours  48  96  48  96  48 
           
MAP-2b
+ cells*  23,1 ± 2,6   28,8 ± 5,9  28,9 ± 5,5  25,1 ± 5,1  37,3 ± 3,8 
NeuN
+ cells*  <1  17,3 ± 2, 6  17,0 ± 7,3  32,2 ± 9,8  36,1 ± 6,4 
 
*Values are expressed as percentage ± s. e. m. 
**PrPA57 cells showed a high cell death rate at the latest time- point with a significant reduction in 
the cell number. This did not allow comparing this line with the other two genotypes at 96 hours after 
the temperature switch. 
 
 
 
 
Table 2. Quantification  of  the  cell  differentiation  as  determined  by  morphological 
  analysis 
 
 
PrP
0/0 ML  PrPA57  PrP32-134 
33°C, 10% 
FCS  39°C, SFM  33°C, 
10% FCS 
39°C, 
SFM 
33°C, 
10% FCS 
39°C, 
SFM 
Hours    48  96    48    48 
Cells with 
neurites*  6,5±3,1  27,8±3,4  41,7±12,1  17,7±3,8  47,0±3,4  15,7±5,1  35,1±0,8 
Mean 
length of 
the longest 
neurites 
per cell** 
50,9±5,3  58,9±4,7  73,6±6,6  71,7±2,5  75,6±5,1  71,2±2,6  73,6±5,7 
 
*Values are expressed as percentage ± s. e. m. 
**Values are expressed in µm ± s. e. m. 
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Figure 5. The PrP
0/0 ML cell line is a unipotent neuronal precursor line which can differentiate 
    into neurons when cultivated under specific conditions 
 
Immunofluorescence  analyses  of  cell  specific  markers  in  PrP
0/0  ML  cells  cultivated  under  both 
permissive  (A-C)  and  nonpermissive  (D-I)  conditions.  PrP
0/0  ML  cells  maintained  in  permissive 
conditions were immunoreactive for nestin (A) and negative for neuron-specific markers, such as the 
neuronal nuclei antigen (NeuN, B). Immunostaining for MAPs revealed the polygonal morphology of 
the  cells  and  the  presence  of  rare  and  short  processes  (C).  Under  conditions  that  promote  cell 
differentiation, a time-dependent expression of NeuN (E and H) accompanied the reduction in the 
expression levels of nestin (D and G). This switch towards a neuronal phenotype is accompanied by 
progressive neuritogenesis, as revealed by anti-MAPs immunolabelling (F and I). Cell nuclei were 
visualized by Hoechst 33342 staining (blue). Scale bar: 50 µm 
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Figure 6. Time-dependent  expression  of  the  neuronal  marker  MAP-2b  in  the  PrP
0/0  ML,
  PrPA57 and PrP32-134 cell lines  
 
Immunofluorescence analyses of the neuronal marker MAP-2b in the PrP
0/0 ML, PrPA57 and PrP32-
134 cells cultivated under both permissive (A-C) and nonpermissive (D-L) conditions. PrP
0/0 ML (A), 
PrPA57 (B) and PrP32-134 cells (C) maintained in permissive conditions were negative for MAP-2b. 
Under conditions that promote cell differentiation, a time-dependent expression of MAP-2b in all the 
three cell lines was observed (D-L). Cell nuclei were visualized by Hoechst 33342 staining (blue). 
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Figure 7. Brain derived neurotrophic factor accelerates the differentiation process of the PrP
0/0 
    ML cell line 
 
Immunofluorescence  analyses  of  cell  specific  markers  in  PrP
0/0  ML  cells  cultivated  under 
nonpermissive conditions both in the absence (A-F) and presence (G-L) of BDNF. PrP
0/0 ML cells 
maintained in nonpermissive conditions for 24h were immunoreactive for nestin (A) and negative for 
neuron-specific markers, such as MAP-2b (B) and NeuN (C). Under conditions that promote cell 
differentiation for 72h, expression of MAP-2b (E) and NeuN (F) accompanied the reduction in the 
expression levels of nestin (D). The presence of BDNF accelerates the switch towards a neuronal 
phenotype as revealed by the earlier and stronger expression of the neuronal markers MAP-2b (H and 
K) and NeuN (I and L). 
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4.1.4  Reconstitution  of  the  PrP
0/0  ML  cell  line  with  the  full-length  prion 
  protein or PrPΔ32-134 
 
In  spite  of  considerable  experimental  efforts  invested  during  the  last  decade,  the  cellular 
function of the prion protein remains obscure. To generate a useful cell system for studying 
the physiological role of this enigmatic protein, the expression of either wild-type PrP
C or its 
truncated form PrPΔ32-134 was reconstituted into the PrP
0/0 ML cells. 
 
4.1.4.1  Construction of the pPrP-IRESpuro or the pPrPΔ32-134-IRESpuro vector 
 
The  bicistronic  expression  vector  pIRESpuro2  (Clontech,  USA)  was  chosen  to  drive 
expression of the murine Prnp gene in the PrP
0/0 ML cells. In this vector, the transcriptional 
regulation of the transgene is under the control of the human cytomegalovirus (CMV) major 
immediate early promoter/enhancer. A multiple cloning site sequence (MCS) that precedes 
synthetic stop codons in all the three reading frames allows insertion of the gene of interest. A 
synthetic intron known to enhance the stability of the mRNA, the encephalomyocarditis virus 
(ECMV)  internal  ribosome  entry  site  (IRES)  sequence,  a  sequence  encoding  for  the 
puromycin-N-acetyl-transferase, a protein which confers puromycin resistance to cells, and 
the  polyadenylation  signal  of  the  bovine  growth  hormone  gene  complete  the  expression 
cassette of the pIRESpuro2 vector (Fig. 8). Ribosomes can enter the bicistronic mRNA at the 
5´end  to  translate  the  gene  of  interest  and  at  the  ECMV  IRES  to  translate  the  antibiotic 
resistance  marker.  Therefore,  the  selection  of  transfected  cells  with  puromycin  ensures  a 
stable expression of the gene of interest over time in culture. 
For the construction of the pPrP-IRESpuro vector, the sequence encoding for the full-length 
PrP (PrP ORF) was inserted into the multiple cloning site of the pIRESpuro2 vector. A 765 bp 
PCR product of the PrP ORF was amplified using the pPrPHG plasmid (Fischer et al., 1996) 
as  template  and  the  primers  5’-P-ORF  and  3’-P-ORF  (see  Materials  and  Methods).  The 
amplicon was cleaved with EcoRI and BamHI and cloned into the EcoRI-BamHI-digested 
pIRESpuro2 backbone to yield the plasmid pPrP-IRESpuro (Fig. 9A). The PrPΔ32-134 ORF 
was prepared by PCR using the same primers and the pPrPHG.F vector (Shmerling et al., 
1998) as template. The PCR product was then ligated into the pIRESpuro2 vector as described 
above  to  yield  the  pPrPΔ32-134-IRESpuro  construct  (Fig.  9A).  Resulting  clones  were 
screened  for  the  presence  of  the  Prnp  fragments  by  restriction  analysis.  The  entire  open 
reading frames of two positive clones for each expression vector were analysed by sequencing 
to exclude the presence of mutations. 45 
 
Figure 8.  Schematic representation of the plasmid pIRESpuro2 
 
Schematic representation of the plasmid pIRESpuro2 used for construction of the pPrP-IRESpuro and 
pPrPΔ32-134-IRESpuro  transgenic  expression  vectors.  The  nucleotide  sequence  of  the  multiple 
cloning site (MCS) region in which the PrP coding sequences were inserted is also depicted. Positions 
of restriction enzymes’ recognition sites are illustrated. 
 
4.1.4.2  Generation of full-length prion protein- or PrPΔ32-134-reconstituted PrP
0/0 ML 
    cells 
 
PrP
0/0 ML cells were transfected by lipofection (see Materials and Methods) with the pPrP-
IRESpuro  or  the  pPrPΔ32-134-IRESpuro  vectors  (Fig.  9A),  respectively,  and  clones  that 
stably expressed the protein of interest were isolated. Furthermore, PrP
0/0 ML cells stably 
transfected with an empty vector were generated as controls for possible insertional effects of 
the transgene. Cells transfected with the plasmid coding for the full-length PrP
C produced 
several clones. Three of these, named PrPA117, PrPA57 and PrPA109 (data not shown), were 
chosen as representative of low, average and high PrP
C expression levels, respectively. The 
PrPA57  line  was  taken  into  particular  consideration,  due  to  morphology  and  growth  rate 
comparable  with  PrP
0/0  ML  cells,  and  was  extensively  characterized.  By  contrast,  cells 
transfected with the plasmid coding for PrPΔ32-134 produced only one clone with high levels 
of PrP expression. However, additional PrPΔ32-134 expressing clones may have been missed 46 
during the screening procedure because of the use of a weakly reacting antibody against the 
truncated  PrP  form  (data  not  shown).  Expression  of  the  proteins  in  all  cell  lines  was 
confirmed by Western blotting (Fig. 9B) and their presence on the outer surface of cell clones, 
because  of  the  GPI-anchor,  was  detected  by  FACS  analysis  (Fig.  9C).  Considering  that 
PrPΔ32-134 induced degeneration of cerebellar neurons in vivo when expressed into a PrP
0/0 
background  (Flechsig  et  al.,  2003;  Shmerling  et  al.,  1998),  one  investigated  whether  the 
truncated PrP similarly caused detrimental effects on the PrP
0/0 ML cells. Surprisingly, the 
reconstitution of the PrP
0/0 ML cells with PrPΔ32-134 was not cytotoxic up to 48 hours in 
culture at both permissive and nonpermissive conditions, as demonstrated by the activity of 
the lactate dehydrogenase (LDH) released into the culture media (Fig. 10). 
 
 
Figure 9. Reconstitution of wild-type PrP
C and PrP32-134 expression in the PrP
0/0 ML cells 
 
Cells were stably transfected with expression vectors encoding either the wild-type PrP
C or the amino-
terminally  deleted  protein  PrP32-134.  Clones  that  stably  expressed  the  protein  of  interest  were 
isolated and characterized. (A) Schematic representation of the plasmid pPrP-IRESpuro that codes for 
either the full-length PrP
C or PrP32-134. (B) PrP expression was evaluated on the reconstituted cell 
lines by immunoblot using the 6H4 monoclonal antibody. The cell lines PrPA117 (lane 3) and PrPA57 
(lane 4) express wild-type PrP
C at different levels whereas PrP32-134 line (lane 2) expresses the N-
terminally truncated form of PrP. As expected, no PrP
C expression is detected in PrP
0/0 ML cells (lane 
1). (C) FACS analysis for cell surface PrP
C-expression using the 6H4 monoclonal antibody. PrP
C–
expression of the different reconstituted cell lines is directly compared to the negative control, i.e. the 
PrP
0/0 ML cells. 
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Figure 10.  Expression of the N-terminally truncated PrP
C is not cytotoxic for the PrP
o/o ML 
  cells 
 
The release of LDH in the supernatant of PrP
0/0 ML and PrP32-134 cells cultivated either at 33°C in 
10%FCS or at 39°C in SFM was monitored 48 hours after the temperature switch. The percentage of 
LDH release was obtained by comparing to the maximal release of cells treated with 1% Triton-X 100. 
No significant difference was detected between each experimental group (p<0.05, ANOVA followed 
by Scheffè’s F-test). Values are the mean ± s.e.m. of four independent experiments. 
 
4.1.5  Neuronal differentiation process in PrP- and PrPΔ32-134-reconstituted 
  PrP
0/0 ML cells 
 
A line of evidence suggests that PrP
C plays a role in cell differentiation, neurite outgrowth and 
synaptogenesis likely via the interaction with NCAMs, laminin or STI1 (Chen et al., 2003; 
Graner et al., 2000a; Kanaani et al., 2005; Lopes et al., 2005; Santuccione et al., 2005; Steele 
et al., 2006). Thus, in order to investigate whether the introduction of either wild-type PrP
C or 
its amino-terminally deleted form PrPΔ32-134 affected the differentiation potential of the 
PrP
0/0 ML cells, immunocytochemical analyses, aiming to visualize both the expression of 
neuron-specific  antigens  and  the  structural  changes  cells  undergo  under  different  growth 
conditions, were performed on the PrPA57 and PrPΔ32-134 cell lines. First, the expression of 
the CNS precursor marker nestin was evaluated and it was found that, at 33°C in serum-
containing medium, this protein was present in both the PrPA57 and PrPΔ32-134 cell lines 
(Fig. 11A, G), although at lower levels than in the PrP
0/0 ML cells (Fig. 5A). This difference 
in nestin expression could be possibly due either to the fortuitous selection of clones that 
originally expressed lower levels of the intermediate filament protein or to a possible role of 
PrP in cell differentiation, which causes a reduction in nestin expression even under normal 48 
growth conditions. As described for the PrP
0/0 ML cell line, the partial removal of the serum 
in  association  with  the  shift  of  temperature  to  39°C  for  48  hours  caused  a  strong 
downregulation of the neuronal progenitor marker in both cell lines (Fig. 11D, J). Similarly to 
the  PrP  knockout  cells,  this  reduction  in  nestin  expression  was  accompanied  by  the 
appearance of the NeuN (Fig. 11E, K and Table 1) and MAP-2b (Fig. 6E, H, K, Fig. 6F, I, L 
and Table 1) antigens in both cell types. However, while the PrP
0/0 ML cells expressed NeuN 
only  after  96  hours  from  the  growth  condition  switch  (Fig.  5H  and  Table  1),  the  PrP-
expressing cells showed NeuN expression already at 48 hours (Fig. 11E, K and Table 1). 
Furthermore, an incremented proportion of cells expressing the neuronal marker MAP-2b was 
observed in the PrP-expressing lines when compared to the PrP
0/0 ML cells (Fig. 6E, H, K, 
Fig. 6F, I, L and Table 1).  
Neuronal  differentiation  in  PrP
0/0  ML  and  PrPA57  cells  was  further  investigated  by 
monitoring the expression levels of nestin, MAP-2b (Fig 12A-B) and NF-H (data not shown) 
at  24  hours  and  96  hours  (Fig.  12C-D)  after  growth  conditions  switch  by  immunoblot 
analyses. As shown in Figure 12, Nestin expression in PrPA57 cells was reduced as compared 
to the PrP
0/0 ML cells under all the four cell growth conditions analyzed. However, nestin 
expression  levels  detected  in  both  cell  lines  at  24  hours  of  cultivation  did  not  differ 
significantly  among  the  different  culture  conditions  used  (Fig.  12A).  On  the  other  hand, 
prolonged cultivation at the nonpermissive temperature of 39°C caused a marked decrease in 
Nestin  expression  as  compared  to  the  cells  grown  at  the  permissive  temperature:  the 
downregulation in the PrPA57 cells was so strong that no signal was detectable anymore by 
immunoblot analysis (Fig. 12C). MAP-2b expression was detected as early as 24 hours of 
cultivation in both cell lines. However the expression levels in PrPA57 cell were higher than 
those  detected  in  the  PrP
0/0  ML  cells  (Fig.  12B). After 96 hours of  cultivation,  MAP-2b 
expression  was  upregulated  in  PrP
0/0  ML  cells  grown  under  both  low  serum  and 
nonpermissive conditions, indicating that the neuronal precursor cells were in the process of 
differentiation. In contrast, PrPA57 cells expressed MAP-2b only at low serum concentration 
and  33°C  but  not  if  they  were  cultivated  at  the  nonpermissive  temperature  (Fig.  12D). 
Furthermore, the expression of the late neuronal antigen NF-H was not detected at the 24 
hours time point in both cell lines and under all the four conditions of cultivation (data not 
shown). However, NF-H expression was specifically detected in PrPA57 cells cultivated at 
the nonpermissive temperature for 96 hours but not in the PrP
0/0 ML cells (data not shown). 
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Noteworthy,  comparative  analyses  of  lines  PrP
0/0  ML,  PrPA117  and  PrPA57  revealed  a 
positive correlation between the degree of PrP
C expression and the number of cells expressing 
both NeuN and MAP-2b (Table 1). Moreover, it is interesting to note that PrP
0/0 ML cells 
stably  transfected  with  an  empty  vector  (PrP
0/0  ML  EV  cells)  differentiated  into  mature 
neurons under nonpermissive conditions with the same kinetic as the parenteral cells (Fig. 
13). Therefore, the identified effect cannot be ascribed to the accidental selection of PrP-
expressing clones with fast-differentiating properties but it is rather the prion protein that 
facilitates the process of neuronal differentiation of the PrP knockout precursor cells. 
To  determine  whether  the  switch  to  nonpermissive  culture  conditions  influenced  also  the 
structure of the cells, one decided to analyze the morphology of both the PrPA57 and PrPΔ32-
134  cell  lines  and  to  compare  them  to  the  PrP
0/0  ML  cells.  Immunostaining  analyses 
performed with an anti-MAPs antiserum (that points out axons and dendrites) revealed that, at 
33°C in serum-containing medium, some of the cells of both reconstituted cell lines already 
showed a polar morphology (Fig. 11C, I). Consistent with this, the proportion of cells with 
neurites resulted about three-fold higher than that of the cells lacking the prion protein (Table 
2). Such effect was reflected also on the length of the processes as both cell lines showed 
about 30% increase in the mean length of the maximal neurites per cell when compared to the 
PrP
0/0 ML cells maintained in the same conditions of culture (Table 2). Switching the cells to 
39°C  in  SFM  for  48  hours  dramatically  incremented  the  process  of  neuritogenesis,  as 
demonstrated  by  the  fact  that  the  number  of  PrPA57  cells  harbouring  neurites  increased 
significantly (Table 2). Also the expression of PrPΔ32-134 boosted the proportion of cells 
with processes, but to a lower extent (Table 2). By contrast, no difference was seen in the 
mean length of the longest neurites per cell in both lines when compared to the same cells 
grown at 33°C in the presence of serum (Table 2). 
 
Altogether,  these  data  indicate  that  the  expression  of  PrP
C  propels  differentiation  to  the 
neuronal  phenotype  and  neuritogenesis  even  under  permissive  conditions  of  culture.  The 
switch of temperature associated with serum withdrawal further accelerates the process. The 
deletion of the N-terminal domain of the cellular prion protein does not impair this activity, 
although it makes the event less efficient. 
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Figure 11.  Accelerated  neuronal  differentiation  of  the  cells  expressing  the  wild-type  or  the 
  truncated PrP
C 
 
Immunofluorescence analyses of cell specific markers in the PrPA57 and PrPΔ32-134 cells cultivated 
under both permissive (A-C and G-I, respectively) and nonpermissive (D-F and J-L, respectively) 
conditions.  At  the  permissive  temperature,  both  the  PrPA57  and  PrPΔ32-134  cell  lines  were 
immunoreactive for nestin (A and G) but were negative for the neuronal marker NeuN (B and H). The 
morphological remodelling of the cytoskeleton was appreciated by anti-MAPs immunostaining (C, F, 
I, L). This revealed more numerous cells with neuritis as well as the presence of longer processes per 
cell (C and I) when compared to the knockout counterpart (Fig. 2C). In nonpermissive conditions, a 
strong downregulation of nestin was observed 48 hours after the switch of temperature (D and J). At 
the same time-point, the specific neuronal marker NeuN was detectable in both the PrPA57 (E) and 
PrPΔ32-134 cell lines (K). Anti-MAPs immunostainings revealed an increase in the proportion of cells 
with processes (F and L) when compared to the permissive conditions of culture. Cell nuclei were 
visualized by Hoechst 33342 staining (blue). Scale bar: 50 m. 
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Figure 12.  Upregulation  of  the  neuronal  marker  MAP-2b  after  neuronal  differentiation 
  induction 
 
Immunoblot analyses of cell specific markers in the PrP
0/0 ML and PrPA57 cells cultivated under both 
permissive and nonpermissive conditions for either 24 hours (A and B) or for 96 hours (C and D). At 
the permissive temperature, both the PrP
0/0 ML and PrPA57 cell lines were immunoreactive for nestin 
(220 kDa) (A) but were negative for the neuronal marker MAP-2b (280kDa) (B).Twenty-four hours of 
cultivation under nonpermissive conditions were not sufficient for changing the expression pattern of 
both neuronal markers (A and B). In nonpermissive conditions, a strong downregulation of nestin was 
observed 96 hours after the switch of temperature (C). At the same time-point, the early specific 
neuronal marker MAP-2b was detectable in the PrP
0/0 ML but not in the PrPA57 (D), which were 
accelerated in the neuronal differentiation process. 
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Figure 13.  PrP
0/0 ML EV cells differentiate into mature neurons with the same kinetic as the 
  parenteral PrP
0/0 ML cell line  
 
Immunofluorescence  analyses  of  cell  specific  markers  in  the  PrP
0/0  ML  and  PrP
0/0  ML  EV  cells 
cultivated  under  both  permissive  (A-C  and  G-I,  respectively)  and  nonpermissive  (D-F  and  J-L, 
respectively) conditions. At the permissive temperature, both the PrP
0/0 ML and PrP
0/0 ML EV cell 
lines were immunoreactive for nestin (A and G) but were negative for the neuronal markers MAP-2b 
(B and H) and NeuN (C and I). In nonpermissive conditions, a strong downregulation of nestin was 
observed 48 hours after the switch of temperature (D and J). At the same time-point, the specific 
neuronal marker MAP-2b was detectable in both the PrP
0/0 ML (E) and PrP
0/0 ML EV cell lines (K) 
but not the neuronal marker NeuN (F and L). 
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4.1.6  Activation of p59Fyn kinase in PrP-mediated neuronal differentiation 
 
Nonreceptor protein tyrosine kinases of the Src family regulate the survival, proliferation, 
differentiation and motility of many cell types (Erpel and Courtneidge, 1995; Kalia et al., 
2004; Parsons and Parsons, 1997; Parsons and Parsons, 2004). The p59Fyn kinase, a member 
of  this  family  (Resh,  1998)  has  been  reported  to  play  a  role  in  PrP-mediated  neurite 
outgrowth, neuronal polarization and neuronal survival (Chen et al., 2003; Kanaani et al., 
2005; Mouillet-Richard et al., 2000; Santuccione et al., 2005). In order to assess whether the 
observed PrP-mediated acceleration of neuronal differentiation in the PrP
0/0 ML cells involves 
the activation of the p59Fyn kinase, the activation state of this kinase by specific detection of 
the p59Fyn inactive form after immunoprecipitation was determined. As shown in Fig. 14, in 
PrPA57 and PrPΔ32-134 cells the levels of Tyr-416 dephosphorylated p59Fyn decreased as 
compared to the PrP
0/0 ML cells already when the cells were cultivated under permissive 
conditions, indicating that in these two cell lines the steady-state activation of the p59Fyn 
kinase was increased. When neuronal differentiation was induced by switching the growth 
conditions for 72 hours, strong reduction in non-phosphorylated p59Fyn kinase levels was 
detected  in  the  PrPA57  cells.  On  the  other  hand,  no  change  was  detected  in  the 
phosphorylation  state  of  p59Fyn  kinase  in  both  PrP
0/0  ML  and  PrPΔ32-134  cells  under 
nonpermissive  conditions  as  compared  to  the  activation  state  observed  under  permissive 
conditions.  To  further  assess  the  role  of  p59Fyn  kinase  signal  pathways  in  PrP-mediated 
acceleration of neuronal differentiation, PP1, an inhibitor of the Src kinase family, was tested 
for its ability to inhibit the effect on neuronal differentiation of both wild type PrP
C and 32-
134 PrP. PP3 was included as negative control. Immunofluorescence analyses showed that 5 
M  of  PP1  inhibited  but  not  completely  blocked  the  enhancing  effects  of  PrP  on  the 
differentiation of PrP
0/0 ML cells under nonpermissive conditions (Fig.15). Altogether, these 
data indicate that PrP-mediated neurodifferentiation in PrP
0/0 ML cells implies the activation 
of the p59Fyn kinase signal pathways. 54 
 
Figure 14. Temperature- and growth factor-dependent activation of the tyrosine kinase p59Fyn 
 
Activation state of the p59Fyn kinase was determined in the PrP
0/0 ML, PrPA57 and PrP32-134 cell 
lines cultivated under both permissive (P) and nonpermissive conditions (NP).The activation state of 
p59Fyn  was  determined  by  the  specific  detection  of  the  p59Fyn  inactive  form  after 
immunoprecipitation.  A  specific  antibody  recognizing  the  non-phosphorylated  Tyr-416  was  used. 
Under permissive conditions, a reduction in the levels of inactive p59Fyn was observed in both the 
PrPA57  and  PrP32-134  cell  lines  as  compared  to  the  PrP
0/0  ML  cell  line.  When  neuronal 
differentiation was induced by switching the growth conditions for 72 hours, a strong reduction in 
non-phosphorylated p59Fyn kinase levels was detected in the PrPA57 cells. On the other hand, no 
change was detected in the phosphorylation state of p59Fyn kinase in both PrP
0/0 ML and PrPΔ32-134 
cells under nonpermissive conditions as compared to the activation state observed under permissive 
conditions. 
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Figure 15.   Partial inhibition of PrP
C-mediated neuronal differentiation by the p59Fyn kinase 
  inhibitor PP1 
 
Immunofluorescence analyses of cell specific markers in the PrP
0/0 ML, PrPA57 and PrP32-134 cells 
cultivated  under  nonpermissive  conditions  for  48  hours  (A-F,  G-L  and  M-R,  respectively).  The 
addition of the inhibitor of the Src kinase family PP1 (5 M) (D-F, J-L and P-R, respectively), but not 
of the control compound PP3 (A-C, G-I and M-O, respectively), inhibited but not completely blocked 
the enhancing effects of PrP on the differentiation of PrP
0/0 ML cells under nonpermissive conditions 
as shown by increased levels of the markers nestin (D, J and P, respectively) and MAP-2b (E, K and 
Q) and decreased levels of late neuronal marker NeuN (F, L and R). These data indicate that PrP
C-
mediated neurodifferentiation in PrP
0/0 ML cells implies the activation of the p59Fyn kinase signal 
pathways. 
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4.1.7  Neural  cell  adhesion  molecule  (NCAM)  and  PrP-mediated  neuronal 
  differentiation 
 
The neural cell adhesion molecule (NCAM) is a cell surface glycoprotein belonging to the 
cell adhesion molecules (CAMs) of the immunoglobulin (Ig) superfamily. NCAM is widely 
expressed during embryonic development, whereas it is found mainly in tissues of neuronal 
origin in the adult organism. NCAM exists in several isoforms, due to alternative splicing of a 
single  gene,  consisting  of  at  least  26  exons.  Three  major  isoforms  are  expressed:  two 
transmembrane isoforms, NCAM 180 and NCAM 140, with apparent molecular weights of 
180  kDa  and  140  kDa,  respectively,  and  a  GPI-anchored  isoform,  NCAM  120,  with  an 
apparent molecular weight of 120 kDa (Barthels et al., 1992; Dickson et al., 1987; Jorgensen 
and  Bock,  1974;  Owens  et  al.,  1987;  Small  et  al.,  1988;  Thompson  et  al.,  1989).  In  the 
vertebrate nervous system, NCAM is the dominant carrier of polysialic acid (PSA). Through 
its  extracellular  region,  NCAM  mediates  both  homophilic  and  heterophilic,  cis  and  trans 
interactions. NCAM and its polysialylated form PSA-NCAM have been found to be involved 
in  various  aspects  of  neuronal  and  synaptic  plasticity  and  play  a  major  role  during 
development of the nervous system. Due to its negative charge and large hydrated volume, 
PSA on NCAMs attenuates cell adhesion and is being studied for its ability to intervene in 
dynamic cellular changes (Theodosis et al., 1999). There is much evidence to support its role 
in the developing CNS in which PSA-NCAM has been shown to intervene in cell migration 
(Thiery et al., 1982), neurite outgrowth (Cremer et al., 1997; Fraser et al., 1984; Silver and 
Rutishauser, 1984; Thanos et al., 1984) and axonal fasciculation (Cremer et al., 1997; Thiery 
et al., 1982) (for reviews, Bruses and Rutishauser, 2001; Rougon and Hobert, 2003). The 
expression of PSA-NCAM markedly decreases during  embryonic development and in the 
adult brain, PSA-NCAM is only expressed in areas which retain a high degree of plasticity 
(Chuong and Edelman, 1984; Rothbard et al., 1982).  
Noteworthy, it has previously been shown that PrP
C and NCAM not only associate with each 
other  at  the  surface  of  hippocampal  neurons,  but  also  directly  interact  with  each  other 
(Santuccione et al., 2005). Furthermore, PrP
C recruits to and stabilizes the transmembrane 
NCAM  isoforms  in  lipid-rich  microdomains  to  activate  the  p59Fyn  kinase  and  promote 
NCAM-mediated neurite outgrowth by cis and trans interactions (Santuccione et al., 2005). 
 
In  order  to  assess  whether  PrP-mediated  acceleration  of  neuronal  differentiation  and 
neuritogenesis in the PrP
0/0 ML cells involves the regulation of PSA-NCAM expression, the 57 
PSA-NCAM expression patterns in the PrP
0/0 ML and PrPA57 cells under both the permissive 
and  nonpermissive  culture  conditions  for  48  and  72  hours  were  determined  by  FACS 
analyses. As shown in Figure 16, PSA-NCAM levels were higher in the PrP
0/0 ML cells as 
compared to the PrPA57 cells under permissive (Fig 16A) as well as under nonpermissive 
(Fig. 16 B) culture conditions. Interestingly, the switch to nonpermissive culture conditions 
increased the PSA-NCAM expression levels in the PrP
0/0 ML cells but not in the PrPA57 
cells.  As  mentioned  above  (see  4.1.5),  expression  of  PrP
C  propels  differentiation  to  the 
neuronal  phenotype  and  neuritogenesis  even  under  permissive  conditions  of  culture. 
Therefore,  the  observed  difference  in  PSA-NCAM  levels  between  the  PrP
0/0  ML  and  the 
PrPA57 cells  could  be ascribed to  the neuronal  differentiation-induced downregulation  of 
PSA-NCAM  expression.  Being  PSA-NCAM  also  a  common  marker  used  to  identify 
immature neurons (Kempermann et al., 2004), these data further reinforce the finding that the 
PrP
0/0 ML cells are neuronal precursor cells (see 4.1.3). 
 
 
Figure 16. PSA-NCAM is expressed in PrP
0/0 ML and PrPA57 cells 
 
FACS  analyses  for  PSA-NCAM  expression  in  the  PrP
0/0  ML  and  PrPA57  cells  cultivated  under 
permissive (upper panels) and nonpermissive (lower panels) conditions for 48 hours (green curve) or 
72 hours (purple curve). PrP
0/0 ML cells expressed higher PSA-NCAM levels as compared to the 
PrPA57 cells under both the permissive and nonpermissive culture conditions. Isotype control (black 
/blue filled curve) was included as negative control. 
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4.2  The role of plasma membrane-released microvesicles in the paracrine 
  diffusion of PrP
C and propagation of prion infectivity 
 
Shedding of membrane-derived microvesicles (MVs) by various cell types is a physiological 
phenomenon.  Evidence  exists  that  MVs  shedding  provide  vehicles  to  transfer  molecules 
among cells, and that MVs are important modulators of cell-to-cell communication (Ratajczak 
et al., 2006). It has previously been shown that neuronal cells release exosomes containing 
numerous proteins and lipids similar to those present in the membranes of the cells from 
which they originate, including typical neuronal proteins such as the GluR2/3 subunits of 
glutamate receptors and the cell adhesion molecule L1 (Faure et al., 2006). Interestingly, the 
exosomes released by cortical neurons also harbor PrP
C (Faure et al., 2006). Furthermore, the 
release of PrP
C and infectious PrP
Sc by prion infected epithelial, neuroglial and neuronal cells 
in association with exosomes has recently been highlighted (Fevrier et al., 2004; Vella et al., 
2007a), suggesting that PrP
Sc-bearing exosomes may provide a mechanism for intercellular 
transmission of infectious prions in addition to cell–cell contact. 
 
4.2.1  Neuronal  cells  release membrane-derived microvesicles  bearing  PrP
C 
  and other lipid rafts components 
 
In  order  to  determine  whether  neuronal  cells  may  also  release  plasma  membrane-derived 
microvesicles (MVs) in addition to exosomes and to investigate whether these MVs contain 
PrP
C and other lipid rafts components, the cell culture supernatants of four different neuronal 
cell lines, namely the Neuro-2a, the PrP
0/0 ML, the PrPA109 and the Neuro-2a PK1 cells, 
were analyzed for the presence of MVs. The isolation of MVs from cell culture supernatants 
was based on a sequential centrifugation steps protocol in which increasing centrifugal forces 
were used (see Materials and Methods). Plasma membrane-derived MVs were collected at 
20000g, a centrifugal force not sufficient to enrich exosomes, which were later isolated from 
the Neuro-2a PK1 cells by ultracentrifugation. 
Electron  microscopy  (EM)  analyses  of  MVs  preparations  negatively  stained  with  uranyl 
acetate from both PrPA109 and PrP
0/0 ML cells demonstrated the presence in the 20000g 
fractions of vesicles with a diameter ranging from 100 nm to 1 m (Fig 17), a size compatible 
with that described for MVs purified from other cells (Ratajczak et al., 2006).  
To exclude the presence of contaminating exosomes within the MV-enriched fractions, the 
levels  of  Tgs101  and  Alix  1,  both  cytoplasmic  proteins  previously  identified  as  specific 59 
markers  for  exosomes  (Geminard  et  al.,  2004;  Thery  et  al.,  2001),  were  assessed  by 
immunoblot  analysis.  As  shown  in  Figure  18,  the  signals  obtained  in  the  MV-enriched 
fraction were lower than those observed in the exosomes-enriched fraction prepared from 
Neuro-2a  PK1  cells.  That  indicates  either  a  low  level  cross  contamination  of  MVs  with 
exosomes  or  that  both  proteins  are  also  incorporated  in  membrane-released  MVs  during 
blebbing of the membrane surface. 
 
Figure 17. Neuronal cells release plasma membrane microvesicles 
 
Electron microscopy analyses of MVs preparations from cell culture supernatants of the PrPA109 (A) 
and the PrP
0/0 ML (B) cells. Both cell lines released plasma membrane-derived MVs in the culture 
supernatants.  MVs  showed  an  average  diameter ranging  from  100  nm  to  1  m.  MVs  aggregates 
formed probably during the serial centrifugation steps used. Scale bar: 500 nm. 
Figure 18. Detection of exosomal specific markers in the microvesicle-enriched fractions 
 
Presence of the exosomal markers Alix 1 (95 kDa) (A) and Tsg101 (45 kDa) (B) were analyzed by 
immunoblot in both MV-enriched (MVs) and in exosome-enriched preparations (Ex). The cytosolic 
proteins were detected in both preparations. The lower levels of both exosomal markers present in the 
MVs  indicated  a  possible  exosomal  contamination  of  these  fractions.  Positions  of  the  molecular 
weight standards (in kDa) are indicated. 
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Like other GPI-anchored proteins, PrP
C as well as PrP
Sc are localized in glycosphingolipid-
enriched  microdomains  (or  lipid  rafts)  of  neuronal  and  lymphocytic  plasma  membranes 
(Loberto et al., 2005; Mattei et al., 2002; Naslavsky et al., 1999; Vey et al., 1996), which are 
also enriched in several cytoplasmatic proteins, including tyrosine kinases (Masserini et al., 
1999; Mouillet-Richard et al., 2000). In particular, in these specialized portions of cell plasma 
membrane PrP
C strictly associates with gangliosides and transducer proteins, such as p59Fyn 
kinase (Mouillet-Richard et al., 2000). Moreover, the association of PrP
C with rafts is required 
for its conversion into the protease-resistant isoform PrP
Sc (Baron et al., 2002; Masserini et 
al., 1999; Naslavsky et al., 1999). 
The presence of PrP
C and other lipid rafts components such as Flotillin-2, gangliosides and 
the tyrosine kinase p59Fyn was therefore tested in MVs released by neuronal cells either by 
EM or by immunoblot analyses. As shown in Figure 19, immunoelectron microscopy (IEM) 
analysis revealed the presence of PrP
C on MVs isolated from the PrPA109 cells but not on 
MVs isolated from the PrP
0/0 ML cells, as expected. The binding of the monoclonal anti-PrP 
antibody 6H4 to PrP
C was visualized by an immunogold labeling (10 nm gold particles). The 
lack of immunogold labeling on PrP
0/0 ML-secreted MVs confirmed the specificity of the 
PrP
C-immunolabeling. Furthermore, IEM analysis of ultrathin sections of Neuro-2a PK1 cells 
revealed the unevenly distribution of PrP
C on the membrane of MVs as well as on the cell 
plasma membrane (Fig. 20). The presence of PrP
C in MVs released from the PrPA109 (Fig. 
21), the Neuro-2a (Fig. 21) and the Neuro-2a PK1 cells (Fig. 23) was then confirmed by 
immunoblot analysis. 
 
 
Figure 19.  Neuronal cells shed PrP
C-bearing plasma membrane-derived microvesicles 
 
Immunoelectron microscopy analyses of PrP
C expression on microvesicles released by the PrPA109 
and the PrP
0/0 ML cell lines (A-C and D, respectively). PrP
C was specifically detected only in MVs 
released by the PrP
C-expressing (A-C) but not by the PrP
C-depleted cells (D). PrP
C was revealed by 
immunogold labelling (10 nm). 
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Figure 20.  Unevenly distribution of PrP
C on the membrane of microvesicles as well as on the cell 
  plasma membrane 
 
Immunoelectron microscopy analyses of PrP
C expression in ultrathin sections of Neuro-2a PK1 cells. 
PrP
C was specifically detected both on the cellular plasma membrane (on the right) as well as on the 
membrane of MVs. PrP
C was revealed by immunogold labelling (10 nm) and indicated on the image 
by the black arrows. 
 
 
Figure 21.  Presence of PrP
C in microvesicles released by different neuronal cell lines  
 
Immunoblot analyses confirmed the presence of PrP
C in MVs derived from the PrPA57 (A, lane 2), 
PrPA109 (A, lane 3) and the Neuro-2a cells (B, lane 1). MVs isolated from PrP
0/0 ML cells were 
negative for PrP
C, as expected (A, lane 1). Crude brain homogenate from wild type mice was included 
as positive control (B, lane 2). 62 
In order to assess the presence of gangliosides GM1 and GM2 in MVs released by the Neuro-
2a cells, acidic glycosphingolipids extracted from MVs were immunostained by an anti-GM2 
antibody (Kotani et al., 1992) and by HRP-CtxB, which stains GM1. The presence of GM2 
but not that of GM1 was detected (Mattei, V.and Barenco, M.G., unpublished results). 
Since p59Fyn as well as flotillin-2 have been indicated as raft components, which may be 
associated with PrP
C (Kramer et al., 1999; Mattei et al., 2004; Mouillet-Richard et al., 2000; 
Slaughter et al., 2003; Stuermer et al., 2004), the presence of both proteins in neuronal cells-
derived MVs was investigated. Western blot analyses showed a 59 kDa band specifically 
recognized by the anti-Fyn antibody (Mattei, V., Barenco, M.G., unpublished results) and a 
42 kDa band specifically recognized by the anti-flotillin-2 antibody (Mattei, V. and Barenco, 
M.G., unpublished results). Furthermore, the axonal membrane protein GAP-43, a neuronal 
protein which binds to rafts via its acylated N-termini, was also detected in MVs derived from 
the Neuro-2a cells (Mattei, V. and Barenco, M.G., unpublished results).  
These findings suggest that raft components strictly associated with PrP
C on the cell plasma 
membrane, such as gangliosides, p59Fyn and flotillin-2, are recruited during the formation of 
MVs in neuronal cells. 
 
4.2.2  Paracrine transfer of PrP
C by microvesicles 
 
It has been shown that microvesicles are involved in paracrine and endocrine transport of 
cellular  components  such  as  membrane  receptors,  proteins,  mRNA  and  organelles  (e.g. 
mitochondria).  Furthermore,  MVs  are  also  important  modulators  of  cell-to-cell 
communication (Ratajczak et al., 2006). As MVs released by neuronal cells harbor PrP
C (see 
4.2.1), they could be involved in the intercellular trafficking of PrP
C. 
In  order  to  experimentally  approach  this  hypothesis,  PrP
C-bearing  (MVs
A109)  and  PrP
C-
negative (MVs
0/0) MVs were first isolated accordingly to the established serial centrifugation 
step protocol (see Materials and Methods) from the PrPA109 and the PrP
0/0 ML cell line, 
respectively. The isolated MVs were then incubated for 2 hours with the PrP
0/0 ML cells to 
allow MVs uptake/fusion by the recipient cells. After intensive washing, cells were fixed and 
processed for immunofluorescence analysis to detect the presence of PrP
C. For PrP
C detection 
two  different  monoclonal  antibodies,  namely  the  6H4  (Prionics  AG,  CH)  and  the  8G8 
antibody (Cayman, USA), were used. The specificity of the staining obtained with the 6H4 
antibody was clearly better than that obtained with the 8G8 antibody (data not shown).  63 
As shown in Figure 22, a perinuclear and a cell membrane PrP
C specific staining was detected 
in  the  PrPA109  cells  (Fig.  22C)  but  not  in  the  PrP
0/0  ML  cells  (Fig.  22A),  as  expected. 
Negative was also the staining obtained with the isotype control antibody, namely the anti-
TNP mouse IgG1,k monoclonal antibody (Fig. 22B and D). This was a further indication for 
the  PrP
C  specificity  of  the  6H4  antibody.  Interestingly,  a  punctuate  and,  very  rarely,  a 
perinuclear PrP
C staining was detected in the PrP
0/0 ML cells incubated with the MVs
A109 
(Fig. 22H and I). The punctuate staining observed could be due to the binding and/or fusion of 
the PrP
C-bearing MVs to the plasma membrane of the recipient cells whereas the perinuclear 
staining could be due to the uptake and intracellular transport of PrP
C after MVs fusion. 
However,  incubation  of  the  PrP
0/0  ML  cells  with  the  MVs
0/0  led  sometimes  to  similar 
observations,  at  least  as  for  the  punctuate  staining  (Fig.  22E).  This  could  indicate  an 
unspecific binding of the 6H4 antibody to MVs. Furthermore, in order to exclude a possible 
contamination of the MVs
A109 preparations with PrPA109 donor cells, a contamination that 
could lead to false positive results, an additional experiment was performed. MVs
A109 were 
isolated by centrifugations (see Materials and Methods) from PrPA109 cell supernatants that 
were first  filtered through a 1,2  m  pore filter in  order to  remove detached and floating 
PrPA109 cells. The exclusion size of the filter allowed specific removal of cells but not that of 
the MVs (0,1-1 m). PrP
C specific staining was not detected in the PrP
0/0 ML cells incubated 
with  filtered  MVs
A109  anymore  (Fig.  22J).  No  PrP
C  signal  was  found  in  the  control 
counterparts, i.e. the PrP
0/0 ML cells incubated with filtered MVs
0/0, as expected (Fig. 22G). 
These  findings  indicated  that  the  detected  PrP
C  signals  were  most  probably  due  to  a 
contamination  of  the  MVs
A109  preparations  with  donor  PrPA109  cells.  This  in  vitro 
immunofluorescence-based assay was therefore considered as unsuitable for studying MV-
mediated intercellular trafficking of PrP
C. 
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Figure 22. Paracrine diffusion of PrP
C 
 
Upper panel: PrP immunostaining in PrP
0/0- (A-B) and PrPA109 (C-D) cell lines. A perinuclear and a 
cell membrane PrP
C specific staining was detected in the PrPA109 cells (C), but not in the PrP
0/0 ML 
cells (A), as expected. Isotype control antibody (B and D) was included as negative control. 
Lower panel: PrP
0/0 cells were incubated with either MVs
0/0 (E-G) or MVs
A109 (H-J). A PrP
C staining 
was detected in the PrP
0/0 ML cells incubated with the non-filtered MVs
A109 (H-I), but not when the 
cells were incubated with the filtered MVs
A109 (J). 
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4.2.3  Prion infected neuronal cells release membrane-derived microvesicles 
  bearing the pathogenic isoform PrP
Sc 
 
The release of PrP
C and infectious PrP
Sc by prion infected epithelial, neuroglial and neuronal 
cells in association with exosomes has recently been highlighted (Fevrier et al., 2004; Vella et 
al.,  2007a),  suggesting  that  PrP
Sc-bearing  exosomes  may  provide  a  mechanism  for 
intercellular  transmission  of  infectious  prions  in  addition  to  cell–cell  contact.  In  order  to 
assess whether prion infected neuronal cells may release membrane-derived MVs harboring 
PrP
Sc  and  prion  infectivity,  MVs  were  isolated  from  cell  culture  supernatants  of  Rocky 
Mountain Laboratory prion strain (RML)-infected and non-infected Neuro-2a PK1 cells. The 
presence of PrP
Sc was then assayed by immunoblot analysis after proteinase K (PK) digestion. 
The abnormally folded PrP
Sc is partially resistant against PK treatment, whereas the cellular 
isoform PrP
C is completely degraded by this protease (Prusiner, 1998). Different amounts of 
PK were used to digest 20 g of proteins in MV- and cell-lysates, i.e. 0,1 g or 0,3 g or 1 g 
PK. As shown in Figure 23, MVs derived from infected Neuro-2a PK1 cells harbored PK-
resistant PrP characterized by the shift of the three bands, corresponding to the di-, mono- and  
Figure 23. Prion infected neuronal cells shed PrP
Sc bearing microvesicles 
 
Left panel: Detection of PrP
Sc in MVs isolated from culture supernatants of prion non-infected and 
infected Neuro-2a PK1 cells. Twenty g total proteins of isolated MVs were PK digested. PrP
Sc was 
specifically detected in MVs released by the infected but not from the non-infected N2a PK1 cells. 
Right  panel:  Detection  of  PrP
Sc  in  infected  Neuro-2a  PK1  cells.  Two  hundred  and  fifty  g  total 
proteins  of  cell  lysates  were  PK  digested.  The  presence  of  PK-resistant  PrP
Sc  was  assessed  with 
increasing amounts of proteinase K and detected by the use of the 6H4 antibody. The positions of the 
molecular weight standards (in kilodaltons) are indicated. 
 
 
unglycosylated forms of PrP, because of the PK-dependent removal of the first 90 aa (Fig. 23 
left panel). This is a clear indication for the presence of PrP
Sc. Interestingly, the levels of PrP
Sc 
detected in the purified MVs were higher than those observed in the parental cell line (Fig. 23 66 
right  panel),  suggesting  that  PrP
Sc  is  enriched  on  the  membrane  of  MVs.  PrP
Sc  was  not 
detected, as  expected, in  MVs secreted by non-infected Neuro-2a PK1 cells  (Fig.  23  left 
panel), confirming that PrP
Sc is released specifically from prion infected neuronal cells. Thus, 
these findings clearly indicate that prion infected neuronal cells such as the Neuro-2a PK1 
shed plasma membrane-derived MVs containing PrP
Sc. 
 
4.2.4  In vitro prion infectivity transmission by PrP
Sc-bearing microvesicles 
 
Having shown that RML-infected Neuro-2a PK1 release MVs harboring PrP
Sc, the hypothesis 
that MVs may act as carriers of prion infectivity was then experimentally challenged. The 
potential role of MVs in prion infectivity transmission was first tested in an in vitro infection 
model. 
Noninfected  Neuro-2a  PK1  cells  were  incubated  with  MVs  isolated  from  cell  culture 
supernatants of either infected (MVs
Inf) or noninfected (MVs
Noninf) Neuro-2a PK1 cells. Brain 
homogenates (1% w/v) either from scrapie sick (Chandler) or from normal healthy (mock) 
mice were used as positive or negative inoculum controls, respectively. De novo amplification 
of PrP
Sc was then followed for longer than 3 months post infection by cell blot assay (Fig. 24). 
Conversion of the endogenous PrP
C into the prion disease-associated pathological isoform 
PrP
Sc was only detected in Neuro-2a PK1 cells treated with MVs derived from prion-infected 
but not from non-infected donor cells (Fig. 24). PK resistant PrP was detected in recipient 
Neuro-2a PK1 cells as early as at passage 1 after inoculation with MVs
Inf and Chandler but 
not after challenge with the negative control preparations (Fig. 24). As the amount of PrP
Sc at 
passage 2 was lower than at passage 1, the PK-resistant PrP detected early after infection was 
most probably due to the persistence of the PrP
Sc-positive inocula and not to prion replication. 
However, all along the first few weeks of cultivation after infection the amount of PrP
Sc 
increased  constantly  in  the  MVs
Inf  and  Chandler  infected  Neuro-2a  PK1  cells.  Prion 
replication was detected up to 30 passages after infection, indicating that MV-dependent prion 
transmission generated a persistent infection in the recipient neuroblastoma cells. 
 67 
Figure 24. In vitro transmission of prion infectivity by PrP
Sc bearing microvesicles 
 
Cell blot assay detecting de novo infected N2a PK1 cells at serial culture passages. N2a PK1 cells 
were incubated with MVs isolated from non-infected (MVs
Noninf) or from infected (MVs
Inf) N2a PK1 
cells. Mock and Chandler infections were also included as negative and positive control, respectively. 
A time-dependent increase of PrP
Sc levels was detected after proteinase K treatment (+ PK). 
 
 
4.2.5  In vivo prion infectivity transmission by PrP
Sc-bearing microvesicles 
 
In order to further confirm the association of prion infectivity with membrane-derived MVs 
and to determine prion titres, in vivo biossay was performed in which purified MVs from 
infected  (MVs
Inf)  and  non-infected  (MVs
Noninf)  Neuro-2a  PK1  cells  or  cell  lysates  were 
intracerebrally inoculated into tga20 indicator mice (Fischer et al., 1996). Brain homogenates 
either from scrapie sick (RML) or from normal healthy (mock) mice were used as positive 
and negative inoculum controls, respectively. Incubation times until development of terminal 
scrapie were determined and infectious titres were calculated by comparing incubation times 
against a calibration curve (Table 3). Indicator mice developed clinical prion disease after 68 
inoculation  with  Rocky  Mountain  Laboratory  mouse-adapted  prions  (RML)  at  the  three 
dilutions tested, but not when they were inoculated with mock control, as expected.  
Interestingly, membrane-derived MVs from infected (MVs
Inf) but not those from non-infected 
(MVs
Noninf) Neuro-2a PK1 cells were capable of transmitting prion disease to tga20 indicator 
mice, demonstrating that MVs
Inf are infectious not only in vitro but also in vivo. Furthermore, 
MV-associated prion titres were higher than those detected as cell-associated (Table 3), a 
finding  confirming  the  observation  that  MVs
Inf  contained  more  PrP
Sc  then  the  cells  from 
which they were derived (see 4.2.3). On the other hand, MVs
Inf seemed to be a little less 
infectious than crude brain homogenate: indeed mice challenged with 6x10
-2 dilution of RML 
(i.e. corresponding to 10 µg of total brain proteins) developed clinical prion disease earlier 
(64±2 days post infection) than those challenged with MVs (68±2 days post infection). 
Thus,  release  of  microvesicles-associated  PrP
Sc  by  infected  cells,  in  addition  to  cell–cell 
contacts, could be considered as an acellular mechanism underlying the spread of prions. 
 
Table 3.  PrP
Sc-bearing microvesicles transmit disease to Tga20 indicator mice 
 
Inoculum 
Indicator mice 
succumbing to 
scrapie 
Scrapie death 
Days  
(mean +/-STDEV) 
Estimated infectivity 
titres (log LD50/ml) 
Mock 10
-4  0/4  >150  <1.5 
RML 10
-4  4/4  78±2  4.6 
RML 10
-2  4/4  68±2  5.5 
RML 6x10
-2  4/4  64±2  5.8 
MVs
Noninf  0/4  >150  <1.5 
MVs
Inf  4/4  68±2  5.5 
Neuro-2a PK1 cells  0/4  >150  <1.5 
Neuro-2 a PK1 inf. cells  4/4  76±6  4.8 
 
Tga20 indicator mice were inoculated intracerebrally with either 30 l (10 g total proteins) of cell 
lysates or MVs or with 30 l of different RML brain homogenate dilutions. Mock-inoculated animals 
were  included  as  negative  controls.  Incubation  time  until  development  of  terminal  scrapie  was 
determinated.  The  relationship  y  =11.45-0.088  x,  where  y  is  logLD50/ml  homogenate  and  x  is 
incubation time in days to terminal disease, was used to calculate infectivity titres (Prusiner et al., 
1982) 
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4.2.6  Establishment of a novel cell-based in vitro prion replication model 
 
Expression  of  PrP
C  is  necessary,  although  not  sufficient,  to  confer  capability  of  prion 
replication. As previously described (see 4.1.4), the neuronal precursor cell line PrP
0/0 ML 
was reconstituted for murine PrP
C expression. Several independent clones showing different 
PrP
C-levels  were selected and further characterized. These clones could  be used as  novel 
models for studying in vitro prion replication and prion neurotoxicity given that they are 
susceptible to prion infection. Furthermore, once established that the PrP
0/0 ML cells are prion 
replication competent, one might reconstitute them for the expression of both human and 
bovine PrP in order to establish in vitro replication models for human and bovine prions. 
These models are nowadays still not available. 
 
4.2.6.1 Susceptibility of the PrPA36 cell line to MV-mediated prion infection 
 
The PrPA36 cells were derived by transfection of the neuronal precursor cell line PrP
0/0 ML 
with an expression cassette encoding for wild type PrP (see 4.1.4.2) and strongly overexpress 
PrP
C (data not shown). Having shown that MVs are efficient carriers of prion infectivity and 
can initiate efficiently prion infection both in vitro and in vivo, susceptibility of the PrPA36 
cell line to prion infection was tested by challenging them with PrP
Sc-bearing MVs. Infectious 
MVs (MVs
22L) were isolated from Neuro-2a 58 cells stably infected with the 22L scrapie 
strain (Nishida et al., 2000). MVs (MVs
Noninf) isolated from noninfected Neuro-2a PK1 cells 
were included as negative control. De novo amplification of PrP
Sc was then followed by cell 
blot assay at each passage. As shown in Figure 25, weak PrP
Sc accumulation was detected in 
PrPA36 cells as early as at passage 2 after challenge with MVs
22L (Figure 25). Amounts of 
PrP
Sc increased  constantly in  the MVs
22L-infected PrPA36 cells  upon time (Figure  25),  a 
finding clearly indicating that in the PrPA36 cells a persistent prion infection was successfully 
established. No PrP
Sc was detected all along the infection period in MVs
Noninf-treated cells, as 
expected. Thus, the PrPA36 cell line is prion replication competent. 
Of interest, the observation that the Neuro-2a PK1 cells were not as susceptible to 22L prions 
as to the Chandler prions (Figure 26). Indeed, upon MVs
22L-mediated infection PrP
Sc was 
detected in the Neuro-2a PK1 cells all along the infection period but  at very low levels. 
Furthermore, the highest PrP
Sc levels were found at the earlier passages, as for example in 
passage 5, and at later passages no increase of PrP
Sc was observed. The different susceptibility 
of a cell line to different prion strains is a well established biological phenomenon. 70 
 
 
Figure 25. Establishment of a novel in vitro replication model for murine prions 
 
The novel PrP
C-reconstituted neuronal progenitor cell line PrPA36 was infected by PrP
Sc-harboring 
MVs enriched from the N2a58 cells stably infected with the murine prion strain 22L. Cell blot assay 
detecting de novo infected PrPA36 cells at serial culture passages. PrPA36 cells were incubated with 
MVs isolated from non-infected (MVs
Noninf) Neuro-2a PK1 or from infected (MVs
22L) N2a58 cells. A 
time-dependent increase of PrP
Sc levels was detected after proteinase K treatment (+ PK). 
 
 
Figure 26. Prion strain specific susceptibility of the Neuro-2a PK1 cells 
 
Neuro-2a  PK1  cells  were infected  by  PrP
Sc-harboring  MVs  enriched  from  the  N2a58  cells  stably 
infected with the murine prion strain 22L. Low levels of prion replication and PrP
Sc accumulation were 
detected by cell blot assay, indicating a reduced susceptibility of the Neuro-2a PK1 cells to the murine 
22L prion strain as compared to the Chandler strain. PrP
Sc levels were detected after proteinase K 
treatment (+ PK). 
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4.2.6.2 Susceptibility of the PrPA36 cell line to prion infection: a coculture approach 
 
As it has previously been shown that cell-to-cell contacts contribute to intercellular spread of 
prions,  a  co-culture  approach  was  chosen  to  confirm  prion  replication  capability  by  the 
PrPA36 cell line. Noninfected PrPA36 cells were co-cultured with the infected N2a58/22L 
cells in a ratio of 2:1. Cells were let grow to confluence and then passaged first at 1:2 dilution 
and  then  at  1:5  dilution.  PrPA36  cells  were  positively  selected  by  addition  of  2  g/ml 
Puromycin, a concentration sufficient to kill all N2a58/22L cells upon time. At passage 10, 
only PrPA36 cells were left, as determined by morphological examination. Cell blot assay 
performed at passage 16 (Fig. 27) showed a strong PrP
Sc accumulation, a finding indicating 
that the PrPA36 were infected. Thus, prion infectivity was efficiently transmitted from the 
infected N2a58/22L cells to the recipient PrPA36 cells and a persistent prion infection was 
then established in the PrPA36 cells.  
The PrPA36 cell line is therefore a prion replication competent cell line, at least for the 22L 
prion strain as shown by two different infection approaches. This cell line could be used as an 
in vitro model for studying prion replication-dependent cellular pathways. 
 
 
 
Figure 27.  Establishment of a novel in vitro replication model for murine prions: an alternative 
  infection approach 
 
Noninfected  PrPA36  cells  were  co-cultured  with  the  infected  N2a58/22L  cells  in  a  ratio  of  2:1. 
PrPA36 cells were positively selected by addition of 2 g/ml Puromycin. Cell blot assay performed at 
passage 16 showed a strong PrP
Sc accumulation, a finding indicating that the PrPA36 were infected. 
PrP
Sc levels were detected after proteinase K treatment (+ PK) 72 
5 DISCUSSION 
 
5.1 The cellular prion protein and neuronal differentiation 
 
The cellular prion protein (PrP
C) is a highly conserved glycoprotein of unknown biological 
function. To gain insight into the physiological role of PrP
C, a novel PrP knockout cell line 
was  generated  by  immortalization  of  neuroepithelial  precursor  cells  derived  from  the 
cerebellum  of  PrP-knockout  mice.  The  differentiation  potential  of  this  cell  line  was  then 
monitored by evaluating structural parameters, including i) the expression of specific markers 
for mature neurons and ii) the development of a typical neuronal morphology.  
 
5.1.1  Establishment and characterization of a novel PrP-knockout cell line 
 
In the present study a novel PrP knockout cell line, PrP
0/0 ML, was successfully established 
by transducing cerebellar neuroepithelial precursors from the PrP knockout Zurich I mice 
(Bueler et al., 1992) with a retroviral vector that carries an expression cassette coding for a 
temperature-sensitive form of the SV40 large T antigen (Jat and Sharp, 1989). Overall the 
PrP
0/0 ML cell line presents some improvements when compared to the presently available 
PrP-depleted  HpL  3-4,  F14,  Zpl  and  NpL2  lines  (Holme  et  al.,  2003;  Kim  et  al.,  2005; 
Kuwahara et al., 1999; Nishimura et al., 2007). The advantages are three-fold: i) the PrP
0/0 
ML  cells  maintain  the  C57BL/6J  x  129sv(ev)  mixed  genetic  background  of  the  original 
Prnp
0/0 Zurich I mouse line (Bueler et al., 1992), ii) the PrP
0/0 ML cells express neither PrP
C 
nor the prion protein homologue Dpl, which is neurotoxic when expressed in a PrP-knockout 
background (Anderson et al., 2004; Genoud et al., 2004; Moore et al., 2001; Rossi et al., 
2001), and iii) immortalization by the tsSV40 large T conditional oncogene allows the control 
of  the  proliferative  potential  of  the  PrP
0/0  ML  cells  in  a  temperature-dependent  manner 
(Frederiksen  et  al.,  1988;  Jat  and  Sharp,  1989),  making  the  cells  suitable  for  studying 
mechanisms  of  cell  differentiation.  In  fact,  the  hippocampal  neuronal  HpL  3-4  cell  line 
(Kuwahara et al., 1999) has been made from PrP-deficient animals of the Nagasaki-type and, 
therefore,  expresses  the  neurotoxic  prion  protein  homologue  Dpl  (Anderson  et  al.,  2004; 
Genoud et al., 2004; Li et al., 2000; Moore et al., 1999; Moore et al., 2001; Rossi et al., 2001). 
The recently established F14, Zpl and NpL2 cell lines (Holme et al., 2003; Kim et al., 2005; 
Nishimura et al., 2007) have been derived from neuronal primary cells of Zurich I-type mice 
(Bueler et al., 1992; Manson et al., 1994). These cells express neither PrP nor Dpl but, being 73 
already differentiated into neurons, might not be suitable for studying the possible role of 
PrP
C in processes of cell differentiation and neurite outgrowth. 
Here  it  is  shown  that  the  PrP
0/0  ML  cells  are  unipotent  neuronal  precursors  which  can 
specifically differentiate into neurons under nonpermissive conditions of culture in a time-
dependent manner, as indicated by the progressive downregulation of nestin, a neuroepithelial 
stem cell marker, concomitantly to the upregulation of the neuronal antigens NeuN, MAP-2b 
and NF-H in association with an increase in the proportion of cells with neurites. 
 
5.1.2  The role of the cellular prion protein in the process of neuronal fate 
     specification 
 
Several lines of evidence indicate that the cellular form of the prion protein is implicated in 
processes  of  neuronal  differentiation,  neurite  outgrowth  and  synaptogenesis  (Chen  et  al., 
2003; Graner et al., 2000a; Kanaani et al., 2005; Lopes et al., 2005; Santuccione et al., 2005; 
Steele et al., 2006). PrP
C has been proposed to be a cell surface adhesion protein (Mange et 
al., 2002; Martins et al., 2002) and its early developmental distribution resembles that of 
adhesion molecules. Previous studies showed that PrP
C interacts with the laminin receptor 
precursor and binds laminin as well as glycosaminoglycans expressed on the surface of other 
cells (Gauczynski et al., 2001; Graner et al., 2000a; Hundt et al., 2001; Pan et al., 2002; 
Rieger et al., 1997; Shyng et al., 1995). It has to be noticed that during brain development, 
both laminin and glycosaminoglycans are developmentally regulated and contribute to axon 
growth and fiber tract formation (for review, Reichardt and Tomaselli, 1991). Indeed it has 
been showed that specific interaction between laminin and PrP
C induced neuritogenesis in 
mouse  hippocampal  neurons  (Graner  et  al.,  2000a)  and  mediated  neurite  adhesion  and 
maintainance  (Graner  et  al.,  2000b).  Moreover,  PrP
C  was  localized  on  elongating  axons 
suggesting a role for the protein in axon growth (Sales et al., 2002).  
To determine the impact of PrP
C on these events, the expression of both the wild-type PrP
C 
and the N-terminally truncated PrPΔ32-134, a form of PrP shown to cause severe ataxia and 
neuronal death limited to the granular layer of the cerebellum and to Purkinje cells when 
expressed in vivo on a PrP-knockout background, was reconstituted in the PrP
0/0 ML cell line. 
Cell lines stably expressing low (PrPA117), average (PrPA57), and high (PrPA109, data not 
shown) PrP
C levels and one line expressing PrPΔ32-134 at high levels were established. Cell 
lines stably expressing the two proteins were then analyzed for their differentiation potential 
and were compared with the PrP-depleted cells. This work demonstrates that the presence of 74 
PrP
C induces differentiation of the PrP
0/0 ML cells to the neuronal phenotype even under 
permissive conditions of culture as indicated by the reduced expression of nestin and by the 
concomitant  occurrence  of  changes  in  cellular  morphology.  Switching  the  temperature  to 
39°C in low serum concentration further incremented this process as shown by the earlier 
appearance  of  antigens  specific  for  mature  neurons  (e.g.  NeuN),  the  increment  of  the 
proportion of cells expressing neuron-specific antigens and the increase in the proportion of 
cells with neurites. It is interesting to note that PrP
0/0 ML cells stably transfected with an 
empty  vector  differentiated  into  mature  neurons  under  nonpermissive  conditions  with  the 
same kinetic as the parenteral cells. Furthermore, a direct correlation between the levels of 
PrP
C expression and the proportion of cells showing the expression of neuronal markers was 
observed, providing definitive evidence that the effect described above is due to the presence 
of PrP
C rather than to the clonal selection of fast-differentiating cells. On the basis of these 
data, one can conclude that the prion protein facilitates the process of neuronal differentiation 
and neuritogenesis in PrP knockout stem/precursor cells. While no difference between wild-
type and PrP
0/0 primary cerebellar neurons on total neurite length per cell was described by 
others  (Chen  et  al.,  2003;  Santuccione  et  al.,  2005),  here  a  correlation  was  established 
between PrP
C expression and an increment in both the mean length of the longest neurite and 
the total length of neurites (data not shown) per cell. Therefore, we postulate that PrP
C plays a 
role in the process of neurite elongation during development but not on mature neurons, i.e. 
when differentiation is complete. 
Contrary to the experiments in transgenic mice (Flechsig et al., 2003; Shmerling et al., 1998), 
the expression of the truncated PrPΔ32-134 induced no cytotoxic effects on the PrP
0/0 ML 
cells in both permissive and nonpermissive conditions of growth for up to 48 hours in culture. 
This  could  be  explained  by  the  fact  that  the  amino-terminally  deleted  form  of  PrP
C  is 
selectively toxic only in fully differentiated cerebellar neurons, such as Purkinje or granule 
cells, whilst the PrP
0/0 ML cells do not differentiate into specific neuronal phenotypes in the 
experimental  conditions  used.  Similarly  to  the  full-length  PrP
C,  it  was  found  that  high 
expression levels of PrPΔ32-134 mediate neuronal differentiation and neuritogenesis, though 
to a lesser extent than the wild-type protein. This last finding is not in agreement with the 
recently published results showing that full-length recombinant PrP
C, but not its C-terminal 
globular  domain  (SHaPrP90-231),  dramatically  enhances  the  development  of  neuronal 
polarity in cultured embryonic rat hippocampal neurons (Kanaani et al., 2005). One possible 
explanation for this discrepancy is that, in the cell model described in this thesis, PrP
C could 
interact with a putative binding partner both in cis and in trans whereas in the system used by 75 
Kanaani and co-workers recombinant PrP induced neuritogenesis in trans (Kanaani et al., 
2005). 
Altogether, the data generated in this work add to the growing body of evidence that PrP
C is 
involved in mechanisms underlying cell differentiation and neuritogenesis. In addition, it is 
reported here for the first time that the N-terminal domain of the cellular prion protein is not 
crucial for PrP
C–mediated induction/acceleration of neuronal differentiation. 
 
The PrP
0/0  ML and PrP-reconstituted cell lines  represent  novel  in  vitro  models  to further 
investigate the cellular physiopathological roles of both the non-pathogenic and the scrapie 
prion  proteins  and  their  signal  transduction  pathways.  The  future  use  of  genome  wide 
screening procedure at both the transcriptome and proteome level on such models may allow 
to gain further information on the still mysterious role of PrP
C in health and disease. 
 
5.1.3 Expression of PrP in PrP
0/0 ML cells accelerates neuronal differentiation 
  via p59Fyn kinase activation 
 
PrP
C  activation  by  antibody  cross-linking  induces  a  signalling  pathway  involving  the 
nonreceptor Src-tyrosine kinase family member p59Fyn in a cell line capable of neuronal-like 
differentiation  (Mouillet-Richard  et  al.,  2000).  Furthermore,  p59Fyn  signal  transduction 
pathway has also been implicated in neurite outgrowth and neuronal survival elicited by PrP
C 
in cell culture of primary neurons (Chen et al., 2003). Recently it has been shown that PrP
C 
interacts directly with the neural cell adhesion molecule (NCAM) at the neuronal cell surface 
leading to NCAM recruitment and stabilization in lipid rafts. NCAM accumulation in lipid 
rafts  activates  then  the  p59Fyn  kinase  pathway  thereby  inducing  NCAM-mediated 
neuritogenesis (Niethammer et al., 2002; Santuccione et al., 2005). 
Since PrP
C expression in the novel cellular system described in this thesis enhanced neuronal 
differentiation and neurite outgrowth, it was assessed whether p59fyn kinase signal pathway 
was  involved  in  this  PrP
C-mediated  process.  It  was  found  that  the  amount  of  inactive 
p59kinase  was  reduced  in  both  wild  type-  and  PrPΔ32-134-expressing  cell  lines  by 
specifically detecting non-phosphorylated Tyr-416 under nonpermissive culture conditions. 
Furthermore, the inhibition of the Src-kinases signalling by the use of a specific inhibitor 
reduced the enhancing effect of PrP
C on neuronal differentiation of PrP
0/0 ML cell line. These 
data therefore further support the hypothesis that one of the signal pathways activated during 
PrP-mediated  induction  of  neuronal  differentiation  and  neurite  outgrowth  is  the  p59Fyn-76 
dependent  one  (Chen  et  al.,  2003;  Kanaani  et  al.,  2005;  Mouillet-Richard  et  al.,  2000; 
Santuccione et al., 2005). 
 
5.2 The role of plasma membrane-released microvesicles in the paracrine 
  diffusion of PrP
C and propagation of prion infectivity 
 
Prion diseases are typically initiated by infection of peripheral sites, as in the case of BSE, 
vCJD, Kuru, and most cases of iatrogenic CJD. The mechanisms by which prions spread from 
the site of peripheral exposure, such as the gastrointestinal tract, to the lymphoreticular system 
where a first replication phase occurs and subsequently to and within the central nervous 
system  are  still  not  completely  elucidated  (for  reviews,  Aguzzi  and  Heikenwalder,  2006; 
Aguzzi  et  al.,  2008;  Aguzzi  et  al.,  2007;  Mabbott  and  Turner,  2005;  Mabbott  and 
Macpherson,  2006).  Although  different  cell  types  of  the  immune  system,  such  as  B 
lymphocytes (Brandner et al., 1999; Frigg et al., 1999; Klein et al., 1997; Klein et al., 1998; 
Montrasio et al., 2001; Raeber et al., 1999), follicular dendritic cells (Brown et al., 2000; 
Mabbott et al., 2003; McBride et al., 1992; Montrasio et al., 2000; Prinz et al., 2003; Prinz et 
al., 2002), macrophages (Beringue et al., 2000; Carp and Callahan, 1981; Maignien et al., 
2005; Prinz et al., 2002) and dendritic cells (Aucouturier et al., 2001; Glaysher and Mabbott, 
2007; Huang et al., 2002; Levavasseur et al., 2007; Luhr et al., 2004; Mohan et al., 2005; 
Raymond et al., 2007; Raymond and Mabbott, 2007; Sethi et al., 2007), and the peripheral 
nervous system  (Favereaux et al., 2004;  Glatzel and Aguzzi, 2000b; Glatzel et al., 2001; 
Groschup et al., 1999; Ishida et al., 2005; Kimberlin et al., 1983; Lee et al., 2005) have been 
recognized as key players in the process of prion neuroinvasion, relatively little information is 
available about the mechanism(s) underlying intercellular prion transfer. 
Microvesicles (MVs) are submicron (0,03-1 m) (Joop et al., 2001; Sabatier et al., 2002), 
membrane-bounded  vesicles  which  are  released  both  from  the  plasma  membrane  or  the 
endosomal  membrane  compartment  after  fusion  of  secretory  granules  with  the  plasma 
membrane (exosomes) of a variety of cells undergoing activation or apoptosis (Combes et al., 
1999). Although the molecular basis of protein sorting during MVs formation is not fully 
understood,  they  result  from  an  exocytotic  budding  process  involving  lipids  and  proteins 
metabolism. The segregation of specific proteins is followed by blebbing of the membrane 
surface, leading to the formation of MVs and their release in the extracellular environment. 
Some evidence shows that MVs components mainly arise from lipid rafts, which therefore 77 
might be involved in setting up sorting platforms to concentrate specific proteins within MVs, 
which could be destined to extracellular secretion. 
The functional role of MVs is still largely unknown, however recent evidence suggests that 
MVs  are  important  modulators  of  cell-to-cell  communication  and  play  an  important 
pleiotropic role in many biological processes. Indeed, MVs may possibly act as paracrine 
vectors  of  transcellular  exchange  of  messages  between  circulating  and  endothelial  cells 
(Martinez et al., 2005), participate in a variety of intracellular adhesion processes, and induce 
cellular  response(s)  (Combes  et  al.,  1999;  Del  Conde  et  al.,  2005).  Moreover,  MVs  may 
“hijack” infectious particles such as the immuno deficiency virus (HIV) from the cytoplasm 
of the releasing cells (Pelchen-Matthews et al., 2004; Rozmyslowicz et al., 2003) and possibly 
even whole intact organelles such as the mitochondria (Spees et al., 2006). 
The release of PrP
C and infectious PrP
Sc by prion infected epithelial, neuroglial and neuronal 
cells in association with exosomes has recently been highlighted (Fevrier et al., 2004; Vella et 
al.,  2007a),  suggesting  that  PrP
Sc-bearing  exosomes  may  provide  a  mechanism  for 
intercellular  transmission  of  infectious  prions  in  addition  to  cell–cell  contact.  It  has 
furthermore been shown that endogenous PrP
C is associated with exosomes released by blood 
platelets (Robertson et al., 2006), and a number of studies have demonstrated that prions are 
present in blood and blood components, buffy coats, plasma, and platelets in animal models 
(Bons et al., 2002; Brown et al., 1999b; Brown et al., 1998; Cervenakova et al., 2003; Holada 
et  al.,  2002).  It  has  also  been  demonstrated  that  blood  as  well  as  plasma  of  animals 
experimentally  infected  with  TSEs  can  efficiently  transmit  prion  infection  by  transfusion 
(Cervenakova et al., 2003; Houston et al., 2000; Hunter et al., 2002; Ludlam and Turner, 
2006; Taylor et al., 2000). Of concern, is the finding that vCJD is most probably efficiently 
transmitted between human patients by blood transfusion (Bishop et al., 2006; Fagge et al., 
2005; Hewitt, 2006; Ironside, 2006; Llewelyn et al., 2004; Wroe et al., 2006). This infection 
process,  in  absence  of  sensitive  vCJD  blood  tests  for  screening  of  blood  and  blood 
components  donations,  could  lead  to  a  horizontal  spread  of  vCJD  within  the  human 
population. 
The aims of this study were to evaluate the potential role of plasma membrane-derived MVs 
in the mechanism(s) of PrP
C diffusion and prion infectivity transmission in vitro and in vivo 
and to characterize the interactions of PrP
C with lipid raft components in MVs. 
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5.2.1  Microvesicles released from neuronal cells harbor PrP
C and other lipid 
   rafts components 
 
It  has  previously  been  shown  that  neuronal  cells  release  exosomes  containing  numerous 
proteins and lipids similar to those present in the membranes of the cells from which they 
originate,  including  typical  neuronal  proteins  such  as  the  GluR2/3  subunits  of  glutamate 
receptors, the cell adhesion molecule L1 and, interestingly, PrP
C (Faure et al., 2006). The 
current  thesis  reports  for  the  first  time  that  neuronal  cells  also  release  plasma-derived 
microvesicles (MVs). Indeed, MVs were isolated from the cell culture supernatants of four 
independent murine neuronal cell lines, namely the Neuro-2a, the PrP
0/0 ML, the PrPA109 
and the Neuro-2a PK1 cells, by sequential centrifugation steps protocol in which increasing 
centrifugal  forces  were  used.  Electron  microscopy  (EM)  analyses  of  MVs  preparations 
negatively stained with uranyl acetate from both PrPA109 and PrP
0/0 ML cells demonstrated 
the presence of vesicles with a diameter ranging from 100 nm to 1 m, a size compatible with 
that described for MVs purified from other cells (Ratajczak et al., 2006). However, MV-
enriched  fractions  were  most  probably  contaminated  with  exosomes,  as  shown  by  the 
detection of Tgs101 and Alix 1, both cytoplasmic proteins previously identified as specific 
markers for exosomes (Geminard et  al., 2004; Thery et  al., 2001).  In fact, both proteins, 
which  interact  together  (Strack  et  al.,  2003;  von  Schwedler  et  al.,  2003),  are  part  of  the 
molecular  machinery  allowing  vesicles  budding  inside  the  intralumenal  membranes  of 
multivesicular bodies (MVBs) of the endocytotic pathway (Katzmann et al., 2002; Raiborg et 
al., 2003) and are enriched in exosomes released by dendritic cells (Thery et al., 2001). Since 
both the density and size of exosomes may partially overlap those of MVs, it could be that at 
20000g  also  a  portion  of  exosomes  or  exosomes  aggregates  sediment  together  with 
membrane-derived MVs.  The development  of density centrifugation protocols  either on a 
continuous or a discontinuous sucrose gradient for the specific enrichment of MVs may in 
future be envisaged in order to minimize exosomal contaminations.  
 
Like other GPI-anchored proteins, PrP
C as well as PrP
Sc are localized in glycosphingolipid-
enriched microdomains, so called lipid rafts, of neural and lymphocytic plasma membranes 
(Loberto  et  al.,  2005;  Mattei  et  al.,  2002;  Naslavsky  et  al.,  1999;  Vey  et  al.,  1996).  In 
particular, in these specialized portions of cell plasma membrane PrP
C strictly associates with 
gangliosides (Mattei et al., 2002) and transducer proteins, such as p59Fyn kinase (Mouillet-
Richard  et  al.,  2000)  and  NCAM  (Niethammer  et  al.,  2002;  Santuccione  et  al.,  2005). 79 
Moreover, the association of PrP
C with rafts is required for its conversion into the infectious 
and protease-resistant isoform PrP
Sc (Baron et al., 2002; Bate et al., 2004; Masserini et al., 
1999; Naslavsky et al., 1999). Lipid raft-associated protein sorting in the process of exosomes 
shedding has been described (de Gassart et al., 2003; Faure et al., 2006; Fevrier et al., 2004) 
emphasizing  the  raft-like  nature  of  the  exosomal  membrane  environment  and  therefore 
suggesting that raft domains may represent weak points on the cell plasma membrane prone to 
outward shedding. 
In the present work, the association of PrP
C with MVs shed by murine neuronal cells was 
demonstrated. Immunoelectron microscopy (IEM) clearly showed that PrP
C is present on the 
surface of MVs isolated from the PrPA109 cells, a cell line that strongly overexpress PrP
C, 
but not on MVs isolated from the PrP
C-depleted PrP
0/0 ML cells. Furthermore, IEM analysis 
of ultrathin sections of Neuro-2a PK1 cells, a murine neuroblastoma cell line endogenously 
expressing PrP
C, revealed the unevenly distribution of PrP
C on the membrane of MVs as well 
as on the cell plasma membrane. The presence of PrP
C in MVs released from three different 
neuronal cell lines, namely the PrPA109, the Neuro-2a and the Neuro-2a PK1 cells, was then 
confirmed by immunoblot analysis. Heterogeneity of PrP
C molecules is attributed mainly to 
various degrees of N-glycosylation on asparagine residues (DeArmond et al., 1997; Endo et 
al., 1989; Haraguchi et al., 1998; Somerville and Ritchie, 1990). Interestingly, MV-associated 
PrP
C displayed an electrophoretic mobility pattern on SDS-polyacrylamide gels resembling if 
not overlapping the one detected for cell-derived PrP
C, suggesting that in MVs fully processed 
and  mature  PrP
C  molecules  are  incorporated  during  membrane  shedding.  However,  in  a 
recently  published  work,  a  novel  processing  pathway  that  involves  the  N-terminal 
modification of PrP
C  and the selection of distinct PrP
C glycoforms  for  incorporation into 
exosomes  has  been  described  (Vella  et  al.,  2007b).  Thus,  a  more  accurate  and  detailed 
analysis of MV-associated PrP
C should in future be performed in order to verify whether a 
similar  processing  pathway  also  occurs  during  incorporation  of  PrP
C  into  plasma-derived 
microvesicles. The presence of lipid rafts components such as the p59Fyn kinase, flotillin-2 
and the ganglioside GM2 was furthermore detected in MVs released by the murine Neuro-2a 
cell line, suggesting that raft components strictly associated with PrP
C on the cell plasma 
membrane are recruited during the formation of MVs in neuronal cells. The neuronal origin of 
the analyzed MVs was confirmed by the detection of the axonal membrane protein GAP-43, a 
neuronal protein which binds to rafts via its acylated N-termini. 
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5.2.2 Paracrine transfer of PrP
C by microvesicles 
 
It has been shown that MVs are involved in paracrine and endocrine transport of cellular 
components such as membrane receptors, proteins, mRNA and organelles (e.g. mitochondria) 
(for a review, Ratajczak et al., 2006). The phenomenon of receptor transfer between cells by 
MVs has been studied in platelet-derived MVs, which transfer platelet-expressed adhesion 
molecules to hematopoietic cells, increasing their adhesion to fibrinogen or endothelium (Baj-
Krzyworzeka et al., 2002; Janowska-Wieczorek et al., 2001). Furthermore, it has recently 
been  shown  that  MVs  derived  from  monocytes  may  transfer  the  HIV  co-receptor  CCR5 
between cells and are responsible for rendering these cells susceptible to R5 HIV infection 
(Mack et al., 2000). Until now only a few evidence suggests a role for MVs in cell-to-cell 
mechanisms of PrP
C diffusion (Faure et al., 2006; Robertson et al., 2006; Simak et al., 2002). 
In this work, the potential role of neuronal cell-derived MVs in the intercellular trafficking of 
PrP
C was challenged by a co-culture assay in which PrP-depleted cells (PrP
0/0 ML cells) were 
cultured in the presence of PrP
C-bearing microvesicles (MVs
A109). Immunoflorescence-based 
detection of PrP was used for monitoring the transfer of PrP
C from the MVs to the recipient 
cells.  Unfortunately,  this  in  vitro  immunofluorescence-based  assay  was  unsuitable  for 
studying MV-mediated intercellular trafficking of PrP
C. Two major limitations of this in vitro 
assay  were  identified:  i)  the  MV-enriched  preparations  were  probably  contaminated  with 
some  of  the  MV-producing  PrP
C-expressing  cells  and  ii)  the  sensitivity  of  the  detection 
system was probably not sufficient for detecting the transfer of a limited number of PrP
C 
molecules  by  MVs.  As  experimentally  shown,  the  implementation  of  a  filtration  step 
efficiently removed contaminating PrP
C-expressing cells from the MV-enriched preparations. 
In order to  increase detection sensitivity, one  might  generate a murine neuronal  cell line 
transgenically expressing high levels of an EGFP-PrP fusion protein, allowing incorporation 
of self-fluorescent PrP
C molecules into the released MVs. The use of self-fluorescent PrP
C 
moieties would avoid problems both with the sensitivity and the background that could arise 
by the use of an indirect immunolabelling detection system. 
 
5.2.3 Prion infected neuronal cells release PrP
Sc- and prion infectivity-bearing 
  microvesicles 
 
The release of PrP
C and infectious PrP
Sc by prion infected epithelial (Rov cells), neuroglial 
(Mov cells) and neuronal cells (GT1-7 cells) in association with exosomes has recently been 81 
highlighted (Fevrier et al., 2004; Vella et al., 2007a), suggesting that PrP
Sc-bearing exosomes 
may provide a mechanism for intercellular transmission of infectious prions in addition to 
cell-to-cell contact. Indeed it was found that both PrP
Sc and PrP
C are present in cell culture 
supernatants in a secreted, exosome-associated form and that exosomes bearing PrP
Sc were 
infectious both in vitro and in vivo (Fevrier et al., 2004; Vella et al., 2007a). 
This  thesis  further  extends  these  findings  showing  for  the  first  time  that  stably  infected 
neuronal cells endogenously expressing PrP
C shed plasma-derived MVs, which are carriers 
both of the pathological isoform PrP
Sc and of prion infectivity. Noteworthy, MVs isolated 
from cell culture supernatants of Rocky Mountain Laboratory prion strain (RML)-infected 
Neuro-2a PK1 harbored PK-resistant PrP, an indication for the presence of PrP
Sc. In fact, the 
abnormally  folded  PrP
Sc  is  partially  resistant  against  PK  treatment,  whereas  the  cellular 
isoform  PrP
C  is  completely  degraded  by  this  protease  (Prusiner,  1998).  Interestingly,  the 
levels of PrP
Sc detected in the purified MVs were higher than those observed in the parental 
cell line, suggesting that PrP
Sc is enriched on the membrane of MVs. PrP
C and PrP
Sc are GPI-
anchored proteins known to partition into lipid rafts (Gorodinsky and Harris, 1995; Harris, 
1999a; Naslavsky et al., 1997; Sarnataro et al., 2002; Taraboulos et al., 1995; Vey et al., 
1996) and the lipid raft-like nature of MVs membranes argues for an efficient insertion of 
PrP
Sc  in  lipid  raft-rich  domains  of  the  plasma  membrane  involved  in  MVs  formation. 
Furthermore, the evidence that lipid rafts play a role in the formation of PrP
Sc in scrapie-
infected culture cells (Baron et al., 2002; Naslavsky et al., 1999) supports the hypothesis of a 
preferential distribution of PrP
Sc within lipid rafts. 
On the other hand, PrP
C but not PrP
Sc was detected in MVs secreted by non-infected Neuro-2a 
PK1 cells, confirming that PrP
Sc is released specifically from prion infected neuronal cells. 
Thus, these findings clearly indicate that prion infected neuronal cells such as the Neuro-2a 
PK1 shed plasma membrane-derived MVs containing PrP
Sc. 
The potential role of plasma membrane-derived MVs in prion infectivity transmission was 
tested both in vitro and in vivo infection models. This study demonstrates that PrP
Sc-bearing 
MVs can transmit prion infectivity both in vitro and in vivo, indicating that MVs contribute 
both to the intercellular mechanism(s) of PrP
C diffusion and to the process of infectious prions 
intercellular trafficking. Indeed, MVs isolated from cell culture supernatants of infected but 
not from noninfected Neuro-2a PK1 cells were capable of initiating de novo amplification of 
prions in the recipient cells. Interestigly, prion replication was detected up to 30 passages after 
infection, indicating that MV-dependent prion transmission generated a persistent infection in 
the  recipient  neuroblastoma  cells.  Hypothetically,  PrP
C  conversion  may  be  initiated  as  a 82 
consequence of the binding of PrP
Sc-bearing  MVs to  acceptor cells.  In this  context,  it is 
noteworthy that the topology of exosomal and, most probably, of MVs membranes is identical 
to that of the plasma membrane (Mattei et al, personal communication and Stoorvogel et al., 
2002). Alternatively, but not mutually exclusive, MVs captured by the target cells could fuse 
with the cell surface or be internalized by an unclear mode of entry to induce conformational 
change of PrP
C at the cell surface and/or in endocytic compartments, respectively. Moreover, 
in vivo biossay in transgenic mice that overexpress murine PrP
C and are highly susceptible to 
murine prions (Fischer et al., 1996) clearly demonstrated that prion infectivity is associated 
with PrP
Sc-harboring MVs shed by prion infected murine neuronal cells. In fact, membrane-
derived MVs from infected but not those from non-infected Neuro-2a PK1 cells were capable 
of transmitting prion disease to tga20 indicator mice. 
These new findings suggest that plasma membrane-derived MVs shed by prion infected cells 
could  actively  participate  in  the  intercellular  trafficking  of  PrP
Sc  and  contribute  to  the 
transmission of infectious prions. One may therefore postulate that MVs act as carriers of 
prion infectivity during prion neuroinvasion and play a pivotal role in the propagation of prion 
infectivity from neuron to neuron, in this way contributing to the pathogenesis of the disease. 
 
MVs are normal constituents of blood plasma and are secreted by leukocytes, endothelium, 
platelets and erythrocytes. Interestingly, only one-third of the PrP
C in human blood is cell 
associated, and the remaining two-third is present in plasma (MacGregor et al., 1999). In this 
context, it has previously been shown that PrP
C is released on exosomes from activated blood 
platelets (Robertson et al., 2006). Furthermore, a number of studies have demonstrated that 
prions are present in blood and blood components, such as buffy coats, plasma, and platelets 
in animal models (Bons et al., 2002; Brown et al., 1999b; Brown et al., 1998; Cervenakova et 
al., 2003; Holada et al., 2002). Noteworthy, it has also been demonstrated that blood as well 
as plasma of animals naturally or experimentally infected with TSEs can efficiently transmit 
prion infection by transfusion (Cervenakova et al., 2003; Houston et al., 2000; Hunter et al., 
2002; Ludlam and Turner, 2006; Taylor et al., 2000). In the frame of a collaborative work, we 
identified PrP
C in association with the lipid raft components p59Fyn, flotillin-2, GM1 and 
GM3 in MVs from blood plasma of healthy human donors (Mattei, V. and Barenco, M.G., 
unpublished results). Accordingly to the findings reported above indicating that MVs released 
by infected neuronal cells are infectious, one can postulate that MVs may also contribute to 
blood transfusion-mediated transmission of prion diseases. However, this working hypothesis 
has to be experimentally challenged by isolating blood-derived MVs from infected animal 83 
models. Association of both PrP
Sc and prion infectivity with blood-derived MVs has then to 
be demonstrated by biochemical and in vivo assays. 
 
5.2.4 Establishment of a novel cell-based in vitro prion replication model 
 
Expression  of  PrP
C  is  necessary,  although  not  sufficient,  to  confer  capability  of  prion 
replication. The neuronal precursor cell line PrP
0/0 ML was reconstituted for murine PrP
C 
expression by the use of an expression cassette encoding for wild type PrP. The clonal cell 
lines PrPA36 was chosen for establishing a novel model for studying in vitro prion replication 
and  prion  neurotoxicity.  By  the  use  of  two  independent  prion  infection  approaches,  a 
persistent prion infection of the PrPA36 cells was successfully established. Thus, the PrPA36 
cell line is prion replication competent. This finding is in line with the recent publications in 
which it was reported that murine neuronal stem cells are susceptible to prion infections (Giri 
et al., 2006; Milhavet et al., 2006; Vilette, 2008). Therefore, prion replication capability is not 
restricted  to  fully  mature  neurons.  Noteworthy,  the  reconstitution  of  homologous  or 
heterologous prion protein expression in PrP-depleted cell lines is a powerful approach to 
develop novel in vitro prion replication models (this work and Maas et al., 2007). Nowadays, 
no in vitro models for human and bovine prion replication are available. Reconstitution of the 
PrP
0/0 ML cell line for the expression of either human or bovine PrP could be envisaged in 
order to establish in vitro replication models for human and bovine prions. 
 
 
 84 
6 REFERENCES 
Aguzzi, A., and Heikenwalder, M. (2006). Pathogenesis of prion diseases: current status and 
future outlook. Nat Rev Microbiol 4, 765-775. 
Aguzzi, A., Sigurdson, C., and Heikenwaelder, M. (2008). Molecular mechanisms of prion 
pathogenesis. Annu Rev Pathol 3, 11-40. 
Aguzzi, A., Sigurdson, C., and Heikenwalder, M. (2007). Molecular Mechanisms of Prion 
Pathogenesis. Annu Rev Pathol. 
Alper, T., and Haig, D. A. (1968). Protection by anoxia of the scrapie agent and some DNA 
and RNA viruses irradiated as dry preparations. J Gen Virol 3, 157-166. 
Alper, T., Haig, D. A., and Clarke, M. C. (1966). The exceptionally small size of the scrapie 
agent. Biochem Biophys Res Commun 22, 278-284. 
Anderson, L., Rossi, D., Linehan, J., Brandner, S., and Weissmann, C. (2004). Transgene-
driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration 
and motor impairment. Proc Natl Acad Sci U S A 101, 3644-3649. 
Aucouturier, P., Geissmann, F., Damotte, D., Saborio, G. P., Meeker, H. C., Kascsak, R., 
Carp, R. I., and Wisniewski, T. (2001). Infected splenic dendritic cells are sufficient for prion 
transmission to the CNS in mouse scrapie. J Clin Invest 108, 703-708. 
Baj-Krzyworzeka, M., Majka, M., Pratico, D., Ratajczak, J., Vilaire, G., Kijowski, J., Reca, 
R., Janowska-Wieczorek, A., and Ratajczak, M. Z. (2002). Platelet-derived microparticles 
stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp 
Hematol 30, 450-459. 
Barber, R. D., Jaworsky, D. E., Yau, K. W., and Ronnett, G. V. (2000). Isolation and in vitro 
differentiation of conditionally immortalized murine olfactory receptor neurons. J Neurosci 
20, 3695-3704. 
Baron, G. S., Wehrly, K., Dorward, D. W., Chesebro, B., and Caughey, B. (2002). Conversion 
of raft associated prion protein to the protease-resistant state requires insertion of PrP-res 
(PrP(Sc)) into contiguous membranes. Embo J 21, 1031-1040. 
Barthels, D., Vopper, G., Boned, A., Cremer, H., and Wille, W. (1992). High Degree of 
NCAM Diversity Generated by Alternative RNA Splicing in Brain and Muscle. Eur J 
Neurosci 4, 327-337. 
Basler, K., Oesch, B., Scott, M., Westaway, D., Walchli, M., Groth, D. F., McKinley, M. P., 
Prusiner, S. B., and Weissmann, C. (1986). Scrapie and cellular PrP isoforms are encoded by 
the same chromosomal gene. Cell 46, 417-428. 
Bate, C., Reid, S., and Williams, A. (2004). Phospholipase A2 inhibitors or platelet-activating 
factor antagonists prevent prion replication. J Biol Chem 279, 36405-36411. 
Bazan, J. F., Fletterick, R. J., McKinley, M. P., and Prusiner, S. B. (1987). Predicted 
secondary structure and membrane topology of the scrapie prion protein. Protein Eng 1, 125-
135. 85 
Beringue, V., Demoy, M., Lasmezas, C. I., Gouritin, B., Weingarten, C., Deslys, J. P., 
Andreux, J. P., Couvreur, P., and Dormont, D. (2000). Role of spleen macrophages in the 
clearance of scrapie agent early in pathogenesis. J Pathol 190, 495-502. 
Bishop, M. T., Hart, P., Aitchison, L., Baybutt, H. N., Plinston, C., Thomson, V., Tuzi, N. L., 
Head, M. W., Ironside, J. W., Will, R. G., and Manson, J. C. (2006). Predicting susceptibility 
and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5, 393-398. 
Blattler, T., Brandner, S., Raeber, A. J., Klein, M. A., Voigtlander, T., Weissmann, C., and 
Aguzzi, A. (1997). PrP-expressing tissue required for transfer of scrapie infectivity from 
spleen to brain. Nature 389, 69-73. 
Bolton, D. C., Bendheim, P. E., Marmorstein, A. D., and Potempska, A. (1987). Isolation and 
structural studies of the intact scrapie agent protein. Arch Biochem Biophys 258, 579-590. 
Bolton, D. C., Meyer, R. K., and Prusiner, S. B. (1985). Scrapie PrP 27-30 is a 
sialoglycoprotein. J Virol 53, 596-606. 
Bons, N., Lehmann, S., Mestre-Frances, N., Dormont, D., and Brown, P. (2002). Brain and 
buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus 
murinus. Transfusion 42, 513-516. 
Bounhar, Y., Zhang, Y., Goodyer, C. G., and LeBlanc, A. (2001). Prion protein protects 
human neurons against Bax-mediated apoptosis. J Biol Chem 276, 39145-39149. 
Brandner, S., Klein, M. A., and Aguzzi, A. (1999). A crucial role for B cells in neuroinvasive 
scrapie. Transfus Clin Biol 6, 17-23. 
Brown, D. R., Wong, B. S., Hafiz, F., Clive, C., Haswell, S. J., and Jones, I. M. (1999a). 
Normal prion protein has an activity like that of superoxide dismutase. Biochem J 344 Pt 1, 1-
5. 
Brown, K. L., Stewart, K., Ritchie, D., Fraser, H., Morrison, W. I., and Bruce, M. E. (2000). 
Follicular dendritic cells in scrapie pathogenesis. Arch Virol Suppl, 13-21. 
Brown, P., Cervenakova, L., McShane, L. M., Barber, P., Rubenstein, R., and Drohan, W. N. 
(1999b). Further studies of blood infectivity in an experimental model of transmissible 
spongiform encephalopathy, with an explanation of why blood components do not transmit 
Creutzfeldt-Jakob disease in humans. Transfusion 39, 1169-1178. 
Brown, P., and Gajdusek, D. C. (1991). The human spongiform encephalopathies: kuru, 
Creutzfeldt-Jakob disease, and the Gerstmann-Straussler-Scheinker syndrome. Curr Top 
Microbiol Immunol 172, 1-20. 
Brown, P., Goldfarb, L. G., Brown, W. T., Goldgaber, D., Rubenstein, R., Kascsak, R. J., 
Guiroy, D. C., Piccardo, P., Boellaard, J. W., and Gajdusek, D. C. (1991a). Clinical and 
molecular genetic study of a large German kindred with Gerstmann-Straussler-Scheinker 
syndrome. Neurology 41, 375-379. 
Brown, P., Goldfarb, L. G., Gibbs, C. J., Jr., and Gajdusek, D. C. (1991b). The phenotypic 
expression of different mutations in transmissible familial Creutzfeldt-Jakob disease. Eur J 
Epidemiol 7, 469-476. 86 
Brown, P., Goldfarb, L. G., Kovanen, J., Haltia, M., Cathala, F., Sulima, M., Gibbs, C. J., Jr., 
and Gajdusek, D. C. (1992). Phenotypic characteristics of familial Creutzfeldt-Jakob disease 
associated with the codon 178Asn PRNP mutation. Ann Neurol 31, 282-285. 
Brown, P., Rohwer, R. G., Dunstan, B. C., MacAuley, C., Gajdusek, D. C., and Drohan, W. 
N. (1998). The distribution of infectivity in blood components and plasma derivatives in 
experimental models of transmissible spongiform encephalopathy. Transfusion 38, 810-816. 
Bruses, J. L., and Rutishauser, U. (2001). Roles, regulation, and mechanism of polysialic acid 
function during neural development. Biochimie 83, 635-643. 
Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., DeArmond, S. J., Prusiner, S. 
B., Aguet, M., and Weissmann, C. (1992). Normal development and behaviour of mice 
lacking the neuronal cell-surface PrP protein. Nature 356, 577-582. 
Calzolai, L., Lysek, D. A., Perez, D. R., Guntert, P., and Wuthrich, K. (2005). Prion protein 
NMR structures of chickens, turtles, and frogs. Proc Natl Acad Sci U S A 102, 651-655. 
Carp, R. I., and Callahan, S. M. (1981). In vitro interaction of scrapie agent and mouse 
peritoneal macrophages. Intervirology 16, 8-13. 
Castilla, J., Saa, P., Hetz, C., and Soto, C. (2005). In vitro generation of infectious scrapie 
prions. Cell 121, 195-206. 
Cattaneo, E., and Conti, L. (1998). Generation and characterization of embryonic striatal 
conditionally immortalized ST14A cells. J Neurosci Res 53, 223-234. 
Cattaneo, E., and McKay, R. (1990). Proliferation and differentiation of neuronal stem cells 
regulated by nerve growth factor. Nature 347, 762-765. 
Caughey, B., Race, R. E., Ernst, D., Buchmeier, M. J., and Chesebro, B. (1989). Prion protein 
biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 63, 175-181. 
Cervenakova, L., Yakovleva, O., McKenzie, C., Kolchinsky, S., McShane, L., Drohan, W. N., 
and Brown, P. (2003). Similar levels of infectivity in the blood of mice infected with human-
derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43, 
1687-1694. 
Chazot, G., Broussolle, E., Lapras, C., Blattler, T., Aguzzi, A., and Kopp, N. (1996). New 
variant of Creutzfeldt-Jakob disease in a 26-year-old French man. Lancet 347, 1181. 
Chen, S., Mange, A., Dong, L., Lehmann, S., and Schachner, M. (2003). Prion protein as 
trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. 
Mol Cell Neurosci 22, 227-233. 
Chesebro, B., Race, R., Wehrly, K., Nishio, J., Bloom, M., Lechner, D., Bergstrom, S., 
Robbins, K., Mayer, L., Keith, J. M., and et al. (1985). Identification of scrapie prion protein-
specific mRNA in scrapie-infected and uninfected brain. Nature 315, 331-333. 
Chuong, C. M., and Edelman, G. M. (1984). Alterations in neural cell adhesion molecules 
during development of different regions of the nervous system. J Neurosci 4, 2354-2368. 87 
Cohen, F. E., Pan, K. M., Huang, Z., Baldwin, M., Fletterick, R. J., and Prusiner, S. B. (1994). 
Structural clues to prion replication. Science 264, 530-531. 
Collinge, J., Harding, A. E., Owen, F., Poulter, M., Lofthouse, R., Boughey, A. M., Shah, T., 
and Crow, T. J. (1989). Diagnosis of Gerstmann-Straussler syndrome in familial dementia 
with prion protein gene analysis. Lancet 2, 15-17. 
Collinge, J., Whittington, M. A., Sidle, K. C., Smith, C. J., Palmer, M. S., Clarke, A. R., and 
Jefferys, J. G. (1994). Prion protein is necessary for normal synaptic function. Nature 370, 
295-297. 
Combes, V., Simon, A. C., Grau, G. E., Arnoux, D., Camoin, L., Sabatier, F., Mutin, M., 
Sanmarco, M., Sampol, J., and Dignat-George, F. (1999). In vitro generation of endothelial 
microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin 
Invest 104, 93-102. 
Come, J. H., Fraser, P. E., and Lansbury, P. T., Jr. (1993). A kinetic model for amyloid 
formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A 90, 5959-
5963. 
Court, L., and Bert, J. (1995). [Electrophysiology of transmissible encephalopathies]. Pathol 
Biol (Paris) 43, 25-42. 
Cremer, H., Chazal, G., Goridis, C., and Represa, A. (1997). NCAM is essential for axonal 
growth and fasciculation in the hippocampus. Mol Cell Neurosci 8, 323-335. 
de Gassart, A., Geminard, C., Fevrier, B., Raposo, G., and Vidal, M. (2003). Lipid raft-
associated protein sorting in exosomes. Blood 102, 4336-4344. 
DeArmond, S. J., McKinley, M. P., Barry, R. A., Braunfeld, M. B., McColloch, J. R., and 
Prusiner, S. B. (1985). Identification of prion amyloid filaments in scrapie-infected brain. Cell 
41, 221-235. 
DeArmond, S. J., Sanchez, H., Yehiely, F., Qiu, Y., Ninchak-Casey, A., Daggett, V., 
Camerino, A. P., Cayetano, J., Rogers, M., Groth, D., et al. (1997). Selective neuronal 
targeting in prion disease. Neuron 19, 1337-1348. 
DeArmond, S. J., Yang, S. L., Lee, A., Bowler, R., Taraboulos, A., Groth, D., and Prusiner, S. 
B. (1993). Three scrapie prion isolates exhibit different accumulation patterns of the prion 
protein scrapie isoform. Proc Natl Acad Sci U S A 90, 6449-6453. 
Debus, E., Weber, K., and Osborn, M. (1983). Monoclonal antibodies specific for glial 
fibrillary acidic (GFA) protein and for each of the neurofilament triplet polypeptides. 
Differentiation 25, 193-203. 
Del Conde, I., Shrimpton, C. N., Thiagarajan, P., and Lopez, J. A. (2005). Tissue-factor-
bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate 
coagulation. Blood 106, 1604-1611. 
Dickson, G., Gower, H. J., Barton, C. H., Prentice, H. M., Elsom, V. L., Moore, S. E., Cox, R. 
D., Quinn, C., Putt, W., and Walsh, F. S. (1987). Human muscle neural cell adhesion 
molecule (N-CAM): identification of a muscle-specific sequence in the extracellular domain. 
Cell 50, 1119-1130. 88 
Doh-ura, K., Tateishi, J., Sasaki, H., Kitamoto, T., and Sakaki, Y. (1989). Pro----leu change at 
position 102 of prion protein is the most common but not the sole mutation related to 
Gerstmann-Straussler syndrome. Biochem Biophys Res Commun 163, 974-979. 
Edenhofer, F., Rieger, R., Famulok, M., Wendler, W., Weiss, S., and Winnacker, E. L. 
(1996). Prion protein PrPc interacts with molecular chaperones of the Hsp60 family. J Virol 
70, 4724-4728. 
Eklund, C. M., Kennedy, R. C., and Hadlow, W. J. (1967). Pathogenesis of scrapie virus 
infection in the mouse. J Infect Dis 117, 15-22. 
Endo, T., Groth, D., Prusiner, S. B., and Kobata, A. (1989). Diversity of oligosaccharide 
structures linked to asparagines of the scrapie prion protein. Biochemistry 28, 8380-8388. 
Erpel, T., and Courtneidge, S. A. (1995). Src family protein tyrosine kinases and cellular 
signal transduction pathways. Curr Opin Cell Biol 7, 176-182. 
Eves, E. M., Tucker, M. S., Roback, J. D., Downen, M., Rosner, M. R., and Wainer, B. H. 
(1992). Immortal rat hippocampal cell lines exhibit neuronal and glial lineages and 
neurotrophin gene expression. Proc Natl Acad Sci U S A 89, 4373-4377. 
Fagge, T., Barclay, G. R., Macgregor, I., Head, M., Ironside, J., and Turner, M. (2005). 
Variation in concentration of prion protein in the peripheral blood of patients with variant and 
sporadic Creutzfeldt-Jakob disease detected by dissociation enhanced lanthanide 
fluoroimmunoassay and flow cytometry. Transfusion 45, 504-513. 
Faure, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., 
Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006). Exosomes are released by cultured 
cortical neurones. Mol Cell Neurosci. 
Favereaux, A., Quadrio, I., Vital, C., Perret-Liaudet, A., Anne, O., Laplanche, J. L., Petry, K. 
G., and Vital, A. (2004). Pathologic prion protein spreading in the peripheral nervous system 
of a patient with sporadic Creutzfeldt-Jakob disease. Arch Neurol 61, 747-750. 
Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., and Raposo, 
G. (2004). Cells release prions in association with exosomes. Proc Natl Acad Sci U S A 101, 
9683-9688. 
Fischer, M., Rulicke, T., Raeber, A., Sailer, A., Moser, M., Oesch, B., Brandner, S., Aguzzi, 
A., and Weissmann, C. (1996). Prion protein (PrP) with amino-proximal deletions restoring 
susceptibility of PrP knockout mice to scrapie. Embo J 15, 1255-1264. 
Flechsig, E., Hegyi, I., Leimeroth, R., Zuniga, A., Rossi, D., Cozzio, A., Schwarz, P., Rulicke, 
T., Gotz, J., Aguzzi, A., and Weissmann, C. (2003). Expression of truncated PrP targeted to 
Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. Embo J 22, 3095-
3101. 
Fraser, H., and Dickinson, A. G. (1970). Pathogenesis of scrapie in the mouse: the role of the 
spleen. Nature 226, 462-463. 
Fraser, H., and Dickinson, A. G. (1978). Studies of the lymphoreticular system in the 
pathogenesis of scrapie: the role of spleen and thymus. J Comp Pathol 88, 563-573. 89 
Fraser, S. E., Murray, B. A., Chuong, C. M., and Edelman, G. M. (1984). Alteration of the 
retinotectal map in Xenopus by antibodies to neural cell adhesion molecules. Proc Natl Acad 
Sci U S A 81, 4222-4226. 
Frederiksen, K., Jat, P. S., Valtz, N., Levy, D., and McKay, R. (1988). Immortalization of 
precursor cells from the mammalian CNS. Neuron 1, 439-448. 
Frederiksen, K., and McKay, R. D. (1988). Proliferation and differentiation of rat 
neuroepithelial precursor cells in vivo. J Neurosci 8, 1144-1151. 
Frigg, R., Klein, M. A., Hegyi, I., Zinkernagel, R. M., and Aguzzi, A. (1999). Scrapie 
pathogenesis in subclinically infected B-cell-deficient mice. J Virol 73, 9584-9588. 
Gage, F. H., Coates, P. W., Palmer, T. D., Kuhn, H. G., Fisher, L. J., Suhonen, J. O., Peterson, 
D. A., Suhr, S. T., and Ray, J. (1995). Survival and differentiation of adult neuronal 
progenitor cells transplanted to the adult brain. Proc Natl Acad Sci U S A 92, 11879-11883. 
Gajdusek, D. C. (1977). Unconventional viruses and the origin and disappearance of kuru. 
Science 197, 943-960. 
Gallo, V., and Armstrong, R. C. (1995). Developmental and growth factor-induced regulation 
of nestin in oligodendrocyte lineage cells. J Neurosci 15, 394-406. 
Gauczynski, S., Peyrin, J. M., Haik, S., Leucht, C., Hundt, C., Rieger, R., Krasemann, S., 
Deslys, J. P., Dormont, D., Lasmezas, C. I., and Weiss, S. (2001). The 37-kDa/67-kDa 
laminin receptor acts as the cell-surface receptor for the cellular prion protein. Embo J 20, 
5863-5875. 
Geminard, C., De Gassart, A., Blanc, L., and Vidal, M. (2004). Degradation of AP2 during 
reticulocyte maturation enhances binding of hsc70 and Alix to a common site on TFR for 
sorting into exosomes. Traffic 5, 181-193. 
Genoud, N., Behrens, A., Miele, G., Robay, D., Heppner, F. L., Freigang, S., and Aguzzi, A. 
(2004). Disruption of Doppel prevents neurodegeneration in mice with extensive Prnp 
deletions. Proc Natl Acad Sci U S A 101, 4198-4203. 
Gensburger, C., Labourdette, G., and Sensenbrenner, M. (1987). Brain basic fibroblast growth 
factor stimulates the proliferation of rat neuronal precursor cells in vitro. FEBS Lett 217, 1-5. 
Giri, R. K., Young, R., Pitstick, R., DeArmond, S. J., Prusiner, S. B., and Carlson, G. A. 
(2006). Prion infection of mouse neurospheres. Proc Natl Acad Sci U S A 103, 3875-3880. 
Glatzel, M., and Aguzzi, A. (2000a). Peripheral pathogenesis of prion diseases. Microbes 
Infect 2, 613-619. 
Glatzel, M., and Aguzzi, A. (2000b). PrP(C) expression in the peripheral nervous system is a 
determinant of prion neuroinvasion. J Gen Virol 81, 2813-2821. 
Glatzel, M., Heppner, F. L., Albers, K. M., and Aguzzi, A. (2001). Sympathetic innervation of 
lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 31, 25-34. 
Glaysher, B. R., and Mabbott, N. A. (2007). Role of the GALT in scrapie agent neuroinvasion 
from the intestine. J Immunol 178, 3757-3766. 90 
Goldfarb, L. G., Brown, P., Goldgaber, D., Garruto, R. M., Yanagihara, R., Asher, D. M., and 
Gajdusek, D. C. (1990). Identical mutation in unrelated patients with Creutzfeldt-Jakob 
disease. Lancet 336, 174-175. 
Goldfarb, L. G., Brown, P., McCombie, W. R., Goldgaber, D., Swergold, G. D., Wills, P. R., 
Cervenakova, L., Baron, H., Gibbs, C. J., Jr., and Gajdusek, D. C. (1991a). Transmissible 
familial Creutzfeldt-Jakob disease associated with five, seven, and eight extra octapeptide 
coding repeats in the PRNP gene. Proc Natl Acad Sci U S A 88, 10926-10930. 
Goldfarb, L. G., Brown, P., Mitrova, E., Cervenakova, L., Goldin, L., Korczyn, A. D., 
Chapman, J., Galvez, S., Cartier, L., Rubenstein, R., and et al. (1991b). Creutzfeldt-Jacob 
disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families. Eur J 
Epidemiol 7, 477-486. 
Goldman, S., Laird, A., Flament-Durand, J., Luxen, A., Bidaut, L. M., Stanus, E., Hildebrand, 
J., and Przedborski, S. (1993). Positron emission tomography and histopathology in 
Creutzfeldt-Jakob disease. Neurology 43, 1828-1830. 
Goldmann, W., Hunter, N., Foster, J. D., Salbaum, J. M., Beyreuther, K., and Hope, J. (1990). 
Two alleles of a neural protein gene linked to scrapie in sheep. Proc Natl Acad Sci U S A 87, 
2476-2480. 
Gordon, W. S. (1946). Vet Rec 58, 516. 
Gorodinsky, A., and Harris, D. A. (1995). Glycolipid-anchored proteins in neuroblastoma 
cells form detergent-resistant complexes without caveolin. J Cell Biol 129, 619-627. 
Graner, E., Mercadante, A. F., Zanata, S. M., Forlenza, O. V., Cabral, A. L., Veiga, S. S., 
Juliano, M. A., Roesler, R., Walz, R., Minetti, A., et al. (2000a). Cellular prion protein binds 
laminin and mediates neuritogenesis. Brain Res Mol Brain Res 76, 85-92. 
Graner, E., Mercadante, A. F., Zanata, S. M., Martins, V. R., Jay, D. G., and Brentani, R. R. 
(2000b). Laminin-induced PC-12 cell differentiation is inhibited following laser inactivation 
of cellular prion protein. FEBS Lett 482, 257-260. 
Groschup, M. H., Beekes, M., McBride, P. A., Hardt, M., Hainfellner, J. A., and Budka, H. 
(1999). Deposition of disease-associated prion protein involves the peripheral nervous system 
in experimental scrapie. Acta Neuropathol (Berl) 98, 453-457. 
Haltia, M., Kovanen, J., Goldfarb, L. G., Brown, P., and Gajdusek, D. C. (1991). Familial 
Creutzfeldt-Jakob disease in Finland: epidemiological, clinical, pathological and molecular 
genetic studies. Eur J Epidemiol 7, 494-500. 
Haraguchi, T., Akaura, K., and Yabuki, S. (1998). [Creutzfeldt-Jakob disease associated with 
ocular dipping--a case report]. Rinsho Shinkeigaku 38, 70-73. 
Haraguchi, T., Fisher, S., Olofsson, S., Endo, T., Groth, D., Tarentino, A., Borchelt, D. R., 
Teplow, D., Hood, L., Burlingame, A., and et al. (1989). Asparagine-linked glycosylation of 
the scrapie and cellular prion proteins. Arch Biochem Biophys 274, 1-13. 
Harmey, J. H., Doyle, D., Brown, V., and Rogers, M. S. (1995). The cellular isoform of the 
prion protein, PrPc, is associated with caveolae in mouse neuroblastoma (N2a) cells. Biochem 
Biophys Res Commun 210, 753-759. 91 
Harris, D. A. (1999a). Cell biological studies of the prion protein. Curr Issues Mol Biol 1, 65-
75. 
Harris, D. A. (1999b). Cellular biology of prion diseases. Clin Microbiol Rev 12, 429-444. 
Hay, B., Barry, R. A., Lieberburg, I., Prusiner, S. B., and Lingappa, V. R. (1987). Biogenesis 
and transmembrane orientation of the cellular isoform of the scrapie prion protein [published 
errratum appears in Mol Cell Biol 1987 May;7(5):2035]. Mol Cell Biol 7, 914-920. 
Heidemann, S. R. (1996). Cytoplasmic mechanisms of axonal and dendritic growth in 
neurons. Int Rev Cytol 165, 235-296. 
Heppner, F. L., Christ, A. D., Klein, M. A., Prinz, M., Fried, M., Kraehenbuhl, J. P., and 
Aguzzi, A. (2001). Transepithelial prion transport by M cells. Nat Med 7, 976-977. 
Herms, J., Tings, T., Gall, S., Madlung, A., Giese, A., Siebert, H., Schurmann, P., Windl, O., 
Brose, N., and Kretzschmar, H. (1999). Evidence of presynaptic location and function of the 
prion protein. J Neurosci 19, 8866-8875. 
Herms, J. W., Kretzchmar, H. A., Titz, S., and Keller, B. U. (1995). Patch-clamp analysis of 
synaptic transmission to cerebellar purkinje cells of prion protein knockout mice. Eur J 
Neurosci 7, 2508-2512. 
Hewitt, P. (2006). vCJD and blood transfusion in the United Kingdom. Transfus Clin Biol 13, 
312-316. 
Hill, A. F., Butterworth, R. J., Joiner, S., Jackson, G., Rossor, M. N., Thomas, D. J., Frosh, 
A., Tolley, N., Bell, J. E., Spencer, M., et al. (1999). Investigation of variant Creutzfeldt-
Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353, 183-
189. 
Hill, A. F., Zeidler, M., Ironside, J., and Collinge, J. (1997). Diagnosis of new variant 
Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 349, 99-100. 
Hirokawa, N., Glicksman, M. A., and Willard, M. B. (1984). Organization of mammalian 
neurofilament polypeptides within the neuronal cytoskeleton. J Cell Biol 98, 1523-1536. 
Hockfield, S., and McKay, R. D. (1985). Identification of major cell classes in the developing 
mammalian nervous system. J Neurosci 5, 3310-3328. 
Holada, K., Vostal, J. G., Theisen, P. W., MacAuley, C., Gregori, L., and Rohwer, R. G. 
(2002). Scrapie infectivity in hamster blood is not associated with platelets. J Virol 76, 4649-
4650. 
Holme, A., Daniels, M., Sassoon, J., and Brown, D. R. (2003). A novel method of generating 
neuronal cell lines from gene-knockout mice to study prion protein membrane orientation. Eur 
J Neurosci 18, 571-579. 
Hope, J., and Hunter, N. (1988). Scrapie-associated fibrils, PrP protein and the Sinc gene. 
Ciba Found Symp 135, 146-163. 
Hope, J., Morton, L. J., Farquhar, C. F., Multhaup, G., Beyreuther, K., and Kimberlin, R. H. 
(1986). The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge 92 
distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). 
Embo J 5, 2591-2597. 
Hope, J., Ritchie, L., Farquhar, C., Somerville, R., and Hunter, N. (1989). Bovine spongiform 
encephalopathy: a scrapie-like disease of British cattle. Prog Clin Biol Res 317, 659-667. 
Hornemann, S., and Glockshuber, R. (1996). Autonomous and reversible folding of a soluble 
amino-terminally truncated segment of the mouse prion protein. J Mol Biol 261, 614-619. 
Hornemann, S., Korth, C., Oesch, B., Riek, R., Wider, G., Wuthrich, K., and Glockshuber, R. 
(1997). Recombinant full-length murine prion protein, mPrP(23-231): purification and 
spectroscopic characterization. FEBS Lett 413, 277-281. 
Houston, F., Foster, J. D., Chong, A., Hunter, N., and Bostock, C. J. (2000). Transmission of 
BSE by blood transfusion in sheep. Lancet 356, 999-1000. 
Huang, F. P., Farquhar, C. F., Mabbott, N. A., Bruce, M. E., and MacPherson, G. G. (2002). 
Migrating intestinal dendritic cells transport PrP(Sc) from the gut. J Gen Virol 83, 267-271. 
Hundt, C., Peyrin, J. M., Haik, S., Gauczynski, S., Leucht, C., Rieger, R., Riley, M. L., 
Deslys, J. P., Dormont, D., Lasmezas, C. I., and Weiss, S. (2001). Identification of interaction 
domains of the prion protein with its 37-kDa/67-kDa laminin receptor. Embo J 20, 5876-
5886. 
Hunter, N., Foster, J., Chong, A., McCutcheon, S., Parnham, D., Eaton, S., MacKenzie, C., 
and Houston, F. (2002). Transmission of prion diseases by blood transfusion. J Gen Virol 83, 
2897-2905. 
Ironside, J. W. (2006). Variant Creutzfeldt-Jakob disease: risk of transmission by blood 
transfusion and blood therapies. Haemophilia 12 Suppl 1, 8-15; discussion 26-18. 
Ishida, C., Okino, S., Kitamoto, T., and Yamada, M. (2005). Involvement of the peripheral 
nervous system in human prion diseases including dural graft associated Creutzfeldt-Jakob 
disease. J Neurol Neurosurg Psychiatry 76, 325-329. 
Izant, J. G., and McIntosh, J. R. (1980). Microtubule-associated proteins: a monoclonal 
antibody to MAP2 binds to differentiated neurons. Proc Natl Acad Sci U S A 77, 4741-4745. 
Janowska-Wieczorek, A., Majka, M., Kijowski, J., Baj-Krzyworzeka, M., Reca, R., Turner, 
A. R., Ratajczak, J., Emerson, S. G., Kowalska, M. A., and Ratajczak, M. Z. (2001). Platelet-
derived microparticles bind to hematopoietic stem/progenitor cells and enhance their 
engraftment. Blood 98, 3143-3149. 
Jarrett, J. T., and Lansbury, P. T., Jr. (1993). Seeding "one-dimensional crystallization" of 
amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058. 
Jat, P. S., and Sharp, P. A. (1989). Cell lines established by a temperature-sensitive simian 
virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature. Mol 
Cell Biol 9, 1672-1681. 
Joop, K., Berckmans, R. J., Nieuwland, R., Berkhout, J., Romijn, F. P., Hack, C. E., and 
Sturk, A. (2001). Microparticles from patients with multiple organ dysfunction syndrome and 
sepsis support coagulation through multiple mechanisms. Thromb Haemost 85, 810-820. 93 
Jorgensen, O. S., and Bock, E. (1974). Brain specific synaptosomal membrane proteins 
demonstrated by crossed immunoelectrophoresis. J Neurochem 23, 879-880. 
Julien, J. P., Meyer, D., Flavell, D., Hurst, J., and Grosveld, F. (1986). Cloning and 
developmental expression of the murine neurofilament gene family. Brain Res 387, 243-250. 
Kalia, L. V., Gingrich, J. R., and Salter, M. W. (2004). Src in synaptic transmission and 
plasticity. Oncogene 23, 8007-8016. 
Kanaani, J., Prusiner, S. B., Diacovo, J., Baekkeskov, S., and Legname, G. (2005). 
Recombinant prion protein induces rapid polarization and development of synapses in 
embryonic rat hippocampal neurons in vitro. J Neurochem 95, 1373-1386. 
Kanu, N., Imokawa, Y., Drechsel, D. N., Williamson, R. A., Birkett, C. R., Bostock, C. J., and 
Brockes, J. P. (2002). Transfer of scrapie prion infectivity by cell contact in culture. Curr Biol 
12, 523-530. 
Katzmann, D. J., Odorizzi, G., and Emr, S. D. (2002). Receptor downregulation and 
multivesicular-body sorting. Nat Rev Mol Cell Biol 3, 893-905. 
Kempermann, G., Jessberger, S., Steiner, B., and Kronenberg, G. (2004). Milestones of 
neuronal development in the adult hippocampus. Trends Neurosci 27, 447-452. 
Kilpatrick, T. J., and Bartlett, P. F. (1993). Cloning and growth of multipotential neural 
precursors: requirements for proliferation and differentiation. Neuron 10, 255-265. 
Kim, B. H., Kim, J. I., Choi, E. K., Carp, R. I., and Kim, Y. S. (2005). A neuronal cell line 
that does not express either prion or doppel proteins. Neuroreport 16, 425-429. 
Kimberlin, R. H. (1990). Transmissible encephalopathies in animals. Can J Vet Res 54, 30-
37. 
Kimberlin, R. H., Field, H. J., and Walker, C. A. (1983). Pathogenesis of mouse scrapie: 
evidence for spread of infection from central to peripheral nervous system. J Gen Virol 64 Pt 
3, 713-716. 
Kimberlin, R. H., and Walker, C. A. (1979). Pathogenesis of mouse scrapie: dynamics of 
agent replication in spleen, spinal cord and brain after infection by different routes. J Comp 
Pathol 89, 551-562. 
Kirkwood, J. K., Wells, G. A., Wilesmith, J. W., Cunningham, A. A., and Jackson, S. I. 
(1990). Spongiform encephalopathy in an arabian oryx (Oryx leucoryx) and a greater kudu 
(Tragelaphus strepsiceros). Vet Rec 127, 418-420. 
Kitamoto, T., Tateishi, J., Tashima, T., Takeshita, I., Barry, R. A., DeArmond, S. J., and 
Prusiner, S. B. (1986). Amyloid plaques in Creutzfeldt-Jakob disease stain with prion protein 
antibodies. Ann Neurol 20, 204-208. 
Klein, M. A., Frigg, R., Flechsig, E., Raeber, A. J., Kalinke, U., Bluethmann, H., Bootz, F., 
Suter, M., Zinkernagel, R. M., and Aguzzi, A. (1997). A crucial role for B cells in 
neuroinvasive scrapie. Nature 390, 687-690. 94 
Klein, M. A., Frigg, R., Raeber, A. J., Flechsig, E., Hegyi, I., Zinkernagel, R. M., Weissmann, 
C., and Aguzzi, A. (1998). PrP expression in B lymphocytes is not required for prion 
neuroinvasion. Nat Med 4, 1429-1433. 
Klein, M. A., Kaeser, P. S., Schwarz, P., Weyd, H., Xenarios, I., Zinkernagel, R. M., Carroll, 
M. C., Verbeek, J. S., Botto, M., Walport, M. J., et al. (2001). Complement facilitates early 
prion pathogenesis. Nat Med 7, 488-492. 
Klohn, P. C., Stoltze, L., Flechsig, E., Enari, M., and Weissmann, C. (2003). A quantitative, 
highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci U S 
A 100, 11666-11671. 
Kocisko, D. A., Come, J. H., Priola, S. A., Chesebro, B., Raymond, G. J., Lansbury, P. T., and 
Caughey, B. (1994). Cell-free formation of protease-resistant prion protein. Nature 370, 471-
474. 
Koperek, O., Kovacs, G. G., Ritchie, D., Ironside, J. W., Budka, H., and Wick, G. (2002). 
Disease-associated prion protein in vessel walls. Am J Pathol 161, 1979-1984. 
Kotani, M., Ozawa, H., Kawashima, I., Ando, S., and Tai, T. (1992). Generation of one set of 
monoclonal antibodies specific for a-pathway ganglio-series gangliosides. Biochim Biophys 
Acta 1117, 97-103. 
Kovacs, G. G., Kalev, O., Gelpi, E., Haberler, C., Wanschitz, J., Strohschneider, M., Molnar, 
M. J., Laszlo, L., and Budka, H. (2004). The prion protein in human neuromuscular diseases. 
J Pathol 204, 241-247. 
Kramer, E. M., Klein, C., Koch, T., Boytinck, M., and Trotter, J. (1999). Compartmentation 
of Fyn kinase with glycosylphosphatidylinositol-anchored molecules in oligodendrocytes 
facilitates kinase activation during myelination. J Biol Chem 274, 29042-29049. 
Kretzschmar, H. A. (1999). Molecular pathogenesis of prion diseases. Eur Arch Psychiatry 
Clin Neurosci 249 Suppl 3, 56-63. 
Kretzschmar, H. A., Kitamoto, T., Doerr-Schott, J., Mehraein, P., and Tateishi, J. (1991). 
Diffuse deposition of immunohistochemically labeled prion protein in the granular layer of 
the cerebellum in a patient with Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 82, 536-
540. 
Kretzschmar, H. A., Prusiner, S. B., Stowring, L. E., and DeArmond, S. J. (1986a). Scrapie 
prion proteins are synthesized in neurons. Am J Pathol 122, 1-5. 
Kretzschmar, H. A., Stowring, L. E., Westaway, D., Stubblebine, W. H., Prusiner, S. B., and 
Dearmond, S. J. (1986b). Molecular cloning of a human prion protein cDNA. DNA 5, 315-
324. 
Kurschner, C., and Morgan, J. I. (1995). The cellular prion protein (PrP) selectively binds to 
Bcl-2 in the yeast two-hybrid system. Brain Res Mol Brain Res 30, 165-168. 
Kurschner, C., and Morgan, J. I. (1996). Analysis of interaction sites in homo- and 
heteromeric complexes containing Bcl-2 family members and the cellular prion protein. Brain 
Res Mol Brain Res 37, 249-258. 95 
Kuwahara, C., Takeuchi, A. M., Nishimura, T., Haraguchi, K., Kubosaki, A., Matsumoto, Y., 
Saeki, K., Yokoyama, T., Itohara, S., and Onodera, T. (1999). Prions prevent neuronal cell-
line death. Nature 400, 225-226. 
Lansbury, P. T., Jr., and Caughey, B. (1995). The chemistry of scrapie infection: implications 
of the 'ice 9' metaphor. Chem Biol 2, 1-5. 
Lee, C. C., Kuo, L. T., Wang, C. H., Scaravilli, F., and An, S. F. (2005). Accumulation of 
prion protein in the peripheral nervous system in human prion diseases. J Neuropathol Exp 
Neurol 64, 716-721. 
Legname, G., Baskakov, I. V., Nguyen, H. O., Riesner, D., Cohen, F. E., DeArmond, S. J., 
and Prusiner, S. B. (2004). Synthetic mammalian prions. Science 305, 673-676. 
Legname, G., Nelken, P., Guan, Z., Kanyo, Z. F., DeArmond, S. J., and Prusiner, S. B. 
(2002). Prion and doppel proteins bind to granule cells of the cerebellum. Proc Natl Acad Sci 
U S A 99, 16285-16290. 
Legname, G., Nguyen, H. O., Baskakov, I. V., Cohen, F. E., Dearmond, S. J., and Prusiner, S. 
B. (2005). Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci U S 
A 102, 2168-2173. 
Lendahl, U., Zimmerman, L. B., and McKay, R. D. (1990). CNS stem cells express a new 
class of intermediate filament protein. Cell 60, 585-595. 
Levavasseur, E., Metharom, P., Dorban, G., Nakano, H., Kakiuchi, T., Carnaud, C., Sarradin, 
P., and Aucouturier, P. (2007). Experimental scrapie in 'plt' mice: an assessment of the role of 
dendritic-cell migration in the pathogenesis of prion diseases. J Gen Virol 88, 2353-2360. 
Li, A., Sakaguchi, S., Atarashi, R., Roy, B. C., Nakaoke, R., Arima, K., Okimura, N., 
Kopacek, J., and Shigematsu, K. (2000). Identification of a novel gene encoding a PrP-like 
protein expressed as chimeric transcripts fused to PrP exon 1/2 in ataxic mouse line with a 
disrupted PrP gene. Cell Mol Neurobiol 20, 553-567. 
Li, G., and Bolton, D. C. (1997). A novel hamster prion protein mRNA contains an extra 
exon: increased expression in scrapie. Brain Res 751, 265-274. 
Liao, Y. C., Lebo, R. V., Clawson, G. A., and Smuckler, E. A. (1986). Human prion protein 
cDNA: molecular cloning, chromosomal mapping, and biological implications. Science 233, 
364-367. 
Liem, R. K. (1990). Neuronal intermediate filaments. Curr Opin Cell Biol 2, 86-90. 
Liu, T., Li, R., Pan, T., Liu, D., Petersen, R. B., Wong, B. S., Gambetti, P., and Sy, M. S. 
(2002). Intercellular transfer of the cellular prion protein. J Biol Chem 277, 47671-47678. 
Lledo, P. M., Tremblay, P., DeArmond, S. J., Prusiner, S. B., and Nicoll, R. A. (1996). Mice 
deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in 
the hippocampus. Proc Natl Acad Sci U S A 93, 2403-2407. 
Llewelyn, C. A., Hewitt, P. E., Knight, R. S., Amar, K., Cousens, S., Mackenzie, J., and Will, 
R. G. (2004). Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. 
Lancet 363, 417-421. 96 
Loberto, N., Prioni, S., Bettiga, A., Chigorno, V., Prinetti, A., and Sonnino, S. (2005). The 
membrane environment of endogenous cellular prion protein in primary rat cerebellar 
neurons. J Neurochem 95, 771-783. 
Locht, C., Chesebro, B., Race, R., and Keith, J. M. (1986). Molecular cloning and complete 
sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl 
Acad Sci U S A 83, 6372-6376. 
Lopes, M. H., Hajj, G. N., Muras, A. G., Mancini, G. L., Castro, R. M., Ribeiro, K. C., 
Brentani, R. R., Linden, R., and Martins, V. R. (2005). Interaction of cellular prion and stress-
inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling 
pathways. J Neurosci 25, 11330-11339. 
Lopez, C. D., Yost, C. S., Prusiner, S. B., Myers, R. M., and Lingappa, V. R. (1990). Unusual 
topogenic sequence directs prion protein biogenesis. Science 248, 226-229. 
Lopez Garcia, F., Zahn, R., Riek, R., and Wuthrich, K. (2000). NMR structure of the bovine 
prion protein. Proc Natl Acad Sci U S A 97, 8334-8339. 
Ludlam, C. A., and Turner, M. L. (2006). Managing the risk of transmission of variant 
Creutzfeldt Jakob disease by blood products. Br J Haematol 132, 13-24. 
Luhr, K. M., Nordstrom, E. K., Low, P., Ljunggren, H. G., Taraboulos, A., and Kristensson, 
K. (2004). Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and 
GT1-1 neuronal cells. J Virol 78, 4776-4782. 
Lysek, D. A., Schorn, C., Nivon, L. G., Esteve-Moya, V., Christen, B., Calzolai, L., von 
Schroetter, C., Fiorito, F., Herrmann, T., Guntert, P., and Wuthrich, K. (2005). Prion protein 
NMR structures of cats, dogs, pigs, and sheep. Proc Natl Acad Sci U S A 102, 640-645. 
Ma, J., Wollmann, R., and Lindquist, S. (2002). Neurotoxicity and neurodegeneration when 
PrP accumulates in the cytosol. Science 298, 1781-1785. 
Maas, E., Geissen, M., Groschup, M. H., Rost, R., Onodera, T., Schatzl, H., and Vorberg, I. 
M. (2007). Scrapie infection of prion protein-deficient cell line upon ectopic expression of 
mutant prion proteins. J Biol Chem 282, 18702-18710. 
Mabbott, N., and Turner, M. (2005). Prions and the blood and immune systems. 
Haematologica 90, 542-548. 
Mabbott, N. A., Bruce, M. E., Botto, M., Walport, M. J., and Pepys, M. B. (2001). Temporary 
depletion of complement component C3 or genetic deficiency of C1q significantly delays 
onset of scrapie. Nat Med 7, 485-487. 
Mabbott, N. A., Mackay, F., Minns, F., and Bruce, M. E. (2000). Temporary inactivation of 
follicular dendritic cells delays neuroinvasion of scrapie. Nat Med 6, 719-720. 
Mabbott, N. A., and Macpherson, G. G. (2006). Prions and their lethal journey to the brain. 
Nat Rev Microbiol. 
Mabbott, N. A., Young, J., McConnell, I., and Bruce, M. E. (2003). Follicular dendritic cell 
dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically 
reduces scrapie susceptibility. J Virol 77, 6845-6854. 97 
MacGregor, I., Hope, J., Barnard, G., Kirby, L., Drummond, O., Pepper, D., Hornsey, V., 
Barclay, R., Bessos, H., Turner, M., and Prowse, C. (1999). Application of a time-resolved 
fluoroimmunoassay for the analysis of normal prion protein in human blood and its 
components. Vox Sang 77, 88-96. 
Mack, M., Kleinschmidt, A., Bruhl, H., Klier, C., Nelson, P. J., Cihak, J., Plachy, J., 
Stangassinger, M., Erfle, V., and Schlondorff, D. (2000). Transfer of the chemokine receptor 
CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human 
immunodeficiency virus 1 infection. Nat Med 6, 769-775. 
Maignien, T., Shakweh, M., Calvo, P., Marce, D., Sales, N., Fattal, E., Deslys, J. P., 
Couvreur, P., and Lasmezas, C. I. (2005). Role of gut macrophages in mice orally 
contaminated with scrapie or BSE. Int J Pharm 298, 293-304. 
Mange, A., Milhavet, O., Umlauf, D., Harris, D., and Lehmann, S. (2002). PrP-dependent cell 
adhesion in N2a neuroblastoma cells. FEBS Lett 514, 159-162. 
Manson, J. C., Clarke, A. R., Hooper, M. L., Aitchison, L., McConnell, I., and Hope, J. 
(1994). 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are 
developmentally normal. Mol Neurobiol 8, 121-127. 
Marsh, R. F., and Hadlow, W. J. (1992). Transmissible mink encephalopathy. Rev Sci Tech 
11, 539-550. 
Marsh, R. F., and Kimberlin, R. H. (1975). Comparison of scrapie and transmissible mink 
encephalopathy in hamsters. II. Clinical signs, pathology, and pathogenesis. J Infect Dis 131, 
104-110. 
Martinez, M. C., Tesse, A., Zobairi, F., and Andriantsitohaina, R. (2005). Shed membrane 
microparticles from circulating and vascular cells in regulating vascular function. Am J 
Physiol Heart Circ Physiol 288, H1004-1009. 
Martins, V. R., Linden, R., Prado, M. A., Walz, R., Sakamoto, A. C., Izquierdo, I., and 
Brentani, R. R. (2002). Cellular prion protein: on the road for functions. FEBS Lett 512, 25-
28. 
Masserini, M., Palestini, P., and Pitto, M. (1999). Glycolipid-enriched caveolae and caveolae-
like domains in the nervous system. J Neurochem 73, 1-11. 
Mattei, V., Garofalo, T., Misasi, R., Circella, A., Manganelli, V., Lucania, G., Pavan, A., and 
Sorice, M. (2004). Prion protein is a component of the multimolecular signaling complex 
involved in T cell activation. FEBS Lett 560, 14-18. 
Mattei, V., Garofalo, T., Misasi, R., Gizzi, C., Mascellino, M. T., Dolo, V., Pontieri, G. M., 
Sorice, M., and Pavan, A. (2002). Association of cellular prion protein with gangliosides in 
plasma membrane microdomains of neural and lymphocytic cells. Neurochem Res 27, 743-
749. 
McBride, P. A., Eikelenboom, P., Kraal, G., Fraser, H., and Bruce, M. E. (1992). PrP protein 
is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and 
scrapie-infected mice. J Pathol 168, 413-418. 98 
McManus, M. F., Chen, L. C., Vallejo, I., and Vallejo, M. (1999). Astroglial differentiation of 
cortical precursor cells triggered by activation of the cAMP-dependent signaling pathway. J 
Neurosci 19, 9004-9015. 
Medori, R., Tritschler, H. J., LeBlanc, A., Villare, F., Manetto, V., Chen, H. Y., Xue, R., Leal, 
S., Montagna, P., Cortelli, P., and et al. (1992). Fatal familial insomnia, a prion disease with a 
mutation at codon 178 of the prion protein gene. N Engl J Med 326, 444-449. 
Milhavet, O., Casanova, D., Chevallier, N., McKay, R. D., and Lehmann, S. (2006). Neural 
stem cell model for prion propagation. Stem Cells 24, 2284-2291. 
Mirsky, R., Winter, J., Abney, E. R., Pruss, R. M., Gavrilovic, J., and Raff, M. C. (1980). 
Myelin-specific proteins and glycolipids in rat Schwann cells and oligodendrocytes in culture. 
J Cell Biol 84, 483-494. 
Mohan, J., Hopkins, J., and Mabbott, N. A. (2005). Skin-derived dendritic cells acquire and 
degrade the scrapie agent following in vitro exposure. Immunology 116, 122-133. 
Montrasio, F., Cozzio, A., Flechsig, E., Rossi, D., Klein, M. A., Rulicke, T., Raeber, A. J., 
Vosshenrich, C. A., Proft, J., Aguzzi, A., and Weissmann, C. (2001). B lymphocyte-restricted 
expression of prion protein does not enable prion replication in prion protein knockout mice. 
Proc Natl Acad Sci U S A 98, 4034-4037. 
Montrasio, F., Frigg, R., Glatzel, M., Klein, M. A., Mackay, F., Aguzzi, A., and Weissmann, 
C. (2000). Impaired prion replication in spleens of mice lacking functional follicular dendritic 
cells. Science 288, 1257-1259. 
Moore, R. C., Lee, I. Y., Silverman, G. L., Harrison, P. M., Strome, R., Heinrich, C., 
Karunaratne, A., Pasternak, S. H., Chishti, M. A., Liang, Y., et al. (1999). Ataxia in prion 
protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein 
doppel. J Mol Biol 292, 797-817. 
Moore, R. C., Mastrangelo, P., Bouzamondo, E., Heinrich, C., Legname, G., Prusiner, S. B., 
Hood, L., Westaway, D., DeArmond, S. J., and Tremblay, P. (2001). Doppel-induced 
cerebellar degeneration in transgenic mice. Proc Natl Acad Sci U S A 98, 15288-15293. 
Moser, M., Colello, R. J., Pott, U., and Oesch, B. (1995). Developmental expression of the 
prion protein gene in glial cells. Neuron 14, 509-517. 
Mouillet-Richard, S., Ermonval, M., Chebassier, C., Laplanche, J. L., Lehmann, S., Launay, J. 
M., and Kellermann, O. (2000). Signal transduction through prion protein. Science 289, 1925-
1928. 
Mould, D. L., Dawson, A. M., and Rennie, J. C. (1970). Very early replication of scrapie in 
lymphocytic tissue. Nature 228, 779-780. 
Mullen, R. J., Buck, C. R., and Smith, A. M. (1992). NeuN, a neuronal specific nuclear 
protein in vertebrates. Development 116, 201-211. 
Murphy, T. H., Schnaar, R. L., and Coyle, J. T. (1990). Immature cortical neurons are 
uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. Faseb J 4, 1624-1633. 99 
Naslavsky, N., Shmeeda, H., Friedlander, G., Yanai, A., Futerman, A. H., Barenholz, Y., and 
Taraboulos, A. (1999). Sphingolipid depletion increases formation of the scrapie prion protein 
in neuroblastoma cells infected with prions. J Biol Chem 274, 20763-20771. 
Naslavsky, N., Stein, R., Yanai, A., Friedlander, G., and Taraboulos, A. (1997). 
Characterization of detergent-insoluble complexes containing the cellular prion protein and its 
scrapie isoform. J Biol Chem 272, 6324-6331. 
Niethammer, P., Delling, M., Sytnyk, V., Dityatev, A., Fukami, K., and Schachner, M. 
(2002). Cosignaling of NCAM via lipid rafts and the FGF receptor is required for 
neuritogenesis. J Cell Biol 157, 521-532. 
Nishida, N., Harris, D. A., Vilette, D., Laude, H., Frobert, Y., Grassi, J., Casanova, D., 
Milhavet, O., and Lehmann, S. (2000). Successful transmission of three mouse-adapted 
scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion 
protein. J Virol 74, 320-325. 
Nishimura, T., Sakudo, A., Hashiyama, Y., Yachi, A., Saeki, K., Matsumoto, Y., Ogawa, M., 
Sakaguchi, S., Itohara, S., and Onodera, T. (2007). Serum withdrawal-induced apoptosis in 
ZrchI prion protein (PrP) gene-deficient neuronal cell line is suppressed by PrP, independent 
of Doppel. Microbiol Immunol 51, 457-466. 
Oesch, B., Westaway, D., Walchli, M., McKinley, M. P., Kent, S. B., Aebersold, R., Barry, R. 
A., Tempst, P., Teplow, D. B., Hood, L. E., and et al. (1985). A cellular gene encodes scrapie 
PrP 27-30 protein. Cell 40, 735-746. 
Owen, F., Poulter, M., Shah, T., Collinge, J., Lofthouse, R., Baker, H., Ridley, R., McVey, J., 
and Crow, T. J. (1990). An in-frame insertion in the prion protein gene in familial Creutzfeldt-
Jakob disease. Brain Res Mol Brain Res 7, 273-276. 
Owens, G. C., Edelman, G. M., and Cunningham, B. A. (1987). Organization of the neural 
cell adhesion molecule (N-CAM) gene: alternative exon usage as the basis for different 
membrane-associated domains. Proc Natl Acad Sci U S A 84, 294-298. 
Paitel, E., Alves da Costa, C., Vilette, D., Grassi, J., and Checler, F. (2002). Overexpression 
of PrPc triggers caspase 3 activation: potentiation by proteasome inhibitors and blockade by 
anti-PrP antibodies. J Neurochem 83, 1208-1214. 
Pan, T., Wong, B. S., Liu, T., Li, R., Petersen, R. B., and Sy, M. S. (2002). Cell-surface prion 
protein interacts with glycosaminoglycans. Biochem J 368, 81-90. 
Parsons, J. T., and Parsons, S. J. (1997). Src family protein tyrosine kinases: cooperating with 
growth factor and adhesion signaling pathways. Curr Opin Cell Biol 9, 187-192. 
Parsons, S. J., and Parsons, J. T. (2004). Src family kinases, key regulators of signal 
transduction. Oncogene 23, 7906-7909. 
Pattison, I. H. (1965). Resistance of the Scrapie Agent to Formalin. J Comp Pathol 75, 159-
164. 
Pearson, G. R., Wyatt, J. M., Gruffydd-Jones, T. J., Hope, J., Chong, A., Higgins, R. J., Scott, 
A. C., and Wells, G. A. (1992). Feline spongiform encephalopathy: fibril and PrP studies. Vet 
Rec 131, 307-310. 100 
Pelchen-Matthews, A., Raposo, G., and Marsh, M. (2004). Endosomes, exosomes and Trojan 
viruses. Trends Microbiol 12, 310-316. 
Prinz, M., Heikenwalder, M., Junt, T., Schwarz, P., Glatzel, M., Heppner, F. L., Fu, Y. X., 
Lipp, M., and Aguzzi, A. (2003). Positioning of follicular dendritic cells within the spleen 
controls prion neuroinvasion. Nature 425, 957-962. 
Prinz, M., Montrasio, F., Furukawa, H., van der Haar, M. E., Schwarz, P., Rulicke, T., Giger, 
O. T., Hausler, K. G., Perez, D., Glatzel, M., and Aguzzi, A. (2004). Intrinsic resistance of 
oligodendrocytes to prion infection. J Neurosci 24, 5974-5981. 
Prinz, M., Montrasio, F., Klein, M. A., Schwarz, P., Priller, J., Odermatt, B., Pfeffer, K., and 
Aguzzi, A. (2002). Lymph nodal prion replication and neuroinvasion in mice devoid of 
follicular dendritic cells. Proc Natl Acad Sci U S A 99, 919-924. 
Prusiner, S. B. (1982a). Novel proteinaceous infectious particles cause scrapie. Science 216, 
136-144. 
Prusiner, S. B. (1982b). Research on scrapie. Lancet 2, 494-495. 
Prusiner, S. B. (1986). Prions are novel infectious pathogens causing scrapie and Creutzfeldt-
Jakob disease. Bioessays 5, 281-286. 
Prusiner, S. B. (1991). Molecular biology of prion diseases. Science 252, 1515-1522. 
Prusiner, S. B. (1998). Prions. Proc Natl Acad Sci U S A 95, 13363-13383. 
Prusiner, S. B., Cochran, S. P., Groth, D. F., Downey, D. E., Bowman, K. A., and Martinez, 
H. M. (1982). Measurement of the scrapie agent using an incubation time interval assay. Ann 
Neurol 11, 353-358. 
Prusiner, S. B., and DeArmond, S. J. (1990). Prion diseases of the central nervous system. 
Monogr Pathol, 86-122. 
Prusiner, S. B., Gabizon, R., and McKinley, M. P. (1987). On the biology of prions. Acta 
Neuropathol (Berl) 72, 299-314. 
Puckett, C., Concannon, P., Casey, C., and Hood, L. (1991). Genomic structure of the human 
prion protein gene. Am J Hum Genet 49, 320-329. 
Raeber, A. J., Klein, M. A., Frigg, R., Flechsig, E., Aguzzi, A., and Weissmann, C. (1999). 
PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-
infected mice. Embo J 18, 2702-2706. 
Raiborg, C., Rusten, T. E., and Stenmark, H. (2003). Protein sorting into multivesicular 
endosomes. Curr Opin Cell Biol 15, 446-455. 
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., 
and Geuze, H. J. (1996). B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183, 
1161-1172. 101 
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., and Ratajczak, M. Z. 
(2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-
to-cell communication. Leukemia 20, 1487-1495. 
Raymond, C. R., Aucouturier, P., and Mabbott, N. A. (2007). In vivo depletion of CD11c+ 
cells impairs scrapie agent neuroinvasion from the intestine. J Immunol 179, 7758-7766. 
Raymond, C. R., and Mabbott, N. A. (2007). Assessing the involvement of migratory 
dendritic cells in the transfer of the scrapie agent from the immune to peripheral nervous 
systems. J Neuroimmunol 187, 114-125. 
Reichardt, L. F., and Tomaselli, K. J. (1991). Extracellular matrix molecules and their 
receptors: functions in neural development. Annu Rev Neurosci 14, 531-570. 
Resh, M. D. (1998). Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol 30, 1159-
1162. 
Reynolds, B. A., Tetzlaff, W., and Weiss, S. (1992). A multipotent EGF-responsive striatal 
embryonic progenitor cell produces neurons and astrocytes. J Neurosci 12, 4565-4574. 
Rieger, R., Edenhofer, F., Lasmezas, C. I., and Weiss, S. (1997). The human 37-kDa laminin 
receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med 3, 1383-1388. 
Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., and Wuthrich, K. (1996). 
NMR structure of the mouse prion protein domain PrP(121-321). Nature 382, 180-182. 
Riek, R., Hornemann, S., Wider, G., Glockshuber, R., and Wuthrich, K. (1997). NMR 
characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS 
Lett 413, 282-288. 
Robertson, C., Booth, S. A., Beniac, D. R., Coulthart, M. B., Booth, T. F., and McNicol, A. 
(2006). Cellular prion protein is released on exosomes from activated platelets. Blood. 
Rossi, D., Cozzio, A., Flechsig, E., Klein, M. A., Rulicke, T., Aguzzi, A., and Weissmann, C. 
(2001). Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl 
level in brain. Embo J 20, 694-702. 
Rothbard, J. B., Brackenbury, R., Cunningham, B. A., and Edelman, G. M. (1982). 
Differences in the carbohydrate structures of neural cell-adhesion molecules from adult and 
embryonic chicken brains. J Biol Chem 257, 11064-11069. 
Rougon, G., and Hobert, O. (2003). New insights into the diversity and function of neuronal 
immunoglobulin superfamily molecules. Annu Rev Neurosci 26, 207-238. 
Rozmyslowicz, T., Majka, M., Kijowski, J., Murphy, S. L., Conover, D. O., Poncz, M., 
Ratajczak, J., Gaulton, G. N., and Ratajczak, M. Z. (2003). Platelet- and megakaryocyte-
derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them 
susceptible to infection by X4-HIV. Aids 17, 33-42. 
Sabatier, F., Roux, V., Anfosso, F., Camoin, L., Sampol, J., and Dignat-George, F. (2002). 
Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-
dependent procoagulant activity. Blood 99, 3962-3970. 102 
Saborio, G. P., Permanne, B., and Soto, C. (2001). Sensitive detection of pathological prion 
protein by cyclic amplification of protein misfolding. Nature 411, 810-813. 
Sales, N., Hassig, R., Rodolfo, K., Di Giamberardino, L., Traiffort, E., Ruat, M., Fretier, P., 
and Moya, K. L. (2002). Developmental expression of the cellular prion protein in elongating 
axons. Eur J Neurosci 15, 1163-1177. 
Santuccione, A., Sytnyk, V., Leshchyns'ka, I., and Schachner, M. (2005). Prion protein 
recruits its neuronal receptor NCAM to lipid rafts to activate p59fyn and to enhance neurite 
outgrowth. J Cell Biol 169, 341-354. 
Sarnataro, D., Paladino, S., Campana, V., Grassi, J., Nitsch, L., and Zurzolo, C. (2002). PrPC 
is sorted to the basolateral membrane of epithelial cells independently of its association with 
rafts. Traffic 3, 810-821. 
Schatzl, H. M., Laszlo, L., Holtzman, D. M., Tatzelt, J., DeArmond, S. J., Weiner, R. I., 
Mobley, W. C., and Prusiner, S. B. (1997). A hypothalamic neuronal cell line persistently 
infected with scrapie prions exhibits apoptosis. J Virol 71, 8821-8831. 
Sethi, S., Kerksiek, K. M., Brocker, T., and Kretzschmar, H. (2007). Role of the CD8+ 
dendritic cell subset in transmission of prions. J Virol. 
Shaw, G., and Weber, K. (1982). Differential expression of neurofilament triplet proteins in 
brain development. Nature 298, 277-279. 
Shmerling, D., Hegyi, I., Fischer, M., Blattler, T., Brandner, S., Gotz, J., Rulicke, T., 
Flechsig, E., Cozzio, A., von Mering, C., et al. (1998). Expression of amino-terminally 
truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93, 203-214. 
Shyng, S. L., Lehmann, S., Moulder, K. L., and Harris, D. A. (1995). Sulfated glycans 
stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J 
Biol Chem 270, 30221-30229. 
Silver, J., and Rutishauser, U. (1984). Guidance of optic axons in vivo by a preformed 
adhesive pathway on neuroepithelial endfeet. Dev Biol 106, 485-499. 
Simak, J., Holada, K., D'Agnillo, F., Janota, J., and Vostal, J. G. (2002). Cellular prion protein 
is expressed on endothelial cells and is released during apoptosis on membrane microparticles 
found in human plasma. Transfusion 42, 334-342. 
Slaughter, N., Laux, I., Tu, X., Whitelegge, J., Zhu, X., Effros, R., Bickel, P., and Nel, A. 
(2003). The flotillins are integral membrane proteins in lipid rafts that contain TCR-associated 
signaling components: implications for T-cell activation. Clin Immunol 108, 138-151. 
Small, S. J., Haines, S. L., and Akeson, R. A. (1988). Polypeptide variation in an N-CAM 
extracellular immunoglobulin-like fold is developmentally regulated through alternative 
splicing. Neuron 1, 1007-1017. 
Somerville, R. A., and Ritchie, L. A. (1990). Differential glycosylation of the protein (PrP) 
forming scrapie-associated fibrils. J Gen Virol 71 ( Pt 4), 833-839. 103 
Son, J. H., Chun, H. S., Joh, T. H., Cho, S., Conti, B., and Lee, J. W. (1999). Neuroprotection 
and neuronal differentiation studies using substantia nigra dopaminergic cells derived from 
transgenic mouse embryos. J Neurosci 19, 10-20. 
Spees, J. L., Olson, S. D., Whitney, M. J., and Prockop, D. J. (2006). Mitochondrial transfer 
between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A 103, 1283-1288. 
Spielhaupter, C., and Schatzl, H. M. (2001). PrPC directly interacts with proteins involved in 
signaling pathways. J Biol Chem 276, 44604-44612. 
Stahl, N., Baldwin, M. A., Burlingame, A. L., and Prusiner, S. B. (1990a). Identification of 
glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. 
Biochemistry 29, 8879-8884. 
Stahl, N., Borchelt, D. R., Hsiao, K., and Prusiner, S. B. (1987). Scrapie prion protein 
contains a phosphatidylinositol glycolipid. Cell 51, 229-240. 
Stahl, N., Borchelt, D. R., and Prusiner, S. B. (1990b). Differential release of cellular and 
scrapie prion proteins from cellular membranes by phosphatidylinositol-specific 
phospholipase C. Biochemistry 29, 5405-5412. 
Steele, A. D., Emsley, J. G., Ozdinler, P. H., Lindquist, S., and Macklis, J. D. (2006). Prion 
protein (PrPc) positively regulates neural precursor proliferation during developmental and 
adult mammalian neurogenesis. Proc Natl Acad Sci U S A 103, 3416-3421. 
Stoorvogel, W., Kleijmeer, M. J., Geuze, H. J., and Raposo, G. (2002). The biogenesis and 
functions of exosomes. Traffic 3, 321-330. 
Strack, B., Calistri, A., Craig, S., Popova, E., and Gottlinger, H. G. (2003). AIP1/ALIX is a 
binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114, 689-699. 
Stuermer, C. A., Langhorst, M. F., Wiechers, M. F., Legler, D. F., Von Hanwehr, S. H., Guse, 
A. H., and Plattner, H. (2004). PrPc capping in T cells promotes its association with the lipid 
raft proteins reggie-1 and reggie-2 and leads to signal transduction. Faseb J 18, 1731-1733. 
Svennerholm, L., and Fredman, P. (1980). A procedure for the quantitative isolation of brain 
gangliosides. Biochim Biophys Acta 617, 97-109. 
Taraboulos, A., Scott, M., Semenov, A., Avrahami, D., Laszlo, L., and Prusiner, S. B. (1995). 
Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion 
protein inhibit formation of the scrapie isoform. J Cell Biol 129, 121-132. 
Taylor, D. M., Fernie, K., Reichl, H. E., and Somerville, R. A. (2000). Infectivity in the blood 
of mice with a BSE-derived agent. J Hosp Infect 46, 78-79. 
Temple, S., and Qian, X. (1996). Vertebrate neural progenitor cells: subtypes and regulation. 
Curr Opin Neurobiol 6, 11-17. 
Thanos, S., Bonhoeffer, F., and Rutishauser, U. (1984). Fiber-fiber interaction and tectal cues 
influence the development of the chicken retinotectal projection. Proc Natl Acad Sci U S A 
81, 1906-1910. 104 
Theodosis, D. T., Bonhomme, R., Vitiello, S., Rougon, G., and Poulain, D. A. (1999). Cell 
surface expression of polysialic acid on NCAM is a prerequisite for activity-dependent 
morphological neuronal and glial plasticity. J Neurosci 19, 10228-10236. 
Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., and 
Amigorena, S. (2001). Proteomic analysis of dendritic cell-derived exosomes: a secreted 
subcellular compartment distinct from apoptotic vesicles. J Immunol 166, 7309-7318. 
Thiery, J. P., Duband, J. L., Rutishauser, U., and Edelman, G. M. (1982). Cell adhesion 
molecules in early chicken embryogenesis. Proc Natl Acad Sci U S A 79, 6737-6741. 
Thompson, J., Dickson, G., Moore, S. E., Gower, H. J., Putt, W., Kenimer, J. G., Barton, C. 
H., and Walsh, F. S. (1989). Alternative splicing of the neural cell adhesion molecule gene 
generates variant extracellular domain structure in skeletal muscle and brain. Genes Dev 3, 
348-357. 
Tobler, I., Deboer, T., and Fischer, M. (1997). Sleep and sleep regulation in normal and prion 
protein-deficient mice. J Neurosci 17, 1869-1879. 
Tobler, I., Gaus, S. E., Deboer, T., Achermann, P., Fischer, M., Rulicke, T., Moser, M., 
Oesch, B., McBride, P. A., and Manson, J. C. (1996). Altered circadian activity rhythms and 
sleep in mice devoid of prion protein. Nature 380, 639-642. 
Turk, E., Teplow, D. B., Hood, L. E., and Prusiner, S. B. (1988). Purification and properties 
of the cellular and scrapie hamster prion proteins. Eur J Biochem 176, 21-30. 
Vella, L., Sharples, R., Lawson, V., Masters, C., Cappai, R., and Hill, A. (2007a). Packaging 
of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol 211, 
582-590. 
Vella, L. J., Sharples, R. A., Lawson, V. A., Masters, C. L., Cappai, R., and Hill, A. F. 
(2007b). Packaging of prions into exosomes is associated with a novel pathway of PrP 
processing. J Pathol 211, 582-590. 
Vescovi, A. L., Reynolds, B. A., Fraser, D. D., and Weiss, S. (1993). bFGF regulates the 
proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated 
CNS progenitor cells. Neuron 11, 951-966. 
Vey, M., Pilkuhn, S., Wille, H., Nixon, R., DeArmond, S. J., Smart, E. J., Anderson, R. G., 
Taraboulos, A., and Prusiner, S. B. (1996). Subcellular colocalization of the cellular and 
scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci U S A 93, 
14945-14949. 
Vilette, D. (2008). Cell models of prion infection. Vet Res 39, 10. 
von Schwedler, U. K., Stuchell, M., Muller, B., Ward, D. M., Chung, H. Y., Morita, E., 
Wang, H. E., Davis, T., He, G. P., Cimbora, D. M., et al. (2003). The protein network of HIV 
budding. Cell 114, 701-713. 
Weissmann, C. (1996). The Ninth Datta Lecture. Molecular biology of transmissible 
spongiform encephalopathies. FEBS Lett 389, 3-11. 105 
Wells, G. A. (1993). Pathology of nonhuman spongiform encephalopathies: variations and 
their implications for pathogenesis. Dev Biol Stand 80, 61-69. 
Wells, G. A., and McGill, I. S. (1992). Recently described scrapie-like encephalopathies of 
animals: case definitions. Res Vet Sci 53, 1-10. 
Westaway, D., Cooper, C., Turner, S., Da Costa, M., Carlson, G. A., and Prusiner, S. B. 
(1994). Structure and polymorphism of the mouse prion protein gene. Proc Natl Acad Sci U S 
A 91, 6418-6422. 
Westaway, D., Goodman, P. A., Mirenda, C. A., McKinley, M. P., Carlson, G. A., and 
Prusiner, S. B. (1987). Distinct prion proteins in short and long scrapie incubation period 
mice. Cell 51, 651-662. 
Westaway, D., and Prusiner, S. B. (1986). Conservation of the cellular gene encoding the 
scrapie prion protein. Nucleic Acids Res 14, 2035-2044. 
White, L. A., Eaton, M. J., Castro, M. C., Klose, K. J., Globus, M. Y., Shaw, G., and 
Whittemore, S. R. (1994). Distinct regulatory pathways control neurofilament expression and 
neurotransmitter synthesis in immortalized serotonergic neurons. J Neurosci 14, 6744-6753. 
Whittemore, S. R., and White, L. A. (1993). Target regulation of neuronal differentiation in a 
temperature-sensitive cell line derived from medullary raphe. Brain Res 615, 27-40. 
Whittington, M. A., Sidle, K. C., Gowland, I., Meads, J., Hill, A. F., Palmer, M. S., Jefferys, 
J. G., and Collinge, J. (1995). Rescue of neurophysiological phenotype seen in PrP null mice 
by transgene encoding human prion protein. Nat Genet 9, 197-201. 
Wiese, C., Rolletschek, A., Kania, G., Blyszczuk, P., Tarasov, K. V., Tarasova, Y., Wersto, R. 
P., Boheler, K. R., and Wobus, A. M. (2004). Nestin expression--a property of multi-lineage 
progenitor cells? Cell Mol Life Sci 61, 2510-2522. 
Wilesmith, J. W., Ryan, J. B., Hueston, W. D., and Hoinville, L. J. (1992). Bovine 
spongiform encephalopathy: epidemiological features 1985 to 1990. Vet Rec 130, 90-94. 
Wiley, C. A., Burrola, P. G., Buchmeier, M. J., Wooddell, M. K., Barry, R. A., Prusiner, S. 
B., and Lampert, P. W. (1987). Immuno-gold localization of prion filaments in scrapie-
infected hamster brains. Lab Invest 57, 646-656. 
Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro, K., Alperovitch, A., Poser, 
S., Pocchiari, M., Hofman, A., and Smith, P. G. (1996). A new variant of Creutzfeldt-Jakob 
disease in the UK. Lancet 347, 921-925. 
Willard, M., and Simon, C. (1983). Modulations of neurofilament axonal transport during the 
development of rabbit retinal ganglion cells. Cell 35, 551-559. 
Williams, E. S., and Young, S. (1993). Neuropathology of chronic wasting disease of mule 
deer (Odocoileus hemionus) and elk (Cervus elaphus nelsoni). Vet Pathol 30, 36-45. 
Wroe, S. J., Pal, S., Siddique, D., Hyare, H., Macfarlane, R., Joiner, S., Linehan, J. M., 
Brandner, S., Wadsworth, J. D., Hewitt, P., and Collinge, J. (2006). Clinical presentation and 
pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: 
a case report. Lancet 368, 2061-2067. 106 
Wyatt, J. M., Pearson, G. R., Smerdon, T. N., Gruffydd-Jones, T. J., Wells, G. A., and 
Wilesmith, J. W. (1991). Naturally occurring scrapie-like spongiform encephalopathy in five 
domestic cats. Vet Rec 129, 233-236. 
Yost, C. S., Lopez, C. D., Prusiner, S. B., Myers, R. M., and Lingappa, V. R. (1990). Non-
hydrophobic extracytoplasmic determinant of stop transfer in the prion protein. Nature 343, 
669-672. 
Zahn, R., Liu, A., Luhrs, T., Riek, R., von Schroetter, C., Lopez Garcia, F., Billeter, M., 
Calzolai, L., Wider, G., and Wuthrich, K. (2000). NMR solution structure of the human prion 
protein. Proc Natl Acad Sci U S A 97, 145-150. 
Zanata, S. M., Lopes, M. H., Mercadante, A. F., Hajj, G. N., Chiarini, L. B., Nomizo, R., 
Freitas, A. R., Cabral, A. L., Lee, K. S., Juliano, M. A., et al. (2002). Stress-inducible protein 
1 is a cell surface ligand for cellular prion that triggers neuroprotection. Embo J 21, 3307-
3316. 
Zlotnik, I., and Rennie, J. C. (1965). Experimental Transmission of Mouse Passaged Scrapie 
to Goats, Sheep, Rats and Hamsters. J Comp Pathol 75, 147-157. 
 
 
 
 
 
 
 
 
 107 
7 ABBREVIATIONS 
 
aa  amino acid 
Arg  arginines 
Asn  asparagines 
BDNF  brain-derived neurotrophic factor 
bFGF  basic fibroblast growth factor 
bp  base pair 
BSA  bovine serum albumin 
BSE  bovine spongiform encephalopathy 
CJD  Creutzfeldt-Jakob disease 
CMF-PBS  calcium- and magnesium-free PBS 
CMV  cytomegalovirus 
CNS  central nervous system 
DCs  dendritic cells 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
EDTA  ethylene di-amine tetra-acetate 
EEG  electroencephalogram 
EM  electron microscopy 
FACS  fluorescent activated cell sorting 
FCS  Fetal calf serum 
FDCs  follicular dendritics cells 
FFI  fatal familial insomnia 
Fig.  Figure 
FITC  fluorescence isothiocyanate 
GABAA  gamma-aminobutyric acid type A 
GFP  green fluorescence protein 
GSS  Gerstmann-Sträussler-Scheinker disease 
GPI  glycosylphosphatidylinositol 
HPTLC  high-performance-thin-layer-chromatography 
HRP  horseradish-peroxidase 
Hsp  heat shock protein 108 
i.c.  intracerebrally 
IEM  immuno electron microscopy 
IF  immunofluorescence 
Ig  immunoglobulin 
IP  immunoprecipitation 
kb  kilobasepairs 
kDa  kilodalton 
LDH  lactate dehydrogenase 
LRS  local lymphoreticular system 
Lys  lysines 
MALT  mucosa-associated lymphoid tissue system 
M cells  membranous epithelial cells 
mRNA  messanger ribonucleic acid 
MVB  multivesicular bodies 
MVs  microvesicles 
NB  Neurobasal Medium 
NCAM  neuronal cell adhesion molecule 
NMR  nuclear magnetic resonance 
ORF  open reading frame 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PFA  paraformaldehyde 
PK  proteinase K 
p.i.  post-infection 
PMSF  phenylmethylsulfonylfluoride 
PNS  peripheral nervous system 
Prnp  mouse prion protein gene 
PrP
C  cellular prion protein 
PrP
0/0  PrP
C knockout (Zurich I) 
PrP
Sc  pathogenic isoform of the prion protein 
PrP*  infectious subspecies of the prion protein 
PrP
U  unfolded intermediate of the prion protein 
PSA  polysialyc acid 
RML  Rocky Mountain Laboratory prion strain 109 
RPE  R-phycoerythrin 
RT  room temperature 
SAF32  anti-PrP antibody binding the N-terminal region 
SDS  sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamid gel electrophoresis 
SFM  serum-free medium 
SOD1  superoxide dismutase 
STI1  stress-inducible protein 1 
SV40  simian virus 40 
6H4  anti-PrP antibody binding epitope aa144-152 
TAE  Tris-acetate-EDTA 
Tris  Tris-(hydroxymethyl)-aminomethane 
ts  temperature sensitive 
TSE  transmissible spongiform encephalopathies 
UV  ultraviolet 
vCJD  new variant CJD 
WB  Western blot 
wt  wild-type 
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